IACUChazchemindex

Document Sample
IACUChazchemindex Powered By Docstoc
					IACUC HAZARDOUS CHEMICAL INDEX (last updated 09/09/11)
Chemicals Reviewed to date by          Other Common and Scientific Names, Related                     Y: Reportable
                                                                                                     Chemicals (required to
IBC - Biosafety Office                 Compounds
                                                                                                     be addressed in
                                                                                                     Appendix C)
                                                                                                     N: Reporting not
                                                                                                     required


(±)-3,4-Methylenedioxymeth             MDMA, Ecstasy                                                   N* see comments
amphetamine hydrochloride

1,2,3,4,7,8,9-                                                                                                 Y
Heptachlorodibenzofuran

1,2,3,4,6,7,8,9-                                                                                               Y
Octachlorodibenzofuran




1,2,3,6,7,8-Hexachlorodibenzo-p-                                                                               Y
dioxin
1-Butyl-3-methylimidazolium            BMIMLC                                                          N* see comments
chloride

1-Ethyl-3-methylimidazolium chloride                                                                           N


2,3,4,6,7,8-Hexachlorodibenzofuran                                                                             Y



2,3-Pentanedione                       Acetyl propanal; acetyl propionyl, β, γ-dioxopentane            N* see comments


2,4-diamino-6-hydroxypyrimidine        DHAP, 2,6-Diamino-4-pyrimidinol, 2,6-Diamino-4-pyrimidinone             N


3,3′,5,5′-Tetraiodothyroacetic acid    Tetrac, 4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-                            Y
                                       diiodobenzeneacetic acid

12-dimethylbenz(a)anthracene           17,12 dimethylbenz(a)anthracene                                         Y

12-o-tetradecanylphorbol-13-actate     12-o-acetyl-phorbol-13-decanoate, phorbol acetate, caprate              Y
(Also see Phorbol Esters)

17-AAG                                 17-(Allylamino-17-demethoxygeldanamycin, Geldanamycin                   N

2-aminoethyl diphenylborinate          2-APB, Borinic acid, 2-aminoethyl ester (9CI)                           N
2-arachidonylglycerol                  2-AG, 2ag                                                               N




2,4 Dichlorophenoxyacetic acid         2,4-D                                                                   Y



2,4-Dinitrofluorobenzene               1-Fluoro-2,4-Dinitrobenzene                                             N



2-Ethylhexly p-methoxycinnamate                                                                                Y
2-Methoxyestradiol                    1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether, 2-ME                     Y




2-Methoxy-4-nitroaniline              4-Nitro-o-anisidine                                                 N* see comments



3,3′,5,5′-Tetraiodothyroacetic acid   Tetrac, 4-(4-Hydroxy-3,5-diiodophenoxy)-3,5-                                Y
                                      diiodobenzeneacetic acid

3-nitropropionic acid                 Propanoic acid, Praponoic acid, Hiptagenic Acid,                            Y
                                      Bivinocidin

4-(methylnitrosamino)-1-(3-pyridyl)   NNAL, NNA, NNK, 4-(N-nitrosomethylamino)-1-(3 pyridyl)-1-                   Y
butanone                              butanone, 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone

4-Aminodiphenyl                       4-Aminobiphenyl, p-aminobiphenyl, 4-Biphenylamine.                          Y



4-cyano-3-methylisoquinoline                                                                                      N
4-Hydroxytamoxifen                    (Z)-4-(1-[4-(Dimethylaminoethoxy)phenyl]-2-phenyl-1-                        Y
                                      butenyl)phenol
5-azacitidine                         5-azacytidine, Mylosar, NCI-CO1569, U1849, Ladakamycin                      Y

5-Chloro-2′-deoxyuridine              chlorodeoxyuridine                                                         N*

5-fluorouracil                        5-F, FU, 5-FU, 2,4-Dihydroxy-5-fluoropyrimidine, 5-Fluoro-                  Y
                                      2,4(1H,3H)-pyrimidinedione, fluorouracil

5-(Hydroxymethyl)furfural             HMF, AMS-13, 5-Oxymethylfurfurole, 5-Hydroxymethyl-2-                      N*
                                      furaldehyde, 5-(Hydroxymethyl)-2-furancarboxaldehyde,
                                      C6H6O3
5-Iodo-2′-deoxyuridine                1-(2-Deoxy-β-D-ribofuranosyl)-5-iodouracil, 2′-Deoxy-5-                     Y
                                      iodouridine, 5-IUdR, IDU, Idoxuridine, Iododeoxyuridine

6-Hydroxydopamine hydrochloride       6-OHDA                                                            Y (upgraded from N*
                                                                                                         on 03/22/08 due to
                                                                                                         accessibility of new
                                                                                                              tox data)
7-hydroxystaurosporin                 UCN-01                                                            N* (downgraded from
                                                                                                        Y on 10/12/09 due to
                                                                                                        accessibility of MSDS
                                                                                                              tox data)

8-OH DPAT                             (R)-(+)-8-hydroxy-DPAT hydrobromide                                         N

8-SPT                                 8-(p-Sulfophenyl)theophylline hydrate                                       N

A769662                               6,7-Dihydro-4-hydroxy-3-(2'-hydroxy[1,1'-biphenyl]-4-yl)-6-oxo-             Y
                                      thieno[2,3-b]pyridine-5-carbonitrile

ABT-737                                                                                                           Y




Acamprosate                           Campral                                                                     N

Acetaminophen                         Tylenol, Acetanilide, 4'-hydroxy-; acetamide, N-(4-                         N
                                      hydroxyphenyl)-; APAP; Paracetamol
acetic acid                           glacial acetic acid, vinegar acid, C2H4O2, methanecarboxylic               N*
                                      acid
Acetone                     Dimethyl ketone, propanone                                          N

Acetylcholine chloride      Ach                                                                 N




Acetylpromazine             Acetylpromazin, Acepromazine, Acepromazine maleate,           N* see comments
                            Immobilon®
Acridine Orange             Basic Orange, Acridine Orange (AO) Base, related              N* see comments
                            acridine/basic orange products



Acrolein                    2-propenal, Acraldehyde, Acrylic Aldehyde, Allyl Aldehyde,          Y
                            Ethylene Aldehyde




Acyclovir                   Aciclovir, Acyloguanodine, Acycloguanosine, Zovirax™                Y

Adalimumab                  Humira®                                                             Y




Adenine                     6-aminopurine, Vitamin B4                                     N* see comments

Adenosine                   Myocol, Nucleocardyl, Boniton, Adonine riboside, 9-β-D-             Y
                            Ribofuranosyladenine,
                            Adenine riboside, Adenine-9-β-D- ribofuranoside, Adenoscan®

Alfaxan®                                                                                  N* see comments

Afrin Hydrochloride         Afrin, Afrazine, Oxymetazoline Hydrochloride                  N* see comments



AICAR                       Acadesine, N1-(β-D-Ribofuranosyl)-5-aminoimidazole-4-         N* see comments
                            carboxamide5-Aminoimidazole-4-carboxamide 1-β-D-
                            ribofuranoside
AIDA                        (+-) -1-aminoindane-1,5-dicarboxylic acid, aminoindan               N
                            dicarboxylic acid
Aldosterone                 Aldocorten, Electrocortin, 18-Oxocorticosterone                     N*


Alhydrogel                                                                                      N


Allopregnanolone            3β-Hydroxy-5α-pregnan-20-one acetate                                Y




Alpha-ethyltryptamine       AET, ET, Trip                                                 N* see comments



Alpha-hexylcinnamaldehyde   Hexyl cinnamaldehyde                                          N* see comments

Alum                        Aluminum potassium sulfate dodecahydrate                      N* see comments
Alytesin                                                                                            N* see comments




AM251                         1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-                       N*
                              piperidinyl-1H-pyrazole-3-carboxamide
AMD3100                       1,1′-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-                             N
                              tetraazacyclotetradecaneoctahydrochloride, JM3100, SID791

Amiloride                     EIPA, Amiprazidine                                                          Y

Aminobutyrate                 y-aminobutyrate, Ethyl-3-aminobutyrate                                      N

Aminoguanidine                Aminate Base, Guanyl Hydrazine, Aminoguanidine                              N
                              Hemisulfate salt, other related compounds
Aminohippuratein              PAH, p-aminohippurate, Aminohippuric acid                                   N
Amitriptyline HCL                                                                                         N*



Ammonium tetrathiomolybdate                                                                               N



AMP397A                       Competitive AMPA receptor antagonist                                        Y




AMPA                          Alpha-amino-3-hydroxy-5- methylsoxazole-4-proprionic acid                   N

Amphetamine                   d-Amphetamine, dexedrine, other amphetamine                           N* see comments



Amprenavir                    Agenerase                                                             N* see comments

Anakinra                      Kineret                                                               N* see comments

Anandamine                    Anandamide, arachidonylethanolamide                                   N* see comments

Androstenediol                Androstenediol dipropionate, Bisexovis, Ginandrin, Stenandiol,        N* see comments
                              5AD, include androstenetriol/5AT, AED
Angiotensin II, human         asp-arg-val-tyr-ile-his-pro-phe acetate, human                              N*



Anibamine                     Aniba sp., Anisamine-TFA                                                    Y




Anirasetam                    1-(4-Methoxybenzoyl)-2-pyrrolidinone, Ro 13-5057                      N* see comments

Anisomycin                    Antibiotic PA-106, Flagecidin, 3,4-Pyrrolidinediol                    N, see comments

Annatto                       cis- bixin, nor -bixin, trans -bixin, CI Natural Orange 4; CI 75120         N
                              Achiote, Achiotl, Achote, Annotta, Arnatta, Arnatto, Arnotta,
                              Bija, Rocou, Roucou, Roucouyer, Roucoyer, Orlean,
                              Orleanstraugh, Terre orellana, Beni-No-Ki, Urucu, Urucum,
                              L.Orange, norbixen

Annexin V                                                                                                 Y
ANP                              Atrial Natriuretic Peptide                                       Y




Anti-a-tenascin C antibody TMF   Monoclonal Anti-Tenascin antibody produced in rat                N

Anti-CD4 antibody                                                                                 N

Anti-CD8 antibody                2.43 Ab                                                          N

Anti-Galactocerebroside          GalC I and II                                                    N

Anti-GR1                         anti-gr-1; anti-gr 1                                             N

Anti-interleukin 13              Anti-IL-13                                                       N

Anti-Sphingosine Kinase 1        Anti S1P monoclonal antibody                                     N

AMPK inhibitor                   Compound C, Dorsomorphin                                         N

Apamin                           Apamine, Bee venom                                         N* see comments

Apocynin                         Acetovanillone, NAD(P)H Inhibitor                                N

Apomorphine                      S(+)-10,11-Dihydroxyaporphine hydrochloride                      N

ARC                              4-amino-6-hydrazino-7-beta-D-ribofuranosyl-7H-                   Y
                                 pyrrolo(2,3-d)-pyrimidine-5-carboxamide
ARC 239 dihydrochloride          2-[2-(4-(2-methoxy phenyl)piperazin-1-yl)ethyl]-4,4-             Y
                                 dimethyl-1,3-(2h,4h)-isoquinolindione dihydrochloride

Arginine compounds               Arginine Monohydrochloride, L-arginine, L-arginine         Y, See comments
                                 monohydrochloride.




Aripiprazole                     Abilify®                                                   N* see comments



Arsenic Trioxide                 ATO                                                              Y




Arylalkylamines                  Anti-Serotonin N-Acetyltransferase (N-Terminal) antibody         N
                                 produced in rabbit
Arylguanidine                                                                               N* see comments




Ascorbic Acid                    Vitamin C, Ascorvit, Vicomin C, Acorbate, Ascorbutina,           N
                                 Catavin C, Cevex, Secorbate; 3-Keto-
                                 Lgulofuranolactone; 3-Oxo-L-gulofuranolactone
Asparagine                       L-Asparagine, Asparaginase                                       Y



Atomoxetine hydrochloride        (R)-Tomoxetine hydrochloride, (R)-N-Methyl-γ-(2-           N* see comments
                                 methyl-phenoxy)benzene-propanamine hydrochloride
Atracurium besylate                                                                               N
Atropine                         atropine sulfate; Hyoscyamine; Tropine tropate; atropine     Y* / or NOT if using an
                                 sulfate monohydrate; alpha-(hydroxymethyl)benzeneacetic           FDA approved
                                 acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester; atropisol    formulation (or as a
                                                                                              presurgery anesthetic)


Avertin®                         Narcolan, bromethol, tribromoethanol,                          N* see comments



Azathioprine                     6-(1-Methyl-4-nitroimidazol-5yl)thiopurine                             Y




AZD2281 (novel PARP inhibitor)                                                                          Y


AZD6244 (novel MEK inhibitor)                                                                           Y


AZD7762 (novel Chk1 inhibitor)                                                                          Y


Azeperone                        azaperone, fluoperidol, strenil                                N* see comments



Azidothymidine (AZT)             Zidovudine                                                             Y




B197C1                           novel Mcl-1 inhibitor                                                  Y



Azoxymethane                     AMO, AOM                                                               Y


β-endorphin                      β-endorphin human, β-Lipotropin 61-91, LPH (61-91), β-         N* see comments
                                 Lipotropin C-fragment, Beta-endorphin




β-Hexachlorocyclohexane          β-HCH, (1a,2b,3a,4b,5a,6b)-1,2,3,4,5,6-                                Y
                                 Hexachlorocyclohexane


BAPTA                            1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′ -tetraacetic                   N
                                 acid, Ethylenedioxybis(o-phenylenenitrilo)tetraacetic acid


Bay 58-2667                                                                                             Y



BDE 47                           2,2',4,4'-Tetrabromodiphenyl ether, 2,2',4,4'-TetraBDE,                Y
                                 PBDE 47
BDE 99                      2,2',4,4',5-Pentabromodiphenyl ether, PBDE 99,                    Y
                            2,2',4,4',5-PentaBDE



BDE 153                     2,2',4,4',5,5'-Hexabromodiphenyl ether, 2,2',4,4',5,5'-           Y
                            HexaBDE,PBDE 153




BDE 209                     Decabromodiphenyl ether, Decabromodiphenyl oxide                  Y




Benazpril Hydrochloride     (3S)-3-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-     N* see comments
                            2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic
                            acid, Daglutril®

Bendroflumethiazide         Benzylhydroflumethiazide, Aprinox, Bentride, BHFT,          N* see comments
                            Naturatin, Pluryl


Benzamide                   Benzoic acid amide                                                Y



Benzamil hydrochloride      N-(Benzylamidino)-3,5-diamino-6-                                  N
                            chloropyrazinecarboxamide hydrochloride


Benzenetetramine            1,2,4,5-Benzenetetramine tetrahydrochloride, 1,2,4,5-       N* see comments
                            Tetraaminobenzene tetrahydrochloride


Benzo(a)pyrene              3,4 Benzopyrene, Benzpyrene, B(a)P                                Y




Benzo(e)pyrene                                                                                Y

Benzodiazepine drugs (see
diazepam and midazolam)


Benzyl Butyl Phthalate                                                                        N*

Benzyl Salicylate           Benzyl 2-hydroxybenzoate, Include salicyalte hydroxylase,         N
                            salicylate


Berberine                   Natural yellow 18, Berberine chloride                             N*




BH4                         (6R)-5,6,7,8 - TETRAHYDROBIOPTERIN                          N* see comments


Bicuculline methiodide                                                                  N* see comments
Bile Acids                           Cholic acid, Chendeoxycholic acid, Chenic acid, Deoxycholic       N* see comments
                                     acid, Ursodeoxycholic acid, Cholestramine, Colesterol,
                                     Colestipol, Bile salts


Bilirubin                            Bilirubin 1X-alpha, Hematoidin, Principle bile pigment, include   N* see comments
                                     biliverdin

Biocytin                             Bct, Nε-(+)-Biotinyl-L-lysine                                            N

Biotinylated Dextran Amine           BDA                                                                      N

Bisphenyl A                          Bisphenol, Bisphenol A, 4,4' Bisphenol A, Bis (4-                        Y
                                     hydroxyphenyl) dimethylmethane, Bis (4-hydroxyphenyl)
                                     propane




Black cohosh                         Actaea racemosa; Cimicifuga racemosa; black snakeroot;                   N
                                     bugbane; bugwort; rattleroot, rattletop; rattleweed; macrotys

Bleomycin                                                                                                     Y


Bombesin                                                                                               N* see comments




Bordetella Pertussis (heat-killed)   For toxin see "Pertussis toxin"                                   N* see comments



Bortezomib                           Velcade, PS 341                                                          Y




Bovine serum albumin                 BSA                                                               N* see comments




BQ-123                                                                                                        N

BQ-788                               N-[N-[N-[(2,6-Dimethyl-1-piperidinyl)carbonyl]-4-methyl-                 N
                                     Lleucyl]-1-(methoxycarbonyl)-D-tryptophyl]-norleucinesodium
                                     salt, 2,6-Dimethylpiperidinecarbonyl-γ-Methyl-Leu-Nin-
                                     (Methoxycarbonyl)-D-Trp-D-Nle
Bradykinin                           Bradykinin acetate, BK, Kallidin.                                 N* see comments
                                                                                                        (status changed
                                                                                                            01/09/08)

Bradykinin receptor                                                                                           N
                                     Anti-B1 Bradykinin Receptor antibody produced in rabbit
Brevital                                                                                                      N

                                     Methohexital sodium
BRL 44408                                                                                                     Y
                                     2-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-2,3-dihydro-1-
                                     methyl-1h-isoindole maleate
Bromocriptine                                                                                                 Y

Bromodeoxyuridine                    BrdU, 5-bromo-2'-deoxyuridine                                            Y
Bromoenol lactone                     BEL, R-BEL, S-BEL                                                      See Comments



Bryostatin 1                          Bugula neritina macrolactone                                           N* see comments



Bupivacaine                           1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide,                N* see comments
                                      Bupuvicaine
Buprenorphine                         Buprenorphine Hydrochloride                                                  N
Bupropion metabolites                 (±)-1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-                       N
                                      propanone hydrochloride, Zyban®, Wellbatrin®, Bupropion
                                      hydrochloride

Buspirone hydrochloride               N-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]butyl]-8-                              N*
                                      azaspiro[4.5]decane-7,9-dionehydrochloride



Butorphanol                           Butorphanol tartrate, BT, Stadol, Torate, Torbutol                     N* see comments



Butyric acid                          Alpha-butanoic acid; Butyrate; Butanic acid, Butanoic acid; 1-               Y
                                      Butyric acid ; 1-Propanecarboxylic acid ; Buttersaeure ; n-
                                      Butanoic acid ; n-Butyric acid ; Propylformic acid ; Kyselina
                                      maselna
Caffeic Acid                          3,4-Dihydroxycinnamic acid, 4-(2'-carboxyvinyl)-1,2-                         Y
                                      hydroxybenzene
Calcitonin                            Carbocalcitonin                                                              N


Cannabidiol                           2-​[1R-​3-​methyl-​6R-​(1-​methylethenyl)-​2-​cyclohexen-​1-​yl]-​5-   N* see comments
                                      ​pentyl-​1,​3-​benzenediol
Candesartan                           Atacand®, (±)-1-Hydoxyethyl 2-ethoxy-1-[p-(o-1H-tetrazol-5-                  N*
                                      ylphenyl)benzyl]-7-benzimidazolecarboxylate, cyclohexyl
                                      carbonate (ester)


Capsaicin                             8-Methyl-N-vanillyl-trans -6-nonenamide, Capsaicine, NCI-              N* see comments
                                      C56564


Capsazepine                           N-[2-(4-Chlorophenyl)ethyl]-1,3,4,5-tetrahydro-7,8-                    N* see comments
                                      dihydroxy-2H-2-benzazepine-2-carbothioamide, TRPV1
                                      antagonist
Carbamazepine                                                                                                      N



Carbobenzoxy-valinyl-phenylalaninal                                                                                N




Carbon monoxide gas                   CO gas                                                                       N*




Carbon tetrachloride                  CCl4, tetrachloromethane                                                     Y




Carbonal cyanide M-                   CCCP, CCP, propanedinitrile                                                  Y
chlorophenylhydrazine
Carboplatin                      cis-Diammine(1,1-cyclobutanedicarboxylato) platinum           Y




Carfilzomib                      PR171                                                         Y

Carnosine                        L-Carnosine, Beta-Alanyl-L-histidine, ignotine                N*


Carprofen®                       6-Chloro-α-methyl-9H-carbazole-2-acetic acid, Rimadyl   N* see comments




Carrageenan                      Carrageen, Gelcarin, Viscarin, Irish moss.              N* see comments




Carvedilol®                      Coreg®, -(9H-carbazol-4-yloxy)-3-[2-(2-                       N
                                 methoxyphenoxy)ethylamino]propan-2-ol

Caspase 9                        ICE-Lap 6                                               N* see comments




Cavedilol                        Coreg, Eucardic                                         N* see comments



CCPA                             2-chloro-N6-cyclopentyladenosine                              N


CDX-S03                                                                                        Y


Cefazolin Sodium Salt            Acef, Ancef, cephazolin                                 N* see comments




Cefpodoxime                      SIMPLICEF, VANTIN (a cephalosporin antibiotic )               N

Celecoxib                        Celebrex®                                               N* see comments


Cerium (III) Chloride            Cerous Chloride                                               N

CEP3891 (novel Chk1 inhibitor)                                                                 Y


Cetuximab                        Erbitux®                                                      Y




CGS19755                         cis-4-[Phosphomethyl]-piperidine-2-carboxylic acid            Y



Charybdotoxin                    CBT                                                           Y




Chelerythrine Chloride           1,2-Dimethoxy-N-methyl(1,3)benzodioxolo(5,6-            N* see comments
                                 c)phenanthridinium chloride
Chloral hydrate                      Trichloroacetaldehyde hydrate                                         Y



Chloralose                           1,2-O-(2,2,2-Trichloroethylidene)-α-D-glucofuranose;            N* see comments
                                     alpha chloralose


Chlorhexidine                        Fimeil, Hexadol, Nolvasan, Soretol, Sterilon.                   N* see comments




Chlorisondamide                      Ecolid®, 4,5,6,7-Tetrachloro-2,3-dihydro-2-methyl-2-[2-         N* see comments
                                     (trimethylammonio)ethyl]-2H-isoindolium diiodide



Chloroethylclonidine Hydrochloride   CEC Dihydrochloride, 2-[2,6-Dichloro(N-β-chloroethyl-N-               N
                                     methyl)-4-aminomethyl]phenylimino-2-imidazolidine
                                     dihydrochloride

Chloroquine                          Chloroquine diphosphate salt, N4-(7-Chloro-4-quinolinyl)-       N* see comments
                                     N1,N1-dimethyl-1,4-pentanediamine
                                     diphosphate salt

Chlorpromazine hydrochloride         2-Chloro-10-(3-dimethylaminopropyl)phenothiazine                N* see comments
                                     hydrochloride



Cholera Toxin B                      CTB, CBT. Vibrio cholerae toxin, Cholera Toxin B.                See comments




Choline                              2-Hydroxyethyl)trimethylammonium hydroxide, Choline             N* see comments
                                     base solution

Choline bitartrate                   2-(Hydroxyethyl)trimethylammonium bitartrate                          N


Chlorprothixene                      Paxyl                                                                 Y


CI-1041                              PD 196860; C0 200461; 6-[2-[4-(4-fluorobenzyl)piperidin-              Y
                                     1-yl] ethylsulfinyl]-3H-benzooxazol-2-one


Cinnamic acid-based oligomers                                                                              Y




Ciprofloxacin                        Cipro IV, Ciprobay, Ciloxin                                           Y


Ciproxifan                           Cyclopropyl[4-[3-(1H-imidazol-4-yl)propoxyl]phenyl]-            N* see comments
                                     methanone hydrochloride


Cisplatin                            Cis Platinum, Cis Platinum (II), Cis-diamminedichloroplatinum         Y
                                     (II), CisPt (II)
Clarithromycin                       6-o-methylerythromycin                                                N

Clofazimine                          N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-                          N* see comments
                                     (isopropylimino)phenazin-2-amine
Clofibrate                   Ethyl 2-(4-chlorophenoxy)-2-methylpropionate; 2-(4-                  N*
                             chlorophenoxy)-2-methylpropionic acid ethyl ester; Ethyl
                             2 -(4-chlorophenoxy)isobutyrate
Clomipramine hydrochloride    Tricyclic antidepressant; inhibits serotonin and              N* see comments
                             norepinephrine transporters. 3-Chloro-10,11-dihydro-N,N-
                             dimethyl-5H-dibenz[b,f]azepine-5-
                             propanaminehydrochloride, Anafranilhydrochloride
Clonidine                    Catapres, Catapresan, 2-(2, 6-dichloranalino)-2-imadazoline    N* see comments
                             hydrochloride

Clozapine                    Clozapin, 8-chloro-11-4-(4-methyl-1-piperazinyl)-SH-dibenzo-         Y
                             (b,e)(1,4)diazapine, HF-1854, Clozaril®, Leponex®, Fazaclo®.




CNQX                         6-Cyano-7-nitroquinoxaline-2,3-dione                                 N




Cobalt Chloride              Cobalt dichloride, Cobalt muriate, CoCl2                             Y




Cobalt Protoporphyrin        Protoporphyrin IX cobalt chloride                                    Y




Cobra venom factor           C3b                                                                  N


Cocaine                                                                                     N* see comments


Coelenterazine               8-Benzyl-2-(4-hydroxybenzyl)-6-(4-hydroxyphenyl)imidazo[1,2-         N
                             a]pyrazin-3(7H)-one

Colchicine                                                                                        Y




Collagenase                  Clostridiopepsidase                                                  N




Collagen Type I              Collagen from rat tail                                               N

Collagen Type II             Collagen from chicken sterum                                         N

Collodian solution           Cellulose nitrate                                                    N*




Combrestatin A4              2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol           N*
                             CA4, 1-(3,4,5-Trimethoxyphenyl)-2-(3'-hydroxy-4'-
                             methoxyphenyl) ethane 3,4,5-trimethoxy-3'-hydroxy-4'-
                             methoxystilbene
Complete Freund's Adjuvant        CFA, FCA, Freund's Complete Adjuvant                                           Y




Concanavalin A                    Con A, NSC-143504, Ricin Toxin Con A                                           Y




Conotoxin                         ά-conotoxin                                                                    Y




CORM-3                            Tricarbonylchlor(glycinato)ruthenium (II), Include iCORM-3                     N




Coseal Surgical Sealant®                                                                                         N

CP101606                          1-[(1S,2S)-2-Hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]-4-                     Y
                                  phenylpiperidin-4-ol mesylate; Traxoprodil mesylate


CP 55,940 (Cannabinoid agonist)   2-[(1S,2R,5S)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-                  N
                                  methyloctan-2-yl)phenol

CP 94, 253                        3-(1,2,5,6-tetrahydro-4-pyridil)-propoxypyrrolo [3,2 -B] pyridine,             N
                                  triprolidine hydrochloride (closely related compound)



CPCCOEt                           7- hydroxyiminocyclopran[b]chromen-1a-carboxalic acid ethyl            N* see comments
                                  ester
CpG ODN adjuvant                  CpG Oligodeoxynucleotides                                                     N*



CPP-ene                           D-CPP-ene, Midafotel, SDZ EAA 494                                              Y




Cremphor RH 40                    Peg-40 hydrogenated castor oil                                                 N


CRGP                              Calcitonin gene-regulated peptide: rat and human sources,                      N
                                  βCRGP
Crotaline                         monocrotaline; MCT                                                             Y


Crystiben                         Penicillin G/Benzathine, Bicillin, Bicillin C-R, Penicillin G                  N
                                  Procaine
CTAP                              Selective μ-opioid receptor antagonist. Amino Acid Sequence:                   N*
                                  H-D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 [Disulfide
                                  Bridge: 2-7]
Cuprizone                         Oxalic acid bis(cyclohexylidenehydrazide), Cuprizon,                 Y (status upgraded 0n
                                  Cuprizane                                                               03/24/08 due to
                                                                                                         availability of new
                                                                                                            hazard data)
CU-Protoporphyrin                                                                                        N* see comments




Curcumin                          (E,E)-1,7-bis(4-Hydroxy-3-methoxyphenyl)-1,6-                          N* see comments
                                  heptadiene-3,5-dione, turmeric, Indian Turmeric
Cyanide               hydrogen cyanide, prussic acid                                   Y



Cyanobalamin          Vitamin B12                                                N* see comments

Cyclohexyladenosine   CHA, N6-cyclohexyladenosine                                      N



Cyclophosphamide      CB-4564, Mitoxan, Clafen, Cytoxan, B518, Genoxal,                Y
                      Endoxan, Sendoxan, NSC 26271, Cyclophosphan (e)


Cyclosporin A         Ciclosporine, Cyclosporine A, Neoral, Anitbiotic S               Y
                      7481F1, OL-27-400, Ramhyphin A, Sandimmune



CYM-5020                                                                               Y


CYM-5442              2-(4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-          Y
                      dihydro-1H-inden-1-yl amino) ethanol
Daidzein                                                                               N*




DAMGO                 DAGO                                                             Y




Dantrolene            Dantrium, F-400, Dantrolene sodium salt                          Y




Dapsone               4,4′-Diaminodiphenyl sulfone, 4,4′-Sulfonyldianiline, 4-         Y
                      Aminophenyl sulfone, Bis(4-aminophenyl) sulfone,
                      Dapsone, DDS, VETRANAL®



Darunavir             Prezista




Daunorubicin          Daunomycin                                                       Y




DCFH-DA               2’,7’-dichlorodihydrofluorescein                                 N


DCPG                  (S)-3,4-dicarboxyphenylglycine                                   Y




D-Cycloserine         Cyclo-D-serine, Seromycin                                        N
DDE                                 4,4′-DDE, 1,1-Dichloro-2,2-bis(4-chlorophenyl)ethene,                 Y
                                    4,4'-dichlorordiphenyl-dichloroethylene
DDT                                 1,1,1-Trichloro-2,2-bis(4-chlorophenyl)ethane, 4,4'-DDT               Y




Deguelin                            (7aS,13aS)-13,13a-Dihydro-9,10-dimethoxy-3,3-dimethyl-                N*
                                    3H-bis[1]benzopyrano[3,4-
                                    b:6′,5′-e]pyran-7(7aH)-one
DEHP                                DI(2-ETHYLHEXYL) PHTHALATE, Bis(2-ethylhexyl)                         Y
                                    phthalate

Dehydroepiandrosterone              Androstenolone, Adrostanolone                                 N* see comments

Deoxycorticosterone acetate         DOC acetate, DOCA                                             N* see comments

Depomedrol                          Methylprenisolone, medrol, Medrone, Urbasone, 6a-             N* see comments
                                    Methylprenisolone
Depsipeptide                        FK 228, Romidepsin                                                    Y

Desferrioxamine                     DFX, Desferoxamine mesylate salt                              Y, status upgraded
                                                                                                        05/22/08




Desipramine                         Dimethylimipramine                                            N* see comments

Detran Sulfate Sodium               Asuro                                                                 N

Dexamethasone - Prednisolone F      (11β,16α)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-   N*, see comments
                                    diene-3,20-dione

Dexamethasone 21 Acetate            Prednisolone F acetate                                        N*, see comments



Dexamethasone - 21 Acetate-O-B-D-                                                                 N*, see comments
Galactopyranoside

Dexamethasone - Cyclodextrin        2-Hydroxyprpyl-B-Cyclodextrin Dexamethasone,                  N*, see comments
Complex                             Dexamethasone - Water Soluble

Dexamethasone Sodium Sulfate                                                                      N*, see comments

Dexamethasone Disodium              Decadron Phosphate, Dexacort, Dexamthasone-21 disodium                Y
Phosphate                           salt, Sodium Dexamethasone Phosphate
Dexrazoxane                         ICRF-187, Cardioxan, Zinecard®                                        Y




Dextran Sulfate Sodium              DSS                                                                   N


DFP                                 Diisopropylfluorophosphate, DIFP, Diisopropyl                         Y
                                    phosphorofluoridate, Phosphoric acid diisopropyl ester
                                    fluoride

D-galactosamine                     D-GaIN                                                                Y

DHEA                                Dehydroxyepiandrosterone, metabolites: Androstenediol and             N*
                                    Androstenetriol
Diacylglycerol                       Diacylglycerol kinase from E. coli                                  N

Diannexin                            Annexin V Homodimer                                                 Y




Diazepam                             Valium                                                              Y



Diazoxide                            Dizoxide, Hypestat, Mutabase                                  N* see comments


Dibenz(a,c) anthracene               DBA, 1,2:5, 6 Benzanthracine                                        Y


Dibenz(a,h) anthracene               DBA, 1,2:5, 6 Benzanthracine                                        Y


Dibutylphalate                       n-Butyl phthalate, DBP, Phthalic acid dibutyl ester                 N*


Dichloromethylene-diphosphonate      Dichloromethane diphosphonate, Sodium clodronate, C12MDP            N


Diclofenac sodium salt               2-[(2,6-Dichlorophenyl)amino] benzeneacetic acid              N* see comments
                                     sodium salt, Diclofenic, Arthrotec®, Valetan®, Voltaren®,
Didox, Trimidox, other sulfamoxole   Voltarol®.
                                     3,4 dihydrobezohydoxamic acid, 3,4,5                                Y
and trimethoprim compounds           trihydroxybenzamidoxime, sulfadoxine/trimethoprim mixtures,
                                     related hydroxybenzohydroxamic and salicylhydroxamic acids,
Dieldrin                             Tridox
                                     1,2,3,4,10,10-Hexachloro-1,4,4a,5,6,7,8,8a-octahydro-6,7-           Y
                                     epoxy-1,4:5,8-dimethanonaphthalene




Diesel Exhaust Particulate           DEP                                                                 Y




Diethylstilbestrol                                                                                       Y


Diethylpyrocarbonate                 DEPC, DEC                                                           N


Dihydro-β-erythroidine               3β-1,6-Didehydro-14,17-dihydro-3-methoxy-16(15H)-             N* see comments
                                     oxaerythrinan-15-one hydrobromide

Dihydro - S1P                                                                                            Y




DiI                                  Xenolight DiR, DilC18, 1,1′-Dioctadecyl-3,3,3′,3′-                  N
                                     tetramethylindocarbocyanine perchlorate

Dimethylamine Borane (complex)       DMAB                                                                Y



Dimethylbenzanthracene               DMBA, 1,4-Dimethyl-2,3-benzophenanthrene, 9,10-Dimethyl-            Y
                                     1,2-benzanthracene
Dimethyl formamide                DMF; N,N-Dimethylformamide; dimethylformamide                         Y




Dimethylhydrazine                                                                                       Y




Dimethylnitrosamine                                                                                     Y

                                  N,N-dimethylnitrosamine, Methanamine, N-
                                  nitrosodimethylamine, ISOPAC (Sigma)
Dimethylsphingosine                                                                                     Y




Dinitrobenzosulfonic acid         DNBSA, DNBS, picrylsolfonic acid                                N* see comments



Dinitrophenol                     2,3-Dinitrophenol, 2,3-DNP, DNP                                 N* see comments




Dioxin                            2,3,7,8 tetrachlorodibenzo-p-dioxin, TCDD, DCDD                       Y




Diphtheria Toxin                  Corynebacterium diphtheriae toxin * Diphtheria                        Y
                                  toxin * Toxine diphterique (French)



Diisononyl Phthalate              DINP                                                                  Y


Disulfiram                        Bis(diethylthiocarbamoyl) disulfide, Bis(diethylthiocarbamyl)         Y
                                  disulfide, Tetraethylthiuram disulfide




Dizocilpine                       M107, (+)- MK-801-hydrogen maleate                                    N


DL-2-Amino-5-phosphonopentanoic   APV, AP5, 2-amino-5-phosphonovaleric acid                             N
acid

DL-Homocysteate                   DL-homocysteine, DHL, 2-Amino-4-mercaptobutyric acid                  N


DL-methionine                     R )-2-Amino-4-(methylmercapto)butyric acid                            N


D-luciferin                       Firefly luciferin, (S )-2-(6-Hydroxy-2-benzothiazolyl)-2-             N
                                  thiazoline-4-carboxylic acid, luciferase
d-Methadone                       d-dolophine hydrochloride                                       N* see comments




DMCM                              4-ethyl-6,7-dimethoxy-9H-pyrido[3,4-b]indole-3-                       N*
                                  carboxylic acid methyl ester
DMOG                       Dimethyoxallyl glycine, N-(methxyoxoacetyl)-glycine methyl             N
                           ester
DMPO                       5,5-Dimethyl-1-pyrroline N -oxide (3)                                  N



DMSO                       Dimethylsulfoxide                                               N* see comments




DNQX                       Dinitroquinoxalone-2,3-dione                                           N




DMT                        dimethyltryptamine, 5-Methyoyx-DMT, 5-Methoyx-N,N-              N* see comments
                           dimethyltryptamine



Dobutamine hydrochloride   (±)-3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-                     N* see comments
                           methylpropyl]-β-phenethylamine hydrochloride

DOI                        D101, (+-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane               Y
                           hydrochloride



DOM                        1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane         2,5-           N
                           Dimethoxy-4-methylamphetamine

Dopram                     Doxapram Hydrochloride, 1-ethyl-4-(2-morpholinoethyl)-3,3-             N
                           diphenyl-2-pyrrolidinone Hydrochloride Hydrate.

Doxorubicin                Adriamycin, 14-hydroxy daunomycin, DX, DXR, 5,12-                      Y
                           napthacenedione, NCI-CO1514, NSC-123127




Doxycyclin                                                                                N* see comments
                           Doxycycline hydrochloride hemiethanolate hemihydrate
DPCPX                      8-cyclopentyl-1,3-dipropylxanthine                                     N

DPDPE                                                                                             Y


                           [pCl-Phe4]-DPDPE, [D-Pen2,5, p-Cl-Phe4]-Enkephalin
Duloxetine hydrochloride   Cymbalta®                                                      N* see comments

DuraSeal                   PolyethyleneFibrin Glue                                                N

Dynorphin A porcine        Dynorphin-(1-17)                                                N* see comments

Echinacea purpurea                                                                                N

E. coli endotoxin          See Lipopolysaccharide                                               Y (see
                                                                                          Lipopolysaccharide)
EGTA                       (Ethylenebis(oxyethylenenitrilo)) tetraacetic acid                      N

EHNA                       Erythro-9(2-hydroxy-3-nonyl) adenosine                                 N
Elastase                                                                                 N*


Emulphor                                                                                 N

Enadoline                 CI-977                                                         Y

Enalapril                 Enalapril Maleate, MK 421, Vasotec®, (S)-N-[1-                 Y
                          (Ethoxycarbonyl)-3-phenylpropyl]-Ala-Pro maleate salt




Enrofloxacin              Baytril®                                                       N



Enterodiol                3,3'-[2,3-Bis(hydromethyl)butane-1,4-diyl]diphenol             N



Enterolactone             trans -α,β-Bis(3,hydroxybenzyl)butyrolactone                   N



Ephedrine                 (1R,2S)-2-Methylamino-1-phenyl-1-propanol, L-α-(1-       N* see comments
                          Methylaminoethyl)benzyl alcohol

Epinephrine               (−)-Adrenalin,(R)-(−)-3,4-Dihydroxy-α-                         Y
                          (methylaminomethyl)benzyl alcohol,L-Adrenaline,L-
                          Epinephrine
Epibatidine               Epibatidine Dihydrochloride, Exo-(+)-1R,2R,4S-2-(6-            Y
                          Chloro-3-pyridinyl)-7-azabicyclo[2.2.1]heptane
                          dihydrochloride


Epidermal Growth Factor   EGF                                                            N



Epigallocatechin          (−)-cis -2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-         Y
                          benzopyran-3,5,7-triol, epigallotechin-3-gallate



Epinephrine               (R )-(−)-3,4-Dihydroxy-α-(methylaminomethyl)benzyl       Y* See comments
                          alcohol, L-adrenaline, Vasotonin




Eplerenone                Cgp 30083, HSDB 7522, Inspra, SC-66110,                        N*
                          Epoxymexrenone
Erlotinib                 N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-                Y
                          quinazolinamine Monohydrochloride
Erythropoietin            EPO, Epogen®, Aranesp®                                   N* see comments
Estrogen Compounds                Estradiol, others                                                              Y




Estrone Sulfate                   1,3,5 (10)-Estratrien-17-one 3-sulfate                                         Y




Eternacept                        (−)-cis -3,3′,4′,5,5′,7-Hexahydroxyflavane                                     Y



Ethacrynic acid                   2,3-dichloro-4-(2-methylenebutyrl) phenoxy acetic acid,                N* see comments
                                  Hydromedin, otacril, MK-595, Edecril.
Ethanol                           Ethyl alcohol                                                          N* see comments




Ethidium bromide                  EtBr, 3,8-Diamino-5-ethyl-6-phenylphenanthridinium                             Y
                                  bromide
Ethosuximide                      2-Ethyl-2-methylsuccinimide, Atysmal®, Capitus®, C.I.                          Y
                                  366, Emeside®, H-920, Suximal®, Zerodan®, Zarontin®



Ethylbenzene                      Phenylethane, Ethyl benzene, Ethybenzol, EB                                    Y



Etoposide                         4′-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-β-                           Y
                                  Dglucopyranoside) VP-16-213

Ethyl ether                       Diethyl ether                                                          N* see comments




Euthasol®                         Pentobarbitol/Phenytoin sodium mixture                                 N* see comments




Evans blue dye                    Direct blue 53                                                         N* see comments



Fast Blue                         o-dianisidine bis (diazotated) zinc double salt, tetrazotized zinc             Y
                                  chloride, Diazo fast blue, fast blue salt, Azoic diazo No. 48



Fenfluramine                      Dexfenfluramine                                                        N* see comments

Fenretinide                       Retinoic acid p-hydroxyanilide , N-(4-                                   Y (upgraded to
                                  hydroxyphenyl)retinamide, 4-HPR, retinol                             reportable on 04/14/08)



Fentanyl citrate                  Phentanyl citrate, leptanal, fentaz                                    N* see comments



Ferriprotoporphyrin IX chloride   Chloro(protoporphyrinato)iron(III), Chlorohemin,                               N
                                  Chloroprotoporphyrin IX iron(III), Ferriprotoporphyrin IX
                                  chloride, Hemin(chloride)
Ferrous ammonium sulfate               FAS, FAS hexahydrate, iron ammonium sulfate hydrate                       N



Fetal Bovine Solution                  Related bovine media/products, see also "Bovine Serum               N* see comments
                                       Albumin"




Fibrin Seal Dressing (bovine-derived Dry Fibrin Seal Dressing, FSD, DFSD                                         N*
thrombin/fibrinogen)


Ficoll                                 Ficoll 400                                                                N




Finasteride                            Proscar, MK-906, L-652,931                                                Y




FK-506                                 Tacrolimus, Tacrolimus hydrate, Prograf®                                  Y



Flagellin                              Bacterial flagella protein                                          N* see comments




Flavopiridol                           Alvocidib®, (-)-2-(2-Chlorophenyl)-5,7-dihydroxy-8-                       Y
                                       [(3s,4r)-3-hydroxy-1-methyl-4-piperidinyl]-4h-1-
                                       benzopyran-4-one hydrochloride, L-86-8276, NSC-
                                       649890


Flumazenil                             RO 15-1788                                                          N* see comments




Flunixin neglumine                     2-[[2-Methyl-3-(trifluoromethyl)phenyl]amino]-3-                          N
                                       pyridinecarboxylic acid meglumine salt, Banamine
Fluorescein isothiocyanate             FITC, FITC-inulin, other related fluorescein compounds              N* see comments




Fluorocarbons                          Freons, Halons, CFCs                                                N* see comments




Fluoroquinolones                       Include all: Ciprofloxacin, Gatifloxacin, Ofloxacin, Norfloxacin,         Y
                                       others



Fluospheres                            blue fluorescent microspheres                                             Y




Fluoxetine HCl                         Prozac®, LY-110,140                                                       Y
Flupenthixol                           Flupentixol dihydrochloride, (Z)-4-[3-[2-(Trifluoromethyl)-9H-         N
                                       thioxanthen-9-ylidene]propyl]-1-piperazineethanol
                                       dihydrochloride                                                        N
Fluvastatin



FN-439                                 4-aminobenzoyl-gly-pro-d-leu-d-ala-hydroxamic acid                     Y




Folic acid                             Vitamin M, PteGlu                                                N* see comments



Folinic Acid                                                                                                  N

Formaldehyde                           Formalin, paraformaldehyde                                       See Comments




Forskolin                              Colforsin, Coleonol, 7β-Acetoxy-8,13-epoxy-1α,6β,9α-                   N*
                                       trihydroxylabd-14-en-11-one



Fractalkine                            CX3CL-1, Neurotactin                                                   N*



FTY720                                 Fingolimod, Fingolimod oral                                            Y




Fucoidan                               Fucoidin                                                               N

Fullerenes                                                                                              Y, see comments



Fumonisin B1                                                                                                  Y




Funaltrexamine hydrochloride           (E)-4-[[(5α,6β)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-           N* see comments
                                       dihydroxymorphinan-6-yl]amino]-4-oxo-2-butenoic acid
                                       methyl ester hydrochloride, ß-Funaltrexamine, ß-FNA

Furan                                  Axole, Furfuran, Divinyline Oxide                                      Y

Furosemide                             BAN, Frisemide, Lasix®, Aisemide, LB 502                               N*




GABA compounds (non radioactive) y-aminobutyric acid, 4-aminobutenoic acid, piperdic acid,                    N
                                       piperidinic acid, 4-Amino-5-hexynoic acid (γ-Acetylenic GABA),
                                       4-Aminobutyric acid-2,2,3,3,4,4-d6 (GABA d6)


Gabapentin                             Neurontin, 1-(Aminomethyl)-cyclohexaneacetic aci                       Y
Gadolinium (dietylenetrinitrilo)   GD-DTPA                                                                N
pentoacetic acid



Galacturonic Acid                  GalA-MRP                                                               N


Galectin-1 (recombinant, human)                                                                          N*


Gallanin                           Galanin, Human galanin, Porcine galanin, Rat galanin                  N*


Gallium Arsenide                   Gray Arsenic, Metallic Arsenic                                         Y



Gamma Hydroxy Butyrate             GHB, β-Hydroxy-γ-(trimethylammonio) butyrate hydrochloride,     N* see comments
                                   (±)-Carnitine chloride, DL-Carnitine hydrochloride


GBR 12909                          1-(2-[bis(4-Fluorophenyl)methoxy]ethyl)-4-(3-                   N* see comments
                                   phenylpropyl)piperazine dihydrochloride


G-CSF (Granulocyte colony-         Filgrastin, Neupogen®                                           N* see comments
stimulating factor): human
glycoprotein
Gemcitabine hydrochloride                                                                                 Y


Genistein                          4',5,7-Trihydroxyflavone                                               Y



Gentamicin                         Garamicin, Genoptic, NSC-82261, RTECS-2625000                  N, see comments



Ghrelin (human)                                                                                   Y (status changed
                                   Amino acid sequence: Gly-Ser-Ser(O-n-octanoyl)-Phe-Leu-             03/07/08)
                                   Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-
                                   Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg
Ghrelin (rat)                      HG Secretagoue                                                 Y (status changed
                                                                                                       03/07/08)


Gliotoxin                                                                                         N* see comments
                                   Gliocladium fimbriatum toxin, Aspergillin, S. N. 12870
Glucagon-like Peptide              GLP-1                                                                  N

Glutaraldehyde                     Cidex                                                                  Y


Glutathione                        Glutide, Deltathione, GSH, Triptide                            N, see comments



Glutathione, Free-Acid                                                                                    Y

Glybenclamide                      Sulfonylurea, Glyburide, Euglucon, HB 419, UR 606, 5-          N* see comments
                                   Chloro-N-[4-(cyclohexylureidosulfonyl)phenethyl]-2-
                                   methoxybenzamide, glibenclamide
Glycerol                                                                                              N
                                1,2,3-Propanetriol, Glycerin
Glycine                         Aminoacetic acid, Glycolixir, Glycocoll                        N* see comments

Glycinergic Antagonists                                                                        N* see comments

Glycopyrrolate                  Glycopyrronium Bromide, Rubinol®, Pyrrolidinium                       N


Glycyrrhizin                    Glycyrrhizinic acid, 3-O-(2-O-β-D-Glucopyranuronosyl-α-D-      N* see comments
                                glucopyranuronosyl)-18β-glycyrrhetinic acid ammonium salt


GLYX 13                         Sequence:TPPT                                                         Y
                                (Modifications: Thr-4 = C-terminal amide)




GM6001                          Gallardin, Galardin, Ilomastat                                        Y




Go-7874                         Go-7874 Hydrochloride                                                 N




Gomori's Trichrome Solution     Trichrome Stain AB solution                                           N




Gonadotrpin releasing hormone   GnRH, Luitenizing factor-relaeasing hormone, Gn-RH                    Y




GS-459679                       novel apoptosis signaling kinase-1 (ASK1) inhibitor                   Y



GW6471                          PPARα antagonist; N-((2S)-2-(((1Z)-1-Methyl-3-oxo-3-(4-        N* see comments
                                (trifluoromethyl)phenyl)prop-1-enyl)amino)-3-(4-
                                (2-(5-methyl-2-phenyl-1,3-oxazol-4-
                                yl)ethoxy)phenyl)propyl)propanamide
Haloperidol                     4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-                  Y
                                fluorophenyl)-1-butanone, 4-[4-(4-Chlorophenyl)-4-
                                hydroxypiperidino]-4′-fluorobutyrophenone, Haldol, R
                                1625
Halothane                       Bromochlorotrofluoroethane, Chalotan, Fluorotane, 2-Bromo-2-   N, see comments/
                                chloro-1,1,1-trifluoroethane, Ethane, Narcotane                 other available
                                                                                                   information



Hank's Solution                 Balanced Salt Solution                                                N



HDAC6 inhibitors (novel                                                                               Y
compounds)
Heme Oxygenase - human             Heme-Oxygenase-2 human, HO-2 human                                 N* see comments



Heme Oxygenase - rat               HO-1, Heat Shock Protein 32 from rat , HSP32                                 N


Hemiasterlin                       Hemiasterlin A and B, Hemiasterlin BF65, HTI-286                             Y




Hemocon Chitosan Bandage®          Chitosan antigen                                                             N




Hemoglobin-based oxygen carriers   HBOCs, Hemapure®, Polyheme®                                                  N



Heparin                            Heparin sodium salt                                                          N



Heptachlor                         1,4,5,6,7,8,8-Heptachlor-3a,4,7,7a-tetrahydro-4,7-                           Y
                                   methanoindene


Heroin                             Acetomorphine                                                      N* see comments



Hespan®                            6% Hetastarch Solution                                                       N



Histidine                          1-a-amino-4(or 5) -imidazoleproprionic acid, D-histidine,                    N
                                   histine, (R)-2-Amino-3-(4-imidazolyl)propionic acid
HOE-140                            Bradykinin antagonist, D-Arg-[Hyp3, Thi5,8, D-Phe7]-                         Y
                                   Bradykinin



Hoechst 33258                      bisBenzimide H 33258, HOE 33258,2′-(4-Hydroxyphenyl)-5-(4-         N* see comments
                                   methyl-1-piperazinyl)-2,5′-bi(1H-benzimidazole)
                                   trihydrochloride, 2-[2-(4-Hydroxyphenyl)-6-benzimidazoyl]-6-(1-
Homocysteine thiolactone           DL-2-Amino-4-mercaptobutyric acid 1,4-thiolactone                            N
                                   hydrochloride
Human chorionic gonadotropin       Choriogonin, HCG, Choriogonadotropin alfa, Gonadex                Y*
                                                                                                          See comments
                                                                                                          (Column K) for
                                                                                                            instructions




Human Serum Albumin                HSA, HAS, Albumin from human serum                                     See comments
                                                                                                          (Column K) for
                                                                                                            instructions




Human Shock Protein                HSP 70, HSP110, Heat Shock Protein 27 human, and other                       N
                                   related human shock proteins.
Human sputum elastase              HSE                                                                          N

Hyaluronic Acid                    Poly(β-glucuronic acid-[1→3]-β-N-acetylglucosamine-                N* see comments
                                   [1→4]), alternating
Hydrazine                   Diamine, Diamide, Phenylhydrazine                                         Y


Hydrochloric acid           Muriatic acid                                                      N* see comments


Hydrochlorothiazide         6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide              N*
                            1,1-dioxide, 6-Chloro-7-sulfamyl-3,4-dihydro-1,2,4-
                            benzothiadiazine 1,1-dioxide

Hydrocortisone              11beta ,17alpha ,21-Trihydroxypregn-4-ene-3,20-dione; 17-                 N*
                            Hydroxycorticosterone; 4-Pregnene-11beta ,17alpha ,21-triol-
                            3,20-dione; Cortisol; Kendall’s compound F; Reichstein’s
                            substance M

Hydroxyethyl starch         Essex 1360, Hespander                                                     N*




IBMECA                      7-Deaza-7-carbamoyladenosine hydrate, MECA,                               Y
                            Sangivamycin hydrate, and related compounds, IB-MECA




Ibotenic acid               a-amino-3-hydroxy-5-isoxazoleacetic acid, Ibotenatic acid,         N* see comments
                            Pramuscimol
ICI 204,448 Hydrochloride   (±)-1-[2,3-(Dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-             N* see comments
                            methylethyl)amino]-2-butanolhydrochloride
                            R,S-[3-[1-[[(3,4-Dichlorophenyl)acetyl]methylamino]-2-(1-
                            pyrrolidinyl)ethyl] phenoxy]-acetic acidhydrochloride

Ifenprodil                  α-(4-Hydroxyphenyl)-β-methyl-4-benzyl-1-                           N* see comments
                            piperidineethanol tartrate salt
IKK-2                       I kappa B kinase 2 inhibitor, TCPA-1                                      Y



IL-1beta, Human             Interleukin-1b, Precursor IL-1B, Human interleukin, Human        See Comments (status
                            interleukin fragments                                              changed 11/10/08)




IL-1beta, mouse             Mouse Interleukin-1b, Precursor IL-1B,Mouse                               N*




Imatinib Mesylate           Gleevec®                                                                  Y



Imiloxan                    RS 21361, 2-[(2,3-dihydro-1,4-benzodioxin-2yl)methyl]-1-ethyl-            Y
                            1h-imidazole
Imipramine                  Imipramine-N-oxide hydrochloride, imidol, NSC-114900                      Y



Immunoglobulin E            IgE, Mononclonal Anti-human IgE antibody. Derived form                    N
                            various sources

Inactin® sodium salt        Thiobutabarbital sodium salt hydrate                                      N

INCB008765                  Cyclohexyl pyrrolidine carboxylate derivative that is an                  Y
                            ADAM10 inhibitor
Incomplete Freund's Adjuvant         IFA, FIA                                                                 N

Indinavir sulfate                    Crixivan®                                                                N*

Indomethacin                         Anthracin, Indocin™, Confortid™, Metacen, Indomed,                       Y
                                     Methazine, 1-(P-chlorobenzoyl)-5-methoxy-2-methylindole-3-
                                     acetic acid
Inosine 5' monophosphate             Inosinic acid, IMP                                                       N

Interferon alpha 2a, 2b, N1, N3                                                                               Y

Interferon beta 1A human,            INFb                                                                     N
recombinant
Interferon beta, recombinant mouse   INFb                                                                     N

Intralipid                                                                                                    N



in vivo-jet PEI™                     Polyethyleneimine in water                                        N* see comments

Ionomycin                            Streptomyces conglobatus-derived , Ionamycin                      N* see comments


Iressa                               Gefiitinib, 4-Quinozolinamine                                            Y




Irinotecan                           SN-38, Camptosar                                                         Y



Iso-E-Super                          Isocyclemone E                                                           N



Isoflurane                           Ethane, Furane, Methylmethane                                     N, see comments/
                                                                                                        other available
                                                                                                           information



Isoproterenol                        (−)-Isoprenaline hydrochloride, (−)-N-Isopropyl-L-noradrenaline          N*
                                     hydrochloride, (R)-3,4-Dihydroxy-α-
                                     (isopropylaminomethyl)benzyl alcohol hydrochloride
Isothiourea                          Pseudothiourea, Thiocarbamate, Thiocarbamide, THU                        Y




JDTic                                (3R)-7-Hydroxy-N-[(1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-              Y
                                     dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-1,2,3,4-
                                     tetrahydro-3-isoquinoline-carboxamide



JG-03-14                             3,5-dibromo-4-(3,4-dimethoxyphenyl)-1H-pyrrole-2-carboxylic              Y
                                     acid ethyl ester


JTE-013                              S1P2 antagonist                                                   N* see comments
                                                                                                        (status changed
                                                                                                            07/08/08)
Kainic acid monohydrate     2-Carboxy-3-carboxymethyl-4-isopropenylpyrrolidine,                     N*
                            Digenic acid



Kanamycin                   Cantrex, Kanamycin A, Kantrex, KM.                               N, see comments/
                                                                                              other available
                                                                                                 information



KB-R7785                    [4-(N-Hdroxyamino)-2(R)-isobutyl-3(S)-methylsuccinyl]-L-                Y
                            phenylglycine-N-methylamide


Ketamine                    Cytohexanone hydrochloride, CI 581, (±)-2-(2-Chlorophenyl)-2-           N
                            (methylamino) cyclohexanone hydrochloride


Ketoconazole                                                                                        N*




Ketoprofen                  Orudis, Oruvail, Propionic acid, Aneol, Capisten, Epatec,               N*
                            Ketoprofene, Dexal, Ketofen, Profenid, Keduril, etc.
Keyhole Limpet Hemocyanin   Megathura crenulata, 2,4,6 trinitrophenyl hapten, TNP-KLH               N



KN-93                                                                                               N



Kreb-Henseleit Solution     propenyl]methylamino]methyl]phenyl]-N-(2-hydroxyethyl)-4′-              N




KT-5720                     methoxybenzenesulfonamidephosphate salt, kt5720                         N


KT-5823                     N-[2-[N-(4-Chlorocinnamyl)-N-methylaminomethyl]phenyl]-N-,              N
                            kt5823

KU-60019                    (2-hydroxyethyl)-4-methoxybenzenesulfonamidephosphate salt              Y



KW-2449                     A novel multikinase inhibitor of FLT3, ABL, ABL-T315I, and              Y
                            Aurora kinase

L-163,255                   Spiropiperidine GH secretagogue.                                        Y




L-655, 708                  Ethyl (S)-11,12,13,13a-Tetrahydro-7-methoxy-9-oxo-9H-            N* see comments
                            imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylate,
                            Imidazobenzodiazepine



L-701, 324                  7-chloro-4-hydroxy-3-(3-phenoxyl)-phenylquinolin-2-[1H]-one             N

L-arginine                  Arginine                                                                N
L-deprenyl HCL         R )-(−)-N,α-Dimethyl-N-(2-propynyl)phenethylamine                    N*
                       hydrochloride, Selegiline hydrochloride, Eldepryl
LBH589                 Cinnamic hydroxamic,                                                  Y



Lactobionic Acid       4-0-B-D-Galactopyranosyl-D-gluconic Acid                              N

Lamivudine             3T3, 2', 3'-dideoxy-3'-thiacytidine, Epivir®; 3TD; 3TC                Y


Lamotrigine                                                                                 N*


Lapatinib ditosylate   Tykerb®, Tyverb®, GW 572016                                           Y




Lead acetate           Lead acetate TS                                                       Y

Leflunomide            5-methylisooxazole-4-(4-trifluoromethyl) carboxanilide, HWA-          Y
                       486
Leucine                D-Leucine, R-Leucine                                                  N



Levetiracetam          Keppra®                                                               N



Levorphanol            Levorphan, Levo-dromoran                                       N* see comments



Limonene               Carvene; (+)-p-Mentha-1,8-diene                                      N*



Lipiodol               Ethiodol iodized oil                                                  N



Lipopolysaccharide     LPS, Lipopolysacharides, Endotoxin, Lipid A                     Y, see comment



Lithium Chloride                                                                            N*



Lisinopril®            MK 521/522, Prinivil, Zestril®                                        N




l-Methadone            Levomethadone                                                  N* see comments

L-NAME                 N-Omega L-Arginine methyl ester, Nω-Nitro-L-arginine methyl           N
                       ester hydrochloride, nitroarginine


L-nil                  L-Lysine ω-acetamidine hydrochloride, L-NIL hydrochloride      N* see comments




L-NNA                  Nϖ-Nitro-L-arginine, NG-NO2-L-Arg, Nitro-L-arginine, N5-              N
                       (Nitroamidino)-L-2,5-diaminopentanoic acid
Lopinavir                     Kaletra                                                         N* see comments


Lorazepam                                                                                           N


Losartan Potassium            2-Butyl-4-chloro-1-{[2′-(1H- tetrazol-5-yl)(1,1'-biphenyl)-4-         N
                              yl]methyl}-1H -imidazole-5-methanol monopotassium salt


Lovastatin                    Mevinolin, MK-803                                               N* see comments



Lupeol                                                                                        N* see comments



Lutetium                      Lu                                                                    N

LY-294,002 hydrochloride      LY294002                                                              N

LY367385                      (S)-(+)-a-Amino-4-carboxy-2-methylbenzeneacetic acid                  Y




LY379268                      (1R,4R,5S,6R)-4-amino-2-oxabicyclo[3.1.0] hexane-4,6-                 Y
                              dicarboylic acid


Lymphopoietin 1               IL-7                                                                  Y



Lysophosphatidic acid         1-Oleoyl-sn -glycerol 3-phosphate sodium salt, 1-oleoyl               N
                              sodium salt


Mafenide                      Marfanil; 4-Aminomethylbenzenesulfonamide                             N
                              hydrochloride; 4-Homosulfanilamide
MAG1                          3-methyladenine DNA glcosylase, Methylpurine DNA                      N
                              glycosylase, 3MEA DNA glycosylase, YER142C


Maleic vinyl ether            Maleic Anhydride;2,5-Furandione; Polymer With                         N
                              Methoxyethene; Maleic Anhydride; Methylvinyl Ether
                              Copolymer
Mannitol                      D-Mannitol, Mannite                                                   N



Marcaine                                                                                            N
                              Bupivacaine
Masson's Trichrome Solution   Trichrome stain LG solution                                           N


MCPG                                                                                                N


mCPP                          1-m-chlorophenylpiperazine, 1-(3-Chlorophenyl)piperazine              N
                              hydrochloride
mCPBG                             1-(M-chlorophenyl)-biguanide HCL, N-(3-chlorophenyl)                N
                                  imidodicarbonimidic diamide monohydrochloride


MCPP                              Methoxone, 4-Chloro-2-methylphenoxyacetic acid, 4-Chloro-o-         Y
                                  tolyloxyacetic acid,




MD-354                            m-chlorophenylguanidine, N-(3-chlorophenyl) guanadine               N


MDL-28170                         Calpain Inhibitor III                                               N


Mecamylamine                      Versamine®, Inversine®                                              N



Medetomidine                      Domitor®, Precedex®                                                 Y


Mefloquine                        (AS)-rel-a-(2R)-2-peperidinyl-2,8-bis(trifluoromethyl)-4-           N
                                  quinolinemethanol monohydrochloride




Melphalan                         4-[Bis(2-chloroethyl)amino]-L-phenylalanine, L-PAM,                 Y
                                   L-Phenylalanine mustard




Memantine                                                                                       N* see comments


MEN 10,376                                                                                            Y




Menadione                         2-Methyl-1,4-naphthoquinone, Vitamin K3                       N* see comments




Mercury chloride                  Mercuric chloride                                                   Y




Metabotropic Glutamate Receptor   L-PAM                                                               N
(mGlur)

Metacam                           Metacam sodium salt hydrate, Mobec sodium salt                      N*
                                  hydrate, UH-AC 62XX sodium salt hydrate, 4-Hydroxy-2-
                                  methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-
                                  carboxamide 1,1-dioxide sodium hydrate
Metformin                           Metaformin, 1,1-Dimethylbiguanide hydrochloride                     N




Metoprolol                          (±)1-(Isopropylamino)-3-[p-(β-methoxyethyl)phenoxy]-2-     N* see comments
                                    propanol tartrate salt, lopressor

Methcathinone                       1-Propanone, 2-(methylamino)-1-phenyl-, hydrochloride,              N
                                    dl-Ephedrone hydrochloride
Methionine                          (R )-2-Amino-4-(methylmercapto)butyric acid                         N


Methotrexate                                                                                            Y

Methoxyflurane                                                                                          N


Methoxyverapamil                    Benzeneacetonitrile                                                 N



Methyl atropine bromide                                                                       *N
                                                                                                   see comments

                                    L-Phenylalanine mustard
Methyl blues, Methylene blue dyes   Swiss blue, Nile blue, Basic blues, tetramethylthionine   *N
                                    chloride, Coomassie blue, other related dyes.                  see comments



Methyl Ethyl Ketone                 MEK, 2-butanone                                            N* see comments

Methylcellulose                                                                                         N

Methylscopolamine bromide           Hyoscine methyl bromide, Scopalamine methyl bromide                N*



Scopolamine Methyl Nitrate          Methylscopolamine nitrate, Mescomine, Skopyl,                      N*
                                    Skopolate, Viscope

Metofane                            Methoflurane, Methoxyfluorane, , Methoxane, Pentran,       N* see comments
                                    Pentrane, Inhalan

Metoprolol                          Lopressor, (±)1-(Isopropylamino)-3-[p-(β-                          N*
                                    methoxyethyl)phenoxy]-2-propanol (+)-tartrate salt

Midazolam                           8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-                   N* see comments
                                    imidazo[1,5a][1,4]benzodiazepine hydrochloride; include
                                    Triazolam, Xanax, and other benzodiazepine agents.

Mifepristone                        RU-38486, RU-486                                                    Y



Minocycline                         Tri-minocycline, Tri-mino, Minocin, Minocyn, Minocyne      N* see comments




Mirex                               Perchloropentacyclodecane                                           Y




Mitoxantrone                        Mitoxanthrone Dihydrochloride, DHAQ                                 Y
MK-0518                             Isentress, Raltegrvir                                          N* see comments



MK 571                              L-660711, 5-(3-(2-(7-Chloroquinolin-2-yl)ethenyl)phenyl)-8-          N
                                    dimethylcarbamyl-4,6-dithiaoctanoic
                                    acidsodium salthydrate
MK-801                              MK-801 hydrogen maleate                                              N

MNU                                 1-methyl-1-nitrourea, N-Methyl-N-nitrosourea, ISOPAC®                Y



MOG 35-55                           Myelin oligodendrite glycoprotein 35-55, MOG peptide (35-55)         Y


Monoacylglycerol lipase inhibitor   MAGL, JZL-184, URB602, URB 602                                       N*

Monoiodoacetate                     Iodoacetic acid                                                      Y

Morphine                            Morphia                                                        N* see comments


Morphine methylbromide/Morphine                                                                    N* see comments
methylsulfonate
Mouse Granulocyte/Macrophage        GM-CSF                                                               N
Colony Stimulating Factor
MPEP                                6-methy-2-(phenylethynyl) pyridine, MS 435                           N
MPL                                 Monophosphoryl lipid A                                               N*
MPMQ                                MPMQ hydrochloride                                                   Y




MPTP                                1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine                         Y




MRS1191                             3-ethyl 5-benzyl-2-methyl-6-phenyl-4-phenylethynyl-1,4-              N
                                    (±)-dihydropyridine-3,5-dicarboxylate
Muscimol                            5-aminomethyl-3-isoxyzole, agarin                                    Y

Mycophenolic Acid                   MPA, Melbex, Myfortic™, Mycophenolate compounds                      Y



N-acetylserotonin                   Normelatonin, N-Acetyl-5-hydroxytryptamine                           N



N-butylpyridinium chloride                                                                               Y




N,N-butylmethylpyrrolidinium                                                                             Y
chloride

NMDA                                N-Methyl-D-aspartic acid                                             N



N,N Dimethylsphingosine             SphK1 Inhibitor, N,N Dimethyl-D-erythro-sphingosine,                 Y
                                    Sphk 1 phosphate, SK1-I, sphingosine kinase inhibitor

N-Formylmethionyl-leucyl-           fMLP, fMLF, N-Formyl-Met-Leu-Phe, N-Formyl-L-                        N
phenylalanine                       Methionyl-L-Leucyl-L-Phenylalanine
N-nitrosodiethylamine               Diethylnitrosamine, Ethanamine, Ethylamine                           Y
Nalbuphine hydrochloride                17-(Cyclobutylmethyl)-4, 5; Alpha-Epoxymorphinan-3, 6                 N*
                                        Alpha, 14-Triol Hydrochloride; Nubain; n-
                                        Cyclobutylmethyl-14-hydroxydihydronomorphine
Naloxone, Naloxone Hydrochloride        hydrochloride
                                        Narcan, I-Naloxone                                                     N


Naltrexone                              Trexan®, Vivitrol®                                                     Y




Naltrindole hydrochloride                                                                                      N




Nandrolone decanoate                    Deca-Durabolin, Deca,                                                  Y




Nanoparticles                                                                                                  Y



NaHS                                                                                                          N*

NBMPR                                   6-(nitrobenzyl mercaptan) purine ribonucleoside, Related               N
                                        nitrobenzyl mercaptan and nitrophenyl mercaptan compounds.

NBQX                                    1,2,3,4-Tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-              N
                                        7-sulfonamide disodium salt
Nelfinavir                              Viracept®                                                              N

Nembutal                                                                                             N* see comments




Neomycin, and cohorts (Neomycin                                                                                N
A, B, C, others)                        FG 9202 disodium salt
Neostigmine methylsulfate                                                                            N
(injection)                                                                                              (see comments)

Neramexane                                                                                                     Y


                                        N-methyl-aspartate antagonist
Neurokinin A                                                                                                   Y




Nevirapine                                                                                                     N
                                    Viramune
Nicotine and nicotine compounds     Nicotine free-base, Black leaf, Nicotine hemisulfate 40%                   Y
LD50 ≤ 50 mg/kg rat oral     LD50 < aqueous solution, Nicotine sulfate, dl-
200 mg/kg rabbit skin               tetrahydronicotyrine, N'-nitrosonornicotine, Nicotine 1'-
                                    nitroso-1'-demethyl, (-)-nicotine, l-nicotine, 1-methyl-2-(3-
                                    pyridyl) pyrrolidine
Nicotine compounds           LD50 > Nicotine tartrate, Nicotine hydrogen tartrate, Nornicotine,      N* see comments
50 mg/kg rat oral or     LD50 > 200 Nicotinamide, Pestanal, Nicotine toluoyltartrate, Nicotine
mg/kg rabbit skin                   chloride, Nicotine dihydrochloride, Nicotine trihydrate,
                                    Benicot, Aminocotin, Niacinamide, Nicotine
                                    Monosalicylate, Oxynicotine, Nicotine-N'-oxide
Nifedipine                  Adalat, Bay 1040, Cordipin, Nifedin, Procardia™                   Y




Nimopidine                  1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-            N* see comments
                            pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl
                            ester

NIP-LPS                     4-Hydroxy-3-iodo-5-nitrophenylacetyl Lipopolysaccharide           Y




Niprisan                    Nix-0699, Hemoxin®                                                N




Nisoxetine hydrochloride    LY-94,939, (±)-γ-(2-Methoxyphenoxy)-N-                            N
                            methylbenzenepropanaminehydrochloride

Nitric Acid                 Aqua fortis, Azotic acid                                   N* see comments

Nitroglycerin               Nitrostat                                                  N*/Y see comments


Nitrous Oxide               Nitrogen Oxide                                              N* see comments




N-Methyl-D-aspartate        NMDA R1                                                           N




Nocodazole                  Oncadozole, NSC 238 159, R 17934, Carbamic Acid                   Y




Nor-BNI                     Norbinaltorphimine Dihydrochloride                                N


Norepinephrine              (R )-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol,                  Y
                            Levarterenol, L-Arterenol, L-Noradrenaline


Norfloxacin                 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-           Y
                            quinolinecarboxylic acid
Norketamine hydrochloride   2-Amino-2-(2-chlorophenyl)cyclohexanone hydrochloride

N-palmoylated serinol       C16-serinol                                                       Y




NS-102                      6,7,8,9-Tetrahydro-5-nitro-1H-benz[g]indole-2,3-dione 3-    N* see comments
                            oxime
Nuflor®                     Florafenicol, Floramphenicol                                N* see comments
NVP-AAM077                NVP-AAM077 tetrasodium hydrate, [[[(1S)-1-(4-                     N* see comments
                          Bromophenyl)ethyl]amino](1,2,3,4-tetrahydro-2,3-dioxo-5-
                          quinoxalinyl)methyl] phosphonic acid tetrasodium hydrate

o-Cresol                  2-Methylphenol                                                          Y

Obatoclax                 GX15-070                                                                Y




Obestatin                                                                                         N




Octenidine salt           Octenidine dihydrochloride                                              N*


ODQ                       1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one                             N*

Ofloxacin                 DL-8280, HOE 280, Oflocet, Ofloxacine                                   Y

O-hydroxy-cis-terpenone   O-HCT                                                                   Y

Okadaic acid              9,10-deepithio-9,10-didehydoracanthafolicin, Acanthafolicin             Y



OL-135                    Novel FAAH inhibitor                                                    Y



Olanzapine                Zyprexa                                                           N* see comments

Ondansetron               Zofran, Ondansetron hydrochloride dihydrate                       N* see comments

OSU03012                  PDK-1 inhibitor, 2-amino-N-[4-[5-(2-phenanthrenyl)-3-                   Y
                          (trifluoromethyl)-1H-pyrazol -1-yl]phenyl]-acetamide
Ovalbumin-aluminum        OVA/alum, Ovalbumin                                               N* see comments



Oxaliplatin               [SP-4-2-(1R-trans)]-(1,2-Cyclohexanediamine-                            N*
                          N,N)[ethanedioata(2- -)-O,O']platinum

Oxychlordane              1,2-epoxy-2,3,4,5,6,7,8,8-octachloro-2,3,4,5,6,7-hexahydro,4            Y



Oxycyte™                  Tert-butyl perfluorocyclohexane, "artificial blood", Hemopure®,         N
                          Polyheme®
Oxyntomodulin                                                                               N* see comments




Oxyphor G-2®              Pd-tetra-(4-carboxyphenyl) tertrabenzoporphyrin dendrimer               N

Palladium Porphyrin       Pd-porphyrin, Pd porphyrin, dye                                         N

Palmitoylisopropylamide   PIA                                                                     N
Pancuronium bromide                       Pancronium, Pavulon                                             N* see comments



Paracetamol                               4-Acetamidophenol sulfate ester potassium salt,                 N* see comments
                                          Paracetamol sulfate potassium salt

60:12:28 paraffin oil: polysorbate 80:                                                                           N
water
Paraoxon                                                                                                         Y



Paraquat                                  1,1′-Dimethyl-4,4′-bipyridinium dichloride hydrate,                    Y
                                          Gramoxone, Methyl viologen dichloride, Paraquat
                                          dichloride




Parathion                                 Parathion-ethyl; Ethylparathione; PESTANAL®; O,O-                      Y
                                          Diethyl O-(4-nitrophenyl) phosphorothioate

Parthenolide                              Sesquiterpene lactone.                                                 Y




PCB 99                                    2,2',4,4',5-Pentachlorobiphenyl                                        Y



PCB 118                                   2,3',4,4',5-Pentachlorobiphenyl                                        Y


PCB 138                                   2,2',3,4,4',5'-Hexachlorobiphenyl                                      Y



PCB 153                                   2,2',4,4',5,5'-Hexachlorobiphenyl                                      Y



PCB 180                                   2,2',3,4,4',5,5'-Heptachlorobiphenyl                                   Y




PCP                                       Elysion, Phencyclidine, Phenylcyclidine Hydrochloride, CL-395   N* see comments




PD184352                                  MEK1/2 inhibitor, MKK 1 inhibitor, PDK-1                               Y




PD98059                                                                                                   N* see comments
                                                                                                          (revised 010808)
                                          PD98,059, Pyridinyl imidazole inhibitor PD98059, 2-(2-
                                          Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
PDK-1                                                                                                            Y



                                    3-Phosphoinositide-dependent kinase
Penicillin G and related compounds, Penicilin streptomycin, Penicillinase from Bacillis cereus,           N* see comments
no confirmed chronic hazards        Amoxicillin, Cefazolin salt [Kefzol], Ampicillin, Valine,
                                          Distamine, Penicillamine hydrochloride
Penicillins with confirmed chronic      Penicillin V, d-penicillamine, Phenoxymethylpenicillic acid,               Y
hazards (mutagenic, teratogenic         Potassium penicillin V
and/or reproductive toxin properties)


Pentazocine                                                                                                        N


Pentobarbitol                           5-ethyl-5-pentobarbituric acid                                             N




Pentoxifylline                          3,7-Dimethyl-1-(5-oxohexyl)xanthine, Trental,                              Y
                                        Pentoxiphyllium, Vasofirin


Pentylenetetrazole                      Metrazole                                                                  N*




Perchlorate                                                                                                        N


Perfluorocarbon emulsions                                                                                          N




Perfluorodecanoic acid                  PFDA,Nonadecafluorocapric acid,                                            Y
                                        Nonadecafluorodecanoic acid, Perfluorocapric acid
Perfluoropropane                        Perfluoropropene, Hexafluoropropene                                        N




Perifosine                              D-21266, KRX-0401                                                          Y




Peroxidase from Horseradish             Horseradish peroxidase                                               N* see comments




Peroxisome proliferated-activated       PPAR                                                                       Y
receptor agents (ie: MK886)



Perphenazine                            2-Chloro-10-3-(1-(2-hydroxyethyl)-4-piperazinyl)pr                         Y
                                        opyl phenothiazine *4-(3-(2-Chlorophenothiazin-10-yl)propyl)-1-
                                        piperaz ineethanol * Decentan * Etaperazin * Etaperazine*
                                        Ethaperazine * Fentazin *1-(2-Hydroxyethyl)-4-(3-(2-chloro-10-
                                        phenothiazinyl)propyl)piperazine *gamma-(4-
                                        (betaHydroxyethyl)piperazin-1-yl)propyl-2 chlorophenothiazine
                                        * 1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina
                                        (Italian) * Perfenazina (Italian)
                                        * Perphenazin * Perphenazine * Trifaron * Trilafon


Pertussis Toxin                                                                                                    Y


PF-3845                                 N-​(pyridin-​3-​yl)-​4-​(3-​(5-​(trifluoromethyl)pyridin-​2-         N* see comments
                                        ​yloxy)benzyl)piperdine-​1-​carboxamide
Phalloidin                              Amanita phalloides toxin, Phalloidine                                      Y
Phenobarbital                         PHNO                                                                N


Phentolamine                          Phentolamine mesylate                                              N*


Phenylalkylamine                      Verapamil, Isoptin®, Vasomil®, Verelan®, Calan®              N* see comments

Phenylephrine                         Adrianol, Benzenemethanol, Fenox, Isophrine hydrochloride,   No, see comments
                                      NCI-55641

Phenylhydrazine                       Monohydrochloride (9CI), Phenylhydrazine Hydrochloride              Y




Phenylpropanolamines                  Norephedrine compounds                                              N
Phenylquinone                         PPQ, Phenyl-p-benzoquinone, P-phenyl-quinone                        Y

Phenyltropane analogs                 D-CPT tartrate                                                      N



Phenytoin                             Dilantin, 5,5-Diphenylhydantoin, DPH, Phentoin, Fentoin,     Y (see comments)
                                      Euthasol (see comments)




PHMB                                  Poly(hexamethylene biguanide hydrochloride)                         N


Phorbol Esters                        Include entire class                                                Y




Phorbol-12-myristate 13 acetate       PMA, TPA                                                            Y




Phosphoinositide-3-kinase inhibitor   PI3K inhibitor, TG100-115                                    N* see comments




Phospho-FTY720                                                                                            Y




PIA                                   R )-N6-(1-Methyl-2-phenylethyl) adenosine, (−)-N6-(2-        N* see comments
                                      Phenylisopropyl)adenosine

Pilocarpine hydrochloride             (3S ,4R )-4,5-Dihydro-3-ethyl-4-(1-methyl-1H -imidazol-5-    N* see comments
                                      ylmethyl)-2(3H )-furanone hydrochloride, almocarpine, MI-
                                      Pilo, Pilocar, Pilocel, Pilocarpine hydrochloride.
Pilocarpine nitrate                   Pilofrin, Pilocarpine nitrate salt                           N* see comments
Pimonidazole                                                                                                  Y




Pimozide                                                                                                      N*



Pinacidil                             2-cyano-3-(4-pyridyl-1-(1,2, 3 trimethyl-propyl) guanidine, P           N
                                      1134.




Piroxicam                             feldene, CP-16171, pyroxicam                                            N

PJ34                                  N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)-(N,N-                           N
                                      dimethylamino)acetamide hydrochloride

Poloxamer 188                         Pluronic F68                                                            N
Poly Ethylene Vinyl Chloride          EVOH                                                                    N
Polyalkylsulfonate                    1_Heptanesulfonic acid sodium salt, Sodium alkylsulfonate               N
                                      surfactant
Polyamidoamine dendrimer G4.5         PAMAM                                                                   N*



Polycaprolactane                      PCL                                                                     N

Polydioxanone                         PDS                                                                     N

Polyethylene Glycol - Superoxide      PEG-SOD                                                           N* see comments
Dismutase
Polyethylene Glycol Human             Hemospan'; MalPEG-Hb; Lactated Ringer's Solution                  N* see comments
Hemoglobin Conjugate
Polyglycolic Acid                     PGA                                                                     N
Polyhexadine salt                      Kerlix AMD; Polyhexamethylene Biguanide Water                          N
Polyinosinic acid : polycytidylic acid pI : pC, Poly C Poly I                                                 Y

Polylactic Acid                       PLA                                                                     N

Polymyxin B, other polymyxins (1, A, Aeromycin                                                          N* see comments
B1)
Polystyrene sulfonate                 Poly(sodium 4-styrenesulfonate); Poly(4-styrenesulfonic acid)           N
                                      sodium salt

Polytetrafluoroethylene               PTFE                                                                    N



Potassium                             bpV                                                                     Y
Bisperoxo(bipyridine)oxovanadate

Potassium chloride                    KCl                                                                     N


Porcine serum                                                                                                 N


PP2 (Protein Tyrosine Kinase          4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine         N
Inhibitor)

PPADS                                 PPADS tetrasodium salt hydrate, 4-[[4-Formyl-5-hydroxy-6-               N
                                      methyl-3-[(phosphonooxy)methyl]-2-pyridinyl]azo]-1,3-
                                      benzenedisulfonic acid tetrasodium salt
Pralidoxime iodide          2-PAM, 2-PAM iodide, 2-Pyridinealdoxime methiodide                    N*



Pramipexole                 pramipexole dihydrochloride, ®Mirapex                                 N*



Prednisone                  Cortan, Delta-cortisone, Zenadrid                               N* see comments


Pregnant mare's serum       PMS, PMSG, Equin gonadotropin, Anteron, Serogonin,              N* see comments
                            Serogan, eCG

Pristane                    2,6,10,14 tetramethylpentadecane                                N* see comments


Probenecid                  p -(Dipropylsulfamoyl)benzoic acid                              N* see comments



Progesterone                4-pregnene-3, 20-dione                                                Y



Prolyl-4-hydroxylase        P4HA2                                                                 N


Propofol                    Diprivan®, Rapinovet®, Diisopropylphenol                        N* see comments


Propylene glycol            1,2-Propanediol                                                       N


Prostacyclin                Prostaglandin I2, 5Z,9α,11α,13E,15S)-6,9-Epoxy-11,15-                 N
                            dihydroxyprosta-5,13-dien-1-oic acid sodium salt
Prostaglandin E2            (5Z,11α,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic             Y
                            acid, 5-Heptanoic Acid, PGE2, 1-PGE2, Prostin, Prostin E2, U-
                            12062, Dinoprostone
Protandim®                                                                                        N




Protease Type VIV           Fungal, bacterial, and bovine sources: alcalase, Bioprase,      N* see comments
                            Maxatase.



PS-1145 dihydrochloride     N-(6-Chloro-9H-pyrido[3,4-b]indol-8-yl)-3-                            N
                            pyridinecarboxamide dihydrochloride


Pseudoephedrine             (1S,2S)-2-Methylamino-1-phenyl-1-propanol                             N


PSS                         Poly(2,3-dihydrothieno-1,4-dioxin)-poly(styrenesulfonate)             N
                            ; PEDOT; Poly(3,4-ethylenedioxythiophene)-
                            poy(styrenesulfonate)
PT-1                        2-Chloro-5-[[5-[[5-(4,5-Dimethyl-2-nitrophenyl)-2-                    Y
                            furanyl]methylene]-4,5-dihydro-4-oxo-2-
                            thiazolyl]amino]benzoic acid
Puromycin dihydrochloride   3'-[α-Amino-p-methoxyhydrocinnamamido]-3'-deoxy-N,N-            N* see comments
                            dimethyladenosine dihydrochloride
PXD101                      N-hydroxy-3-[3-{(phenylamino) sulfonyl} phenyl]-2-propenamide         Y
Pyridostigmine bromide               3-(Dimethylaminocarbonyloxy)-1-methylpyridinium bromide                   Y




Pyridoxine                           NADPH oxidase inhibitor                                             N* see comments




Pyrrolidine-1                        cPLA2 inhibitor                                                           Y


Pyrrolidinediethyl-dithiocarbamate   Ammonium pyrrolidinediethyl-dithiocarbamate, PDTC                         Y




Pyrrophenone                                                                                                   N



PYY                                  Peptide YY3-36                                                            N


Quantum dots (novel compound)                                                                                  Y


Quercetin                            Quercetin hydrate, Quercetin dihydrate                                    N*

Quetiapine                           Seroquel® (AstraZeneca)                                                   N*

Quinapril hydrochloride              (3S)-2-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-                         N* see comments
                                     phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-
                                     isoquinolinecarboxylic acid hydrochloride
Quinine                                                                                                        N*



Quinpirole HCL                       trans -(–)-(4aR)-4,4a,5,6,7,8,8a,9-Octahydro-5-propyl-1H-           N* see comments
                                     pyrazolo[3,4-g]quinoline monohydrochloride, LY 171555




Raclopride                           3,5-Dichloro-N-(1-ethylpyrrolidin-2-ylmethyl)-2-hydroxy-6-                N*
                                     methoxybenzamide (+)-tartrate salt


Radicicol                            Monorden, [1aS-(1aR*,2Z,4E,14*,15aR*)]-8-Chloro-                          Y
                                     1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-6H-
                                     oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione

Raffinose                            d-raffinose, D-(+)-raffinose pentahydrate, Melitose, Melitriose     N* see comments




Ranitidine Hydrochloride             N-[2-[[5-[(Dimethylamino)methyl]furfuryl]thio]ethyl]-n'-methyl-2-   N* see comments
                                     nitrovinylidenediamine hydrochloride
Ranolazine                   Ranolazine dihydrochloride; N-(2,6-Dimethylphenyl)-4-[2-              N
                             hydroxy-3-(2-methoxyphenoxy)propyl]-1-
                             piperazineacetamidedihydrochloride (±) -4-[2-hydroxy-3-(o-
                             methoxyphenoxy)propyl]-1-piperazineaceto-2′,6′-
                             xylididedihydrochloride
Rapamycin                    AY 22989, NSC 226080, Sirolimus                                 N* see comments

Refanalin                    Small Molecule HGF Mimetic                                            Y



Remifentanil hydrochloride   Ultiva'; 'Arcod'                                                      N


Resinferatoxin               Toxin from Euphorbia poisonii                                         N*




Resveratrol                  3,5,4'-trihydroxystilbene, 3,4',5-trihydroxy-trans-stilbene,          N
                             Reservatrol (commonly misspelled)



Retrorsine                   12,18-Dihydroxysenecionan-11,16-dione Beta-Longilobine                Y

Rhodamine GC                 Include all rhodamine dyes: Basic Red 1, RhGC, Fanal Red,       N* see comments
                             Tetraethylrhodamine, others
Ribose                       d-Ribose                                                              Y



Rimonabant                   Acomplia®, Zimulti®, SR141716A                                  N* see comments




Ringer's Solution            Lactated Ringer's Solution                                            N




Riociguat                    BAY 63-2521                                                           Y


Risperidone                  Risperdal®                                                      N* see comments

Ritonavir                    Norvir, Kaletra (with lopinavir)                                      N*

Ro 25,5881                                                                                         Y


Ro 25,6981                   (αR,βS)-α-(4-Hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-              Y
                             piperidinepropanol maleate

Rocephin                     Ceftriaxone disodium salt, Ceftriaxonesodium crude                    N



Rolipram                     4-(3-(cyclopentyloxy)-4-methophenyl-2-pyrrolidinone, ZK 62711         N

Rocuronium Bromide                                                                                 N*

Roscovitine                  2-(R )-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-                Y
                             purin-2-yl]amino]-1-butanol


Rosiglitazone                Avandia, thiazolidinedione                                      N* see comments
RTI-113        dopamine-selective uptake inhibitor; 3β-(4-                            Y
               chlorophenyl)tropane-2β-carboxylic acid phenyl ester
               hydrochloride]


Rubinium       Rb                                                                     N


Ruthenium      Ru                                                                     N



Rutin          Rutin Hydrate, Eldrin, Rutinic acid, Melin, Birutan, Vitamin P   N* see comments


RX-10045       Resolvin E2 analog, synthetic resolvin                                 N*


Ryanodine      9,21 didehydroryanodine                                                N


S3I-201        NSC 74859, Stat3 Inhibitor VI                                          Y


Saccharin      2,3-Dihydroxy-1,2-benzisothiazol-3-one-1,1-dioxide, 2-                 N
               Sulfobenzoic acid imide, o-Benzoic sulfimide

Saffan         Alfadione, Alphadione, Alphathesin, CT-1341, alfaxan,            N* see comments
               alphaxalone, propofol

SAHA           Histone Deacetylases, Suberloanilide, Vorinostat, Zolinza®,            Y
               Suberoylanilide hydroxamic acid




Salvinorin A   U69, 593                                                               N




Saquinavir     Saquinovir, Fortovase®, Invirase®                                      N



SB202190       4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-               N
               imidazole


SB203580                                                                              N
               Pyridinyl imidazole inhibitor SB203580, 4-(4-Fluorophenyl)-2-
               (4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole

SB225002       N-(Bromophenyl)-N'-(2-hydroxy-nitrophenyl) urea, CXCR2                 Y
               Antagonist



SB-366791      N-(3-methoxyphenyl)-4-chlorocinnamide, 4'-chloro-3-                    Y
               methoxycinnamanilide



SD169          Indole-5-carboxamide                                                   N*
S-DHPG                        (S)-3,5-dihydroxyphenylglycine hydrate                                   Y




Sepiapterin                   L-Sepiapterin, S-(−)-2-Amino-7,8-dihydro-6-(2-hydroxy-1-                 N
                              oxopropyl)-4(1H)-pteridinone



Serotonergic Antagonists                                                                         N* see comments



SEW2871                       5-[4-phenyl-5-(trifluoromethyl)-2-thienyl]-3-[3-(trifluoromethyl         Y
                              )phenyl]-1,2,4-oxadiazole;

Sildenafil                    Viagra                                                                   N

Silver Chloride                                                                                        N

Simvastatin                   Simvustatin, Zocor, Sinemet, Simvastin                             N* see comments

siPORT Amine                                                                                           N

SKF-3839                      SKF-38393                                                                N*




SKI-II                        4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol, Sphingosine             N*
                              Kinase Inhibitor 2, SK1-I2

SL 327                        α-[Amino-(4-aminophenylthio)methylene)-2-                                N
                              (trifluoromethyl)phenylacetonitrile

SLV334                                                                                           N* see comments



S-methylisothiourea           Methyl thiopseudourea sulfate, Carbomimidothoic acid methyl              N
                              ester sulfate


S-Methylisothiourea Sulfate   SMT, Carbomimidothoic acid methyl ester sulfate, 2-Methyl-2-             N
                              thiopseudourea hemisulfate salt



SN50                          NF-kappaB SN50 cell permeable inhibitor protein.                         N




SNC80                         (+)-4-[(αR)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-            N
                              methoxybenzyl]-N,N-diethylbenzamide
Sn-protoporphyrin             Tin protoporphyrin, stannous protoporphyrin, stannous              N* see comments
                              mesoporphyrin



SNX-5422                                                                                         N* see comments

Sodium boranocarbonate        CORM-A1                                                                  Y




Sodium 5-hydroxydecanoate     5HD, 5-hydroxydecanoic acid, 5-hydroxydecanoate sodium                   N
                              salt, 5-HD
Sodium fluorescein                 Uranine yellow, Acid yellow 87, Uranine; NaFl                     N* see comments




Sodium gluconate                   D-gluconic Acidsodium salt, Sodium D-gluconate, 2,3,4,5,6-                N
                                   Pentahydroxycaproic acidsodium salt, D-gluconatesodium salt

Sodium lactobionate                Na-lactobionate, na lactobionate (salt of lactobionic acid)               N

Sodium Nitrite                                                                                               Y


Sodium Nitroprusside               Sodium Nitroferricyanide, SNP, Nitroprusside Sodium               N* see comments



Sodium tungstate dihydrate                                                                                   Y



Sol Medrol                         Methylprednisolone sodium succinate, Solu Medrone, Urbason        N* see comments
                                   soluble


Sorafenib                          Nexavar™, 4-[4-[[4-chloro-3-                                              Y
                                   (trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-
                                   pyridine-
                                   2-carboxamide
Sorbitol                                                                                                     N



Sphingosine-1-Phospate             S1P agonist                                                              N*



Spironolactone                     Aldactazide, Aldactone, Spiridon, Spirone, Uractone,                      Y
                                   Verospiron
SR-144528 (CB2 antagonist)         N-[(1S)-Endo-1,3,3-trimethylbicyclo-[2.2.1]heptan-2-yl]-5-(4-             Y
                                   chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-
                                   carboxamide
SR49059                            Vasopressin V1a receptor antagonist; SR 49059                    N* see "Vasopressin
                                                                                                    Receptor Antagonists


SR 57227A                          4-Amino-1-(6-chloro-2-pyridyl)piperidine monohydrochloride, 1-           N*
                                   (6-chloro-2-pyridyl)-4-piperidinamine monohydrochloride,
                                   CM57227a, 4-amino-1-(6-chloro-2-pyridyl)-piperidine
                                   hydrochloride
SRT1720                            SIRT 1933, CAY10559, N-[2-[3-(1-                                          Y
                                   piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-
                                   quinoxalinecarboxamide

St. Thoman flush solution                                                                                    N

STO-609 - acetic acid              7-Oxo-7H-benzimidazo[2,1-a]benz[de]isoquinoline-3-carboxylic              N
                                   acid - acetic acid
ST2825                             MyD88 inhibitor                                                           Y



Stattic                            Stat three inhibitory compound, 6-Nitrobenzo[b]thiophene-1,1-             N
                                   dioxide


Stilbenes, novel, not previously   Stilbene 5c, PD7, others                                                  Y
listed on this database

Streptozocin                       Streptozoticin                                                            Y
Su 5416                1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-                N
                       2H-indol-2-one


Substance P                                                                                   Y




Sulfadimethoxine       4-Amino-N-(2,6-dimethoxy-4-                                      N* see comments
                       pyrimidinyl)benzenesulfonamide, Sulfa

Sulfamethazine         Sulfamethoxazol, Bactrim, 4,6-Dimethylsulfadiazine, 4-Amino-     N* see comments
                       N-(4,6-dimethyl-2-pyrimidinyl)benzenesulfonamide

Sulfamylon             5% Sulfamylon cream                                                    N


Sulpiride              (S )-5-Aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-             N
                       methoxybenzamide, Levosulpiride

Sunitinib              Sutent, SU 011248, SU 11248, N-[2-(Diethylamino)ethyl]-5-[(Z)-         Y
                       (5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-
                       dimethyl-1H-pyrrole-3-carboxamide (2S)-2-hydroxybutanedioic
                       acid (1:1) salt
Superoxide dismutase   SOD                                                                    N




Tachykinin receptor    NK2 Tachykinin receptor                                                N




Tadalafil              Cialis®                                                                N




Tamoxifen              Tamoxifen citrate, novadex, tamofen, nolvadex                          Y

Tartaric Acid          D-Threaric Acid                                                        N

Taurine                5 Taurine                                                              N



Taxol                  Paclitaxel, Taxol A                                                    Y



TCRN                   Targeted charge-reversal nanoparticles                                 Y



Temozolomide           TMZ, Temodar, Temodal, NSC-362856, 3,4-dihydro-3-methyl-               Y
                       4-oxoimidazole

Tempol                 Tanol, Tempo, 2,2,6,6-tetramethylpiperidinooxy, "Free radical          N
                       scavenger."

Terbutaline            Brethine, Bricanyl                                                     Y


Testosterone                                                                                  Y



Tetanus toxin          Tetanus toxin from Clostridium tetani                                  Y
Tetanus toxoid                                                                                            N



Tetrachloroazobenzene              3,3',4,4' Tetrachloroazobenzene, BIS(3,4'-dichlorophenyl)-             Y
                                   diazene, TCA, TCAB

Tetrachloroethylene                Perchloroethylene, PCE                                                 Y



Tetrahydrocannabinol               Other cannabinols, Delta 9 tetrahydrocannabinol, Marijuana,      N* see comments
                                   Delta-9-tetracannabinol; U50; THC

Tetrodotoxin                       TTX, Fugutoxin                                                         Y




TG-100115                          select P13Kgamma inhibitor                                             Y



TFMPP                              T 8948, 1-(a, a, a-trifluoro-m-tolyl) piperazine hydrochloride         N



TGF-β1 Recombinant cDNA            Transforming growth factor beta 1                                      N



TGF-β3 Recombinant cDNA            Transforming growth factor beta 3                                      N
Thalidomide                        2,6-dioxo-3-phthalimidopiperdine, Glutarimide                          Y

Thapsigargin                       Thapsia sp. derivatives                                          N* see comments




THC                                Tetrahydrocannabinols                                            N* see comments




Thiazide




Thioglycolates (Thioglycollates)   Thioglycolate broth, Sodium Thioglycolate, Ammonium                    N
                                   Thioglycolate



Thiopental sodium                  Sodium thiopental                                                N* see comments




Thioperamide, maleate salt         MR-12842                                                               N


Thioridazine                       10-[2-(1-Methyl-2-piperidyl)ethyl]-2-(methylthio)-10H-                 Y
                                   phenothiazine hydrochloride, Mellaril, Melleril

Thyroxine                                                                                                 N



Tisseel VH                         Fibrin Sealant                                                         Y
Tipranovir                          Aptivus                                                        N* see comments



Tirilizad                           Freedox®, 21-aminosteroid                                            Y



Titanium (IV) oxide                 Titanium dioxide                                                     N

Titermax Gold Adjuvant®                                                                                  N



TGF-β1                                                                                                   Y



TGF-β3                             TGF-β sRIII                                                           Y




TNF-a Human                        Human Recombinant Tumor Necrosis Factor - a, Recombinant              Y
                                   Human Tumor Necrosis Factor Alpha, TNF-alpha - Human,
                                   Cachectin
TNF-a Mouse                        Mouse Recombinant Tumor Necrosis Factor - a, Recombinant              N*
                                   Mouse Tumor Necrosis Factor Alpha, TNF-alpha - Mouse,
                                   Cachectin - Mouse

TNF-a Rat                          Rat Recombinant Tumor Necrosis Factor - a, Recombinant Rat            N*
                                   Tumor Necrosis Factor Alpha, TNF-alpha - Rat, Cachectin - Rat

Tobacco smoke (environmental)                                                                            Y

Toluene                            Methylbenzene, Toluol, Antisal 1a                               N* see comments

Topotecam                          Hycamtin                                                              Y

trans- Nonachlor                                                                                         Y

TraumaDex®                                                                                               N



Trehalose                          Neotrehalose; Alpha, Beta-Trehalose                                   N

Trenbolone acetate                 TZOH, Finaplix Gold®, Fina                                            Y



Tricarbonyldichlororuthium (II)dimer CORM-2                                                              N*



Tricaine Methanosulfonate          Metacaine, Ethyl 3-aminobenzoate methanesulfonate salt; ms-           N
                                   222; ms222
Trichloroethane                    1,1,2,2 trichloroethane, 1,1,2 trichloroethane, 1-1-1                 Y
                                   trichloroethane, Chlorothene, Methychloroform, Entire
                                   chloroethane group


Trichloroethylene                  TCE, Acetylene trichloride, ethylene trichloride, NCI-CO4546,         Y
                                   Triad, Trilene
Trichostatin A (TSA)               TSA                                                                   N*




Trimidox, see Didox                                                                                      Y
Trinitrobenzesulfonic acid   TNBSA, TNBS, picrylsolfonic acid,                                  N* see comments


Tripterygium                 PG-490, Triptolide, Tripterygium wilfordii                               Y

Tropicamide                  N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide,                N* see comments
                             Mydral, Mydrin


Tropisetron                  ICF 205-930, 3-Tropanylindole-3-carboxylate                              N


TTC Solution                 2,3,5 triphenyl-tetrazolium chloride sloution                            N



Tyrphostin AG 490                                                                                     N

UCN-01                       KW-2401, 7-Hydroxystaurosporine                                    N* see comments




U0126 ethanolate             ,4-Diamino-2,3-dicyano-1,4-bis(o-                                        N
                             aminophenylmercapto)butadiene ethanolate
U-50488                      U50488H, trans -(±)-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)          N
                             cyclohexyl]benzeneacetamide methanesulfonate salt
U69593                       (+)-(5α,7α,8β)-N-Methyl-N-[7-(1-pyrrolidinyl-1-oxaspiro[4.5]dec-         N
                             8-yl]-benzeneacetamide


UCM707                       N-(3-furanylmethyl)-5Z,8Z,11Z,14Z-eicosatetetraenamide                   Y




Urapidil Hydrochloride       5-Methylurapidil, B66256, Ebrantil                                 N* see comments



URB597                       Cyclohexylcarbamic acid, Selective FAAH inhibitor, URB 597         N* see comments




URB602                       N-biphenyl-3-cyclohexylcarbamic acid, cyclohexyl ester                   N




Urea hydrogen peroxide       Carbamide peroxide, Urea dioxide                                   N* see comments




Urethane                     Ethyl Urethane, Ethyl Carbamate                                          Y




Valproic Acid                2-propylpentanoic acid, valproate, Depakote®, Depakene®,                 Y
                             Depacon®, and Stavzor®, sodium valproate
Valsartan                          Diovan®, Valsartane                                              N* see comments




Vannilloid receptor agents (ie:    TRPV1 compounds                                                        Y
capsaicin)


Vardenafil                         Levitra®                                                               N




Varenicline                        Chantix®, VAR                                                    N* see comments

Vasopressin Receptor Antagonists   SR49059, Relcovaptan, Conivaptan                                 N* see comments

VEGF-human                         Vascular Endothelial Growth Factor - human                       N* see comments




VEGF-mouse                         Vascular Endothelial Growth Factor - human                             N




Verapamil                          Verapamil hydrochloride                                                Y



Vercuronium bromide                                                                                       N


Viaspan®                           UW, Universal aortic flush, Belzer Machine Perfusion Solution,         N
                                   Kidney preservation solution, KPS-1.
Vinblastine                        Vincaleukoblastine                                                     Y

Vinpocetin                         Cavinton, Ethyl apovincaminate, RGH-4405, TCV-3B                 N* see comments



Vitamin D analogs                  EB 1089, 1, 25, dihydroxy vitamin D3, others                     N* see comments

VPC 23019                          (R)-Phosphoric acid mono-[2-amino-2-(3-octyl-                          N
                                   phenylcarbamoyl)-ethyl] ester (VPC 23019) , S1P
                                   antagonist
VPC 44                                                                                                    Y




W140                               (S)-3-amino-4-(3-hexylphenylamino)-4-                                  Y
                                   oxobutylphosphonic acid (TFA salt)


W146                               R)-3-Amino-(3-hexylphenylamino)-4-oxobutylphosphonic                   N
                                   acid (TFA salt)

WIN 55, 212-2, mesylate salt       (R )-(+)-[2,3-Dihydro-5-methyl-3[(4-                                   N
                                   morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-
Wortmannin                         naphthalenyl)methanone mesylate salt
                                   KY 12420                                                               Y
Xanthine/Xanthine Oxidase   X/XO, Superoxide Generator, 2, 6-Dihydroxypurin, oxygen           N* see comments
                            oxireductase, relate xanthine compounds..

Xenon                                                                                               N
Xylazine                                                                                            N



Xylene                      Xylol, Dimethylbenzene                                            N* see comments

YC-30                       3,4,5 trichlorphenylguanidine                                           N




YM782                                                                                               Y



Yohimbine                   Yohimbin(e) (mono)hydrochloride, antigonil, NIH 9689,                   N*
                            Aphrodine hydrochloride, methyl ester, monohydrochloride, 17-
                            alpha-hydroxy-, Yohimban-16-apha-carboxylic acid
Z-asp                       Z-N-L-aspartic acid, Z-asp OH                                           N


Z-WEHD-FMK                  Caspace-1 inhibitor                                                     Y




Zaleplon                    Sonata                                                                  N




Zidovudine                  3'-azido-3'-deoxythymidine, retrovir                                    Y



Zinc Deuteroporphyrin       1X 2,4, bis-glycol ZnBG                                                 N


Ziprasidone                 CP-88059, Geodon, 5-[2-[4-(1,2-Benzisothiazol-3-yl)-1-                  N*
                            piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one
                            hydrochloride monohydrate
ZnPP                        Protoporphyrin IX zinc(II) complex, 3,7,12,17-Tetramethyl-8,13-         N
                            divinyl-2,18-porphinedipropionic acid, 8,13-Divinyl-3,7,12,17-
                            tetramethyl-21H,23H-porphine-2,18-dipropionic acid zinc
Zolpidem                    derivative
                            N,N,6-Trimethyl-2-(4-methylphenyl)-imidazo[1,2-                         N
                            a]pyridine-3-acetamide
Zygosporin A                Cytochalasin D                                                          Y




Zymosan                     Zymosan A from Saccharomyces cerevisiae                                 Y
IARC:                           NTP:                OSHA                  NIOSH   EPA
   1: Known human                       K: Known                                  Regulations and
carcinogen             2A:      human carcinogen
                                                                                  References
Suspected human carcinogen             S:
                 2B: Possible   Reasonably
human carcinogen                anticipated
                                (suspected) human
                                carcinogen




                                                    Toxic by ingestion,
                                                    irritant

                                                    Irritant




             2B                          S                                        EPA Genetic Toxin
                                                                                  Program




             2B
1    K




                                              EPA Genetic Toxin
                                              Program

2B   S                                        EPA Genetic Toxin
                                              Program

1        Select Carcinogen




2A   S                       Hazardous Drug   EPA Genetic Toxin
                             List             Program



         Hazardous Drug List Hazardous Drug   EPA Extreme
                             List             Hazard List
                EPA Genetic Toxin
                Program


OSHA PEL: 0.1   EPA Extreme
ppm             Hazard List
1   K   Select Carcinogen   Occupational       Extreme Hazard
                            Carcinogen List,   List
                            Hazardous Drug
                            List




                            Hazardous Drug
                            List
1    K   Toxic by ingestion,
         irritant,carcinogen,
         mutagen, teratogen




2B       Hazardous Drug         Hazardous Drug
         List                   List




2B




2B   S   Carcinogen,Toxic
         by ingestion.
         Harmful by skin
         absorption
2A   S   OSHA-TRI List



3    S
2B   hazardous drug list   hazardous drug list




                                                 EPA Genetic
                                                 Toxicity Program
2B




2B   Toxic by inhalation,
     ingestion, or skin
     abosorbtion.
     Carcinogen
Target Organ       Hazardous drug list
Effect, Toxic by
ingestion
2A   Hazardous Drug List Hazardous Drug
                         List
2B                          EPA Genetic Toxin
                            Program




     Target Organ
     Effect, Highly toxic
     by inhalation,
     Highly toxic by
     ingestion, Irritant,
     Teratogen
2B
1    K   Hazardous Drug   Hazardous Drug
         List             List


1    K   Hazardous Drug   Hazardous Drug
         List




2B       Hazardous Drug   Hazardous Drug
         List             List
2B   S   Toxic by
         ingestion,Toxic by
         skin absorption,
         Carcinogen

         Target organ
         effect in lungs

2B   S   Probable             Probable
         carcinogen           carcinogen




         Highly toxic by
         inhalation,
         ingestion, and
         absorption.
2A   S   OSHA-TRI List          Genetic Toxin
                                Program

2A   S   OSHA-TRI List          Genetic Toxin
                                Program




                                Genetic Toxin
                                Program

         Target Organ
         Effect, Highly toxic
         by inhalation,
         Highly toxic by
         ingestion, Toxic by
         skin absorption



2A   S




     K




2A                              EPA Genetic Toxin
                                Program
2B




2B   K   Select Carcinogen    Occupational      Genetic Toxin
                              Carcinogen List   Program




2B   S


         Target Organ
         Effect: Toxic by
         ingestion, Skin
         sensitizer. Target
         organs: Liver,
         Nerves., Kidney
2A   K   Hazardous Drug   Hazardous Drug
EPA Genetic Toxin
Program
1    K   Hazardous Drug List Hazardous Drug
                             List




1    K




f




2B   K                                          Genetic Toxicology
                                                Program

2A       Carcinogen



                                                Genetic Toxicology
                                                Program




2B   S




2B   S                      Fast Blue dyes:
                            "Reduce to lowest
                            possible
                            concentration"
Hazardous Drug
List


Hazardous Drug
List
1    K   Select Carcinogen     Occupational      Extreme Hazard
                               Carcinogen List   List




         Target Organ
         Effect: Smooth
         muscle, harmful by
         skin absorption




2B       Target organ effect
         of liver & kidneys




2B   S                                           Extreme Hazard
                                                 List
                                                 EPA Genetic Toxin
                                                 Program
1   K   Select Carcinogen   Occupational          Extreme Hazard
                            Carcinogen List       List




                            Hazardous drug list




        Established 8-                            Genetic Toxicology
        hour exposure                             Program
        limit: 0.2 ppm
                                                  Genetic Toxicology
                                                  Program
Hazardous drug
List (Gonadatropin)




                      Genetic Toxicology
                      Program
2B   Carcinogen




                  Hazardous Drug
                  List
2B   S   Select Carcinogen   Occupational      Extreme Hazard
                             Carcinogen List   List




                             Hazardous Drug
                             List
         Hazardous Drug List Hazardous Drug
                             List




                            Hazardous Drug
                            List




2B   S                                        EPA Genetic Toxin
                                              Program
EPA Genetic Toxin
Program
2A   S   Select Carcinogen                      Genetic Toxicology
                                                Program, strict
                               Hazardous Drug   disposal
                               List




         Target Organ effect
         (CNS, cardio,
         kidney, etc.)
                                             Genetic Toxin
                                             Program




1   K   Hazardous Drug List Hazardous Drug
                            List




        Toxic by ingestion




        Hazardous Drug List Hazardous Drug   Extreme Hazard
                            List             List. Strict disposal
                                             requirements apply
         Hazardous Drug List Hazardous Drug
                             List
                                                EPA Genetic
                                                Toxicology Program




                                                Some dyes are
                                                registered in EPA
                                                Genetic Toxin
                                                Program




                                                Genetic Toxin
                                                Program




                               Hazardous Drug
                               List




2B   S   Carcinogen,Target
         Organ Effect, Toxic
         by ingestion, Toxic
         by skin absorption
2B       Hazardous Drug List Hazardous Drug
                             List
2A   S




                          Extreme Hazard
                          List
         Hazardous Drug   EPA Genetic Toxin
         List             Program




2A   S
2B (N'-nitrosonornicotine)   S (nitrosonornicotine)   Extreme Hazard
                                                      List, Genetic
                                                      Toxicity Program



                                                      Genetic Toxicity
                                                      Program
Extreme Hazard
List




Carbamides: EPA
Extreme Hazard
List
                                                 EPA Genetic Toxin
                                                 Program




         Target Organ effect
         (CNS, blood, heart,
         eyes, liver)
         Listed chemical       Listed chemical
         hazard                hazard




         Target Organ effect
         (CNS, blood, heart,
         eyes, liver)




2A   S


2A   S


2A   S



2A   S



2A   S




                                                 Genetic Toxin
                                                 Program
Genetic Toxin
Program
2B (Hydrazine)   S (Hydrazine)   Select Carcinogen   Occupational
                                 (Hydrazine)         Carcinogen List




     2B               S          OSHA-TRI List
Target organ effect:
CNS
                                              EPA Genetic Toxin
                                              Program

2B   S   Hazardous Drug List Hazardous Drug
                             List




                            Hazardous Drug
                            List
     Highly toxic by
     inhalation,
     ingestion, and
     absorption. Skin
     sensitizer.




     Target organ effect:
     nerves


2B
3- not classifiable as to it's
 carinogenicity to humans
1   K   Hazardous Drug List Hazardous Drug
                            List
1    K   Hazardous Drug List Hazardous Drug
                             List




                            Hazardous Drug
                            List




         Hazardous Drug List Hazardous Drug
                             List




2A   S                      Hazardous Drug
                            List
2A   S   Carcinogen




                      Hazardous Drug
                      List
1   K




                              Hazdarous drug list

        Toxic by ingestion,
        Irritant




                              NIOSH                 Genetic Toxin
                              Occupational          Program
                              Carcinogen List


    S   OSHA-TRI list         NIOSH                 Genetic Toxin
                              Occupational          Program
                              Carcinogen List
2A   S   OSHA-TRI List   Genetic Toxin
                         Program
Target organ effect,
highly toxic by
inhalation




Hazardous Drug List Hazardous Drug
                    List
                                          Genetic Toxin
                                          Program




                                          Genetic Toxin
                                          Program




2B   Hazardous Drug List Hazardous Drug
                         List
Other available information (based on review of available
product MSDSs and other published data)




USDEA Schedule I drug. Strong toxin with irritant effects via all
exposure routes.

MSDS: Flammable (do not breathe vapor), may cause CNS
depression, eye and skin irritation. Toxicological properties not fully
investigated
MSDS: Toxic. Dangerous for the environment. The toxicological
properties of Octachlorodibenzofuran have not been fully
investigated. It should be assumed to have toxic effects and,
therefore, procedures appropriate for the safe handling of
hazardous chemicals should be followed.

Acute toxin, possible human carcinogen/teratogen: NIOSH advises
reducing exposure potential to lowest possible degree




MSDS: Irritant - avoid contact with skin and eyes.

MSDS: Toxic. Teratogen, exposure may cause eye irritation,
chloracne, allergic dermatitis, loss of body weight, excessive fatigue,
hemorrhage, and lymphoid depletion
Flammable liquid, Irritant. TOXIC DOSE 1 - LD 50 3000 mg/kg (oral
rat),TOXIC DOSE 2 - LD 50 >2500 mg/kg (skn-rbt)




OSHA Hazards:Target Organ Effect, Highly toxic by ingestion


MSDS: Human mutagen, possible reproductive toxin.

MSDS: Tumor promoting agent, highly toxic by all routes -
especially by inhalation. Bone marrow toxin, possible carcinogen,
experimental neoplastic agent.


MSDS: Irritant - avoid contact with skin and eyes.
MSDS appears to indicate that primary hazard associated with
agent is related to acetonitrile (cyanotic toxin effects) which it is
combined with to make solution. 2-AC should be handled carefully
whether in pure state or in solution.
MSDS: IARC 2B poss. carcinogen with confirmed mutagenic and
potential teratogenic/reproductive toxin properties


MSDS: Irritant - avoid contact with skin and eyes.



Novel compounds
NTP classifies all estrogen compounds as "known" human
carcinogens. 2-ME is potent inhibitor of endothelial cell
proliferation and angiogenesis. The agent is a potent toxin
(targeting nerves, kidneys, liver, eyes) and a sensitizing agent
(skin).
Target Organ Effect (blood), Harmful by ingestion., Irritant.
LD50 Oral - rat - 997 mg/kg

OSHA Hazards:Target Organ Effect, Highly toxic by ingestion
Target Organs:Thyroid.

MSDS: Confirmed human mutagen with possible carcinogenic
properties (neoplastic agent). Strong toxin by all exposure routes,
exposure may produce brain lesions.
MSDS: Confirmed carcinogen with possible mutagenic, teratogenic,
and neoplastic hazard properties.

IARC/ACGIH confirmed Human Carcinogen, California Prop 65
carcinogen, NIH: Human carcinogen, teratogen, mutagen, special
hazard: aerosols. Avoid all exposure.
MSDS: No known toxic properties.
Suspected human reproductive toxin

MSDS: Cytotoxic agent, probable human carcinogen, suspected
mutagen, teratogen, and reproductive toxin.
Carcinogenicity: Limited evidence of carcinogenicity in animal
studies
MSDS: Confirmed human teratogen, mutagen, and reproductive
toxin. Potential sensitizing agent. California Prop 65 developmental
toxin.
Sickle-cell anemia drug, handle with care.


Acute toxicity:LD50 Oral - mouse - > 10,000 mg/kg; LD50
Intraperitoneal - mouse - 1,000 mg/kg OSHA Hazards:Target Organ
Effect, Irritant, Teratogen, Mutagen
RTECs animal testing data indicating possible
tumorigenic/antineoplastic properties, MSDS indicates
possible reproductive toxin effects. Exposure may also
induce Parkinsonian-like disease.
Possible irritant. Toxicity: Intraperitoneal Mouse 25 MG/KG LD50




MSDS: Possible irritant

MSDS: Possible irritant/harmful effects, possible neurotoxin

The chemical, physical, and toxicological properties of this agent
have not been thoroughly investigated. Target Organs: Eyes;
Respiratory system; Skin
Novel antineoplastic drug with limited toxicological data.




Potent irritant of respiratory tract and skin, possible neurotoxic
effects.
Severe overdosage may produce nausea, vomiting,
perspiration, and general discomfort. Massive overdosage
Causes severe burns; combustible; harmful in contact with skin.
May be harmful if inhaled.
MSDS: Moderate toxin, possible irritant and sensitizing agent.
California Prop 65 developmental toxin.
MSDS: Exposure may result in possible cardiotoxic effects,
possible skeletal muscle damage, irritant.



Strong poison all route (rat oral LD50 400 mg/kg), irritant, possible
sensitizing agent, acute (irritant) effects.
Hazard effects vary widely from compound to compound. Some
MSDS' show mutagenic effects in laboratroy experiments. Review of
correct MSDS for specific dye(s) in use is essential for developing
safe handling procedures.
Extremely toxic: rat oral LD50 26 mg/kg. Possible mutagenic and
reproductive toxin effects, severe irritant effects and possible
cardiotoxicity. Possible delayed hypersensitivity affecting multiple
organs following exposure. ACGIH TLV: 0.1 ppm, DFG MAK
confirmed animal carcinogen - human relevance unknown. Possibly
deadly via ingestion, skin permeation, and inhalation - avoid all
contact.
Human mutagenic and teratogenic effects reported, possible
reproductive toxin.
FDA-approved drug, utilized in rheumatoid arthritis treatment,
protein, TNF-a blocker, immunosuppressant, limited information
available. Carcinogenic studies not yet complete, in vivo mouse
and Ames tests have not indicated clastogenic/mutagenic
properties. FDA pregnancy category B agent (not expected to have
ill effects on unborn baby). FDA 2005 labeling change cited
possible increase in malignancies related to Humira® use (attached,
column M).
Potent irritant of respiratory tract and skin, may be toxic if ingested.

Moderate toxin by all exposure routes, possible human mutagen
(human test data available). FDA-approved drug with use in cardiac
medication.




Acute Toxin (extremely toxic): LD50 rat oral 0.68 mg/Kg. Avoid
exposure by all routes.

OSHA Hazards: Irritant



Irritant and possible harmful effect via all exposure routes.

Irritant and has regulatory influence on metabolism of electrolytes
and water




The chemical, physical, and toxicological properties of this agent
have not been thoroughly investigated.


USDEA Schedule I controlled substance, limited toxicological data
available.

Corrosive, possible sensitizer

Irritant, possible harmful if inhaled/ingested. Teratogenic data in rats
Amphibian bombesin-like peptide. Stimulates
gastric acid secretion, intestinal contraction, rat uterine
contraction and hypertension in vivo in the dog. Also
modulates thermoregulation following central administration
in vivo.
Possible risk to man and the environment
Irritating to eyes, respiratory system and skin.




Hypertension treatment drug: highly toxic. LD50 rat oral ranges
from 36 - 85 mg/kg.
Moderate to strong toxin
Irritant possible harmful if inhaled/ingested.

Low hazard, irritant
Toxic by inhalation, contact w/ skin, and if swallowed. My cause
sensitization by inhalation and skin contact. Possible risk to unborn
child.
Low hazard


Novel compound with limited available chemical, physical, and
toxicological information.


Product description/MSDS: Potent excitatory amino acid: possible
irritant and harmful effects via all exposure routes.
Acute toxin: Rat oral LD50 38 mg/kg, USDEA schedule I and II
drugs, possible fetal toxin, suspected human teratogen, extremely
toxic, avoid inhalation/exposure by all routes.
Possible reproductive toxin effects, FDA pregnancy category C.

Recombinant protein used in therapy for rheumatoid arthritis. FDA
pregnancy category B. Immunosuppressive properties.
Possible reproductive toxin, possible irritant/harmful effects via
ingestion/inhalation.
Experimental teratogenic and reproductive toxin properties,
moderately toxic by ingestion.
The toxicological properties have not been thoroughly investigated.
Is a potent vasoconstrictor. With chronic exposure is a reproductive
hazard.
Novel compound with possible antineoplastic/antiviral properties,
derived from Aniba sp. (tropical plant genus with wide range of
medicinal value).

Possible reproductive toxin (limited animal data), possible irritant
and harmful effects by all exposure routes.
Strong toxin (sub-acute) LD50 rat/oral 72 mg/kg. Avoid all contact -
significant ingestion hazard.




Novel compound with limited available chemical, physical, and
toxicological information.
Novel compound with limited available chemical, physical, and
toxicological information.



Irritant to mucous membrane and upper respiratory tract, potentially
harmful if ingested.




MSDS indicates limited hazards.

MSDS indicates limited hazards.

Irritant to mucous membrane and upper respiratory tract, potentially
harmful if ingested.
Not known to be associated with chronic hazards, however;
toxicological properties have not been thoroughly investigated.
May cause care and avoid exposure.
Handle withskin, eye, and inhalation irritation.

Strong toxin of lungs and CNS (primary intravenous threat),
sensitizer/allergen,
Strong irritant.

MSDS indicates irritant properties and other potentially harmful
effects.
Novel nucleoside analogue/transcriptional inhibitor of P-TEFb
kinase (CDK9/CyclinT1 complex

Toxicological effects have not been thoroughly investigated.



Arginine compounds display wide range of toxicity from mild to
strong toxins via multiple exposure routes. Chronic exposure
hazards vary from known/suspected teratogenic, mutagenic, and/or
reproductive toxin effects to no evidence of chronic hazards.



Possible reproductive toxin ("Pregnancy Category C") and possible
teratogen: animal test data only. Possible CNS damage.

NIH: Acute toxin, confirmed human carcinogen, teratogen,
mutagen, exposure risk via all routes


Irritant/possible harmful effects to mucous membrane and
respiratory tract.
Guanidines are moderate to strong toxins with potential mutagenic,
teratogenic, and reproductive hazards. Includes several anti-
malarial drugs. Limited specific information available for
arylguanadine.
Mutagenic for mammalian somatic cells. Mutagenic for bacteria
and/or yeast.

Strong sensitizing agent, suspected reproductive toxin. Confirmed
reproductive toxin effects, questionable carcinogen - neoplastic
properties reported.
Possible neurotoxin effects, limited toxicological data.

Strong irritant, possibly harmful by all exposure routes. Targets
skeletal muscles.
Suspected human teratogen, possible reproductive toxin, strong
poison.




Acutely toxic anesthetic agent (rat oral LD50: 1 mg/kg).


Carcinogen, mutagen, and teratogen. Acute LD50 rat-oral-400mg/kg




A novel PARP inhibitor in human clinical trials as a anti-cancer drug


A novel MEK kinase inhibitor in Phase II trials as a anti-cancer drug


A novel kinase inhibitor in Phase 1 trials as a anti cancer drug


Possible sensitizing agent, a butyrophenone derived drug used as
an antipsychotic and large animal tranquilizer.


Confirmed tumorigenic, mutagenic, and reproductive toxin
properties.



Novel compound with limited available chemical, physical, and
toxicological information.



Possible carcinogenic properties, exposure may also lead to
heritable genetic damage. Toxic if swallowed. Causes severe
burns.
Although the physiological role of the endorphins has not
been completely elucidated, they are known to block inhibitory
pathways in the vertebrate CNS and their possible effects on
pain perception, addictive states, and psychiatric disorders
have been investigated.
Possible carcinogen and toxic to fish




Potent irritant, effecting eyes, mucus membrane, respiratory
system, and skin. Avoid contact by all routes. Calcium
chelating agent.

Novel compound with limited available chemical, physical, and
toxicological information.


Flammable. Irritating to skin. Very toxic to aquatic organisms, may
cause long-term adverse effects in the aquatic environment.
Harmful: may cause lung damage if swallowed. Vapors may cause
drowsiness and dizziness
Flammable, dangerous for the environment, possible teratogen.
Inhalation studies on toluene have demonstrated the development
of inflammatory and ulcerous lesions of the penis, prepuce, and
scrotum in animals. Lung irritation, chest pain, and edema which
may be fatal.
Flammable, dangerous for the
environment. Irritating to skin. Very toxic to aquatic organisms, may
cause long-term adverse effects in the aquatic environment. May
cause lung damage if swallowed. Vapors may cause drowsiness
and dizziness.

Flammable, dangerous for the environment, possible teratogen.
Inhalation studies on toluene have demonstrated the development
of inflammatory and ulcerous lesions of the penis, prepuce, and
scrotum in animals. Lung irritation, chest pain, and edema which
may be fatal.
Renal and hepatic toxin with possible teratogenic/reproductive
toxin effects (limited animal data). Daglutril is currently in
phase II clinical trials as a potential therapy for victims of
traumatic brain injury.
FDA-approved hypertension treatment drug. possible
mutagen. Avoid contact by all exposure routes.


Human mutagen with strong irritant and other possible
harmful properties. Potentially harmful effects via ingestion.


Strong irritant effecting eyes, mucus membrane, respiratory
system, and skin. Possible harmful effects by all exposure
routes - avoid contact. Selective and potent blocker of
Na+/H+ and Na+/Ca2+ channels.
irritant: may cause skin, eye and respiratory irritation



Confirmed human mutagen, suspected human carcinogen,
teratogen and reproductive toxin. Strong sensitizing agent.
California Prop 65 carcinogen..

Human mutagen data; reasonably anticipated to be a human
carcinogen. Limited information availible.




Highly toxic to aquatic organisms

Irritant, possibly harmful by ingestion/inhalation.



MSDS indicates possible mutagenic properties (limited animal data).
Possible irritant/harmful effects via all exposure routes.


Harmful, may cause nervous system disorders


Neurotoxin, convulsant, handle as toxic agent.
RTECs lists cholestramine as "human carcinogen," and deoxycholic
acid as "equivocal tumorigenic agent." Possible carcinogenicity in
addition to possible mutagenic, teratogenic, and reproductive toxic
effects. All bile acids appear to be irritants and possibly sensitizing
agents. teratogen and reproductive hazard
Possible


Irritant, possibly harmful by ingestion/inhalation.

MSDS indicates possible irritant/harmful effects via all exposure
routes.
Suspected human mutagenic, teratogenic, and reproductive toxin
properties. Strong irritant and sensitizing agent - exposure may
cause permanent damage to eyes, mucous membrane, and/or
respiratory system. Toxic effects also target liver and bone marrow.
Environmental toxin - highly damaging to aquatic life. Avoid contact
- dispose of all contaminated waste and stocks through OEHS.

Slightly hazardous in case of skin contact, eye contact, or ingestion
(irritant).
Suspected human mutagenic and reproductive toxin properties.


Neuropeptide with many biological effects
including hormone release, stimulation of pancreatic
enzyme secretion, inhibition of gastric emptying and
modulation of gastric acid secretion.

Handle with care, exposure may produce high fever and other
symptoms, NIH: Lists as acutely toxic. Highly toxic via ingestion,
inhalation, skin permeation.
FDA: "Fast Track" cancer drug, proteasome inhibitor, the limited
available information does not identify as carcinogen, however;
mutagen, teratogen, and possible reproductive hazard properties
are noted.
European Union Biosafety Office guidance document cautions
against possible presence of bovine spongiform encephalopathy
prions (BSE) in bovine products (see source provided in "Additional
Links" column). PIs should select BSA products which provide
assurance that potential for BSE-contamination has been eliminated
or sufficiently minimized.




Possible mutagen, teratogen, and/or reproductive toxin effects.
Limited health and safety information exists for this agent. Strong
irritant and toxin effects are suspected, exposure by all routes
should be avoided.
 Possible neurotoxin and irritant effects.


Irritant, may depress central nervous system. Exposure may have
negative impact on liver, cardiac, and other system function.

Toxicological effects have not been thoroughly investigated.


Confirmed human teratogen and reproductive toxin.

Confirmed teratogen, human mutagen, suspected teratogen/
reproductive toxin, strong toxin/sensitizing agent: avoid contact.
Consult product specific MSDS. The pure powder does not need
to be registered, but in combination w/solvent often used (methyl
acetate) it does need to be reigstered.
Potent toxin by all exposure routes, possible mutagenic properties
(limited animal test data). Initially activates then down-regulates
PKC.
Highly toxic via ingestion, skin contact and inhalation: avoid
exposure.
Moderate toxin, possible teratogen and reproductive hazard
Possible neurotoxin and irritant effects.




Acute toxin




Evidence of teratogenic/reproductive toxin effects in animals,
possible teratogenic properties. USDEA Schedule IV Drug:
narcotic/analgesic.

Human mutagen (human test data available), extremely destructive
to mucous membranes and respiratory tract, CNS depressor,
ecotoxin.


Possible human carcinogen, teratogen, and mutagen

Possibly harmful via ingestion, skin contact, or inhalation. Avoid
contact
DEA Schedule 1 Regulated compound

May pose risk of fetal and neonatal morbidity and death when
administered to pregnant women



Possible mutagen, potential sensitizing agent, and strong poison by
all routes - avoid exposure.

Potent irritant by all exposure routes, neurotoxin. Synthetic analog
of capsaicin which is possible mutagen, strong toxin, and sensitizing
agent. OEHS advises handling capsazecine with the same care
given to capsaicin.
Hazardous if ingested. Slight hazard to eye contact.



Chemical, physical, and toxicological properties have not been
thoroughly investigated. Handle with care and avoid exposure.



Highly flammable and toxic by inhalation - adequate ventilation is
critical. May cause health damage due to prolonged inhalation. May
cause harm to unborn child.


Toxic by inhalation, ingestion, or skin absorption. IARC group 2B
possible carcinogen.



Acute toxin
Suspected human reproductive toxicant. NCI: A second-generation
platinum compound with a broad spectrum of antineoplastic
properties


Novel compound

Suspected reproductive system toxin; target organ damage

Strong toxin: rat oral LD50 74 mg/kg; possibly harmful via ingestion,
skin contact, or inhalation. Possible reproductive toxin (animal test
data only). Avoid contact


Possible carcinogenic properties including possible
neoplastic/tumorigenic properties. Limited animal evidence of
possible carcinogenicity.


FDA-approved vasodilating/antihpertension medication, possible
allergic skin reactions upon exposure, minimal toxicity cited.

irritant and sensitizer




Dangerous to environment, toxic to aquatic organisms. Irritant,
animal data indicates chronic teratogen and reproductive hazard.

Possible irritant and other harmful effects, potential cardiotoxin,
avoid all contact
Novel agent

Moderate toxin, possible teratogenic/mutagenic effects, possible
teratogenic, mutagenic, and reproductive toxin effects (extensive
animal testing data available, no human data provided. Possible
sensitization effects: avoid exposure.



LD50 >10000 mg/kg s.c.;3502 i.p.;8000 mg/kg orally.
FDA Pregnancy Category C. Possible teratogenic and reproductive
toxin effects.
Potent irritant to eyes, skin, and respiratory tract.

Novel compound with unknown chemical, physical, & toxicological
properties (Cephalon, preclinical development)

Antineoplastic agent, used in squamous head and neck carcinoma
and colorectal cancer. No long-term carcinogenesis studies
available/limited toxicological information.


Novel compound with unknown chemical, physical, & toxicological
properties


Extremely toxic, toxicological properties have not been determined.
Avoid exposure by all routes. Agent will be reportable as an acute
toxin until adequate toxicological information becomes available.


Possible blood/neuro/cardiotoxin effects: avoid exposure via all
routes.
Suspected mutagen (human test data available), strong toxin
targeting nervous/cardiac system, kidney, and liver.


Strong toxin targeting central nervous system, possible carcinogenic
properties (limited animal data).



Sensitizing agent (may induce photosensitivity), possible
reproductive toxin, poses significant hazard to the environment
(aquatic organisms). Avoid contact and dispose of all contaminated
waste/stocks through OEHS.
Nicotine antagonist, strong poison by all exposure routes (rat oral
LD50 300 mg/kg).



Irritant, avoid exposure to dust.




Genotoxicity in vitro - rat - Liver
Sister chromatid exchange (LD50 Oral - rat - 623 mg/kg, animal test
data only). OSHA Hazards:Target Organ Effect. Harmful by
ingestion.Target Organs: Eyes, Heart
Possible teratogenic, mutagenic, and/or reproductive toxin effects
(animal test data only). Strong toxin (sub-acute) with potential for
inducing photosensitization effects.


Some products are acute toxins with rat oral LD50 as low as 0.25
mg/kg. Possible mutagenic/teratogenic hazards and reproductive
toxicity.

Strong corrosive, contact with skin or mucous membrane may
induce serious burns. Readily absorbs through skin, avoid all
exposure.

Essential nutrient grouped in vitamin B complex, irritating to eyes,
respiratory tract, and skin.
Human teratogen & reproductive toxin


Investigational drug, toxicological information was not available at
the time of review.



Investigational drug, toxicological information was not available at
the time of review.



Confirmed human mutagen, potent irritant.

Irritant, possibly harmful by ingestion/inhalation/skin contact,
possible sensitizing agent - avoid all contact. Histamine H3 inverse
agonist/antagonist.


Suspected human carcinogen, confirmed human mutagen, possible
teratogen/reproductive toxin, acute toxin (LD50 rat oral 28.5 mg/kg)-
extremely toxin
Moderate dangerous by all exposure routes.

Evidence of chronic reproductive toxicity - animal data only
Irritant effects and harmful by ingestion. Target organ effect: liver.



OSHA target organ effect on the CNS & heart, harmful by ingestion.
Chronic reproductive toxin data in mice & rats.



Antihypertensive drug, highly toxic by all exposure routes, possible
teratogenic/reproductive toxin properties (animal test data only).

FDA-approved antipsychotic drug. Suspected human mutagen
(human test data available), possible teratogen/reproductive toxin
(animal test data only). Strong toxin (subacute). Possible
additional hazard: residual methylene chloride (OSHA carcinogen)
in some preparations.
Irritant effects, avoid inhalation and contact with dust.




Suspected human carcinogen (IARC 2B), human mutagen,
suspected human reproductive toxin. Strong toxin (subacute) and
sensitizing agent: avoid contact

The toxicological properties of this compound have not been
thoroughly investigated. Agent must be handled with extreme
caution until sufficient information becomes available for fully
determining hazards.



Strong toxin, possible reproductive toxin/teratogen, sensitizing
agent. Avoid contact by all exposure routes.

Possible irritant effects, limited hazards.


Laboratory experiments have shown teratogenic effects. LD50 Oral -
mouse - 5.886 mg/kg; Eyes - rabbit - Severe eye irritation - 3 h.




Strong irritant, respiratory tract sensitizing agent - avoid contact.




Possible irritant effects, limited hazards.

Possible irritant effects, limited hazards.

Irritant and possible harmful effects to central nervous system,
heart, and kidneys, possible neurotoxin. sensitizing agent.
Exposure may result in serious damage to eyes, avoid exposure by
all routes.


OSHA Hazards: Target Organ Effect
Target Organs: Cardiovascular system.
Several case studies available indicating significant exposure
threats in relation to agent: inflammatory/sensitizing agent,
interference with TB test, possible reproductive toxin. For additional
information refer to OEHS webpage.


Confirmed human mutagen, possible teratogen and reproductive
toxin, potent sensitizing agent: avoid inhalation, skin contact and
other exposure.


CDC "Select Agent", acute toxin, may be deadly by all exposure
routes - avoid contact.


Limited information available, MSDSs for components/related
compounds (glycine, ruthenium (II) dicarbonyl chloride) indicate
related irritant and poison properties by all exposure routes.

Surgical sealant compose of two polethylene glycol polymers,
product information sheets indicate low toxicity.
Novel compound with limited available chemical, physical, and
toxicological information.

No known OSHA hazards


Moderate toxin. Droperidine and troprolidine hydrochloride are
closest relatives that could be identified = inference made. PI's
should review specific MSDS information when conducting hazard
assessments. Possible irritant and neurotoxic effects.
Irritant, potentially harmful by all exposure routes, limited data
available.




Novel compound with limited available chemical, physical, and
toxicological information.



No known significant hazards to man or environment

Irritant, potentially harmful by all exposure routes - inhibits gastric
secretion.
Suspected human carcinogen (IARC 2B)

Low to moderate toxicity.

May cause irritation


MSDS indicates that agent is strong neurotoxin, exposure may
induce nerve demylenation and MS-like effects. Potent irritant and
with possible mutagenic and/or reproductive toxin effects (animal
data only).
A weak hemeoxygenase inhibitor . Protoporphyrins are potent
irritants, may be harmful via inhalation and ingestion.



Possible mutagenic properties, irritant to eyes, skin, and respiratory
system.
Acute toxin, multiple exposure routes



Irritant and possible sensitizing agent. Possible teratogenic and
reproductive toxin effects (animal data only).
Irritant, low toxicity



Confirmed human carcinogen, teratogen, mutagen,
embryotoxin, IARC group 1, NTP "known" human carcinogen,
OSHA/NIOSH hazardous drug (antineoplastic agent).

Confirmed human carcinogen, teratogen, mutagen,
embryotoxin, IARC group 1, NTP "known" human carcinogen,
OSHA/NIOSH hazardous drug (antineoplastic agent).

Agent has unknown toxicological properties.


Agent has unknown toxicological properties.

Potent irritant and possible immunosuppressant




Although the physiological role of the enkephalins has not
been completely elucidated, they are known to block inhibitory
pathways in the vertebrate CNS and their possible effects on
pain perception, addictive states, and psychiatric disorders
have been investigated
FDA-approved muscle relaxer. Suspected human reproductive
toxin and possible teratogen. Toxic effects on liver - exposure may
induce hepatitis (hepatic necrosis).



Can cause hemolytic anemia in those persons with glucose-6-
phosphate dehydrogenase deficiency in the erythrocyte. May cause
methemoglobin formation. Suspected human mutagen.




FDA pregnancy category B, no mutagenic activity, limited toxicity
information available




Possible carcinogenic properties, animal test data indicating
mutagenic properties, strong toxin and possible sensitizing agent.




May cause irritation to eyes, skin and respiratory system.
May be harmful if swallowed.
Product MSDS states that toxicological, chemical and physical data
has not yet been fully investigated.




Possible irritant/harmful effects via all exposure routes. Exposure
may also cause disturbances to nervous system.
Possible carcinogen, mutagenic & reproductive toxin properties,
dangerous to the environment
Acute toxin, toxic to fish, other aquatic invertebrates and algae




OSHA target organ effect in the lungs



Flammable & toxic. IARC Group 2B/NTP/OSHA probable
carcinogen, teratogen & reproductive toxin. Environmental toxin

Possible reproductive toxin effects, California Prop 65
developmental toxin.
Possible teratogenic, carcinogenic, and reproductive toxin
properties. Irritant/ moderate toxin
Exposure may damage adrenal cortex, eyes, bones, immune
system. Limited animal test data available indicating possible
teratogenic properties.
FDA: "Fast Track" cancer drug, proteasome inhibitor, the limited
available information does not identify as carcinogen, mutagen or
teratogen, possible reproductive hazard properties are noted.
Strong irritant and potential sensitizing agent - avoid exposure.
Limited evidence of possible antineoplastic properties.




Possible teratogenic and reproductive toxin properties (animal data
only). Possible sensitizing agent.
Moderate poison

FDA-approved drug for treatment of hormonal/allergy disorders.
Sensitizing agent, possible mutagen, suspected teratogen and
reproductive hazard properties.
FDA-approved drug for treatment of hormonal/allergy disorders.
Sensitizing agent, possible mutagen, suspected teratogen and
reproductive hazard properties.
FDA-approved drug for treatment of hormonal/allergy disorders.
Sensitizing agent, possible mutagen, suspected teratogen and
reproductive hazard properties.
FDA-approved drug for treatment of hormonal/allergy disorders.
Sensitizing agent, confirmed human mutagen, suspected teratogen
and reproductive hazard.
Irritant and sensitization effects.

Suspected reproductive toxin and potential teratogenic/mutagenic
properties. Sensitizing agent.
Suspected human mutagen, possible reproductive toxin.




Highly toxic; rat oral LD50 of 5 mg/kg; may be fatal if inhaled,
absorbed through the skin, or swallowed.



Possibly carcinogenic and tumorigenic: liver tumors

Possible carcinogenic, mutagenic, teratogenic, and reproductive
toxin properties (animal data available)
Irritant, poison by all routes - avoid contact with/breathing of dust.

Limited information available, double subunit cellular protein that
binds calcium to phospholipids, functions in coagulation.


Human mutagen, teratogen, and reproductive toxin, California Prop
65 developmental toxin. USDEA Schedule IV drug.


Poison by all routes, possible teratogen, California Prop 65
developmental toxin.

Suspected human carcinogen, possible mutagenic, teratogenic and
reproductive toxin effects.

Suspected human carcinogen, possible mutagenic, teratogenic and
reproductive toxin effects.

Toxic to aquatic organisms


Moderate poison, toxin, possible irritant.


Possible reproductive toxin (FDA Pregnancy Category C), possible
teratogen. Highly toxic (rat oral LD50: 53 mg/kg).
Suspected human mutagen. Other sources indicate that
riboneucleotide inhibitors are possible teratogenic/ reproductive
toxins and strong poisons. Closely related compound (2-
hydroxybenzohydroxamic acid) is suspected human mutagens. if
May be fatal if inhaled. May cause respiratory tract irritation. Toxic
absorbed through skin. May cause skin irritation. May be fatal if
absorbed through skin. May cause eye irritation. May be fatal if
swallowed. Target Organs Central nervous system, Liver, Blood.
Toxicity to fish mortality LC50 - Carassius auratus (goldfish) - 1.6
μg/l - 96 h Toxicity to daphnia and other aquatic invertebrates.
Immobilization EC50 - Daphnia magna (Water flea) - 79.5 μg/l - 48 h


NIST MSDS (attached): IARC Group 2A carcinogen, NTP
suspected carcinogen. Avoid exposure by all routes.


NTP "known" human carcinogen; toxic to the reproductive
system.
MSDS indicates possible irritant/harmful effects via all exposure
routes.

Highly toxic (oral/skin/inhalation LD50s not provided). Neurotoxin:
Avoid contact via all exposure routes.

Novel compound with no available toxicological information: handle
with extreme caution



Possible irritant effects, may be harmful if absorbed through skin or
inhaled.

MSDS indicates that agent is highly toxic (approaching acute level)
via ingestion and skin contact. Suspected mutagenic properties.

IARC 2A Carcinogen, confirmed human mutagen (extensive human
data), suspected teratogen/reproductive toxin (extensive animal test
data).
Not classifiable as human carcinofgen. Possible teratogenic effects
and classified (female) / possible (male) reproductive toxin. Toxic to
liver, kidneys and CNS. May be toxic to blood and NS.

IARC 2B Carcinogen, highly toxic by inhalation and ingestion, target
organ effect,




Highly toxic; acutely toxic by inhalation. Possible carcinogen.




Novel compound with no available toxicological information: handle
with extreme caution



Possible sensitizing agent, exposure may be extremely destructive
to mucous membrane, respiratory tract, and eyes. Also may pose
explosion hazard if managed improperly.
Toxic by inhalation and ingestion, readily absorbed through skin.
Neurotoxin, hepatotoxin, may also damage eyes, kidneys, and lung
tissue.



Acute toxin, possible human carcinogen/teratogen: NIOSH advises
reducing exposure potential to lowest possible degree



Pyrogen. Acute toxin, parenteral child 488 NG/KG LDLO




Possible carcinogen, teratogen, and reproductive toxin with chronic
exposure (animal data only)

Inhalation: May be harmful if inhaled. May cause respiratory tract
irritation. Skin: May be harmful if absorbed through skin. May cause
skin irritation. Eyes: May cause eye irritation. Ingestion: Toxic if
swallowed.Target Organs: Liver, Nerves., Kidney. Human
mutagenic data, also ecotoxin

NMDA receptor antagonist/channel blocker, irritant and strong
neurotoxin
NMDA receptor antagonist, potent irritant to eyes, respiratory
system and skin - avoid contact.

Possible irritant/harmful effects via all exposure routes.


An essential amino acid, hazards appear to be limited: avoid
breathing breath dust, avoid contact with skin.

Possible irritant/harmful effects via all exposure routes.


Suspected human mutagen, reproductive toxin, and
teratogenic hazards, strong poison all routes.



Harmful by inhalation, skin contact, and swallowing. May
cause harm to unborn child
Irritant, potential harmful effects by all exposure routes. No
information available regarding chronic effects.
Chemical, physical, and toxicological properties have not been
thoroughly investigated. Handle with care and avoid exposure.


DMSO has low toxicity and no confirmed chronic health effects, but
serves as a highly effective vehicle for the delivery of a number of
hazardous chemical agents thereby greatly increasing exposure
potential.

Competitive kianate, non-NMDA glutamate receptor antagonist:
possible irritant and harmful effects via all exposure routes.



The toxicological properties of this compound have not been
thoroughly investigated. Agent must be handled with extreme
caution until sufficient information becomes available for fully
determining hazards.

β1-Adrenoceptor receptor agonist with cardiotoxic and
possible teratogenic and reproductive toxin effects (animal
test data only). EU: possible fetotoxin.
Extreme sensitizer of lung tissue and mucus membrane and a
potent neurotoxin of unknown strength (no published information
regarding LD50s could be located) - avoid exposure.




There are formulations for both veterinary & human use.


NIH: Confirmed human carcinogen and mutagen, suspected
teratogen and reproductive toxin. Refer to MSDSs/Additional
links for additional resources.




Irritant, low toxicity

Novel compound with no available toxicological information: handle
with extreme caution



Pregnancy Category C, possible hepatic and renal toxicity.



May be harmful if inhaled, absorbed through skin, or swallowed.
May cause skin, eye, or respiratory tract irritation.
Slightly hazardous in case of skin contact, eye contact, or ingestion
(irritant).
Acute toxin

Moderate toxin/irritant

Moderate toxin/irritant by all exposure routes.
Irritant and sensitizer


Irritant




FDA-approved angiotensin converting enzyme inhibiting drug.
Moderate toxin, with confirmed teratogenic/reproductive toxin
hazards (human test data available).



FDA-approved veterinary antibiotic similar to Cipro®, irritant.


Irritant


Irritant


Possible teratogen (limited animal data), possible
neurotoxin/cardiotoxin effects.


Highly toxic, may cause harm to unborn child. Toxic by inhalation,
skin contact and swallowing. Irritating to eyes, respiratory system
and skin
LD50 is between 7 to 67 nmol/Kg, but does not distinguish
administration route or test animal. MSDS warns that agent is
highly toxic (neurotoxic effects) but does not provide MSDS.



Acute toxicity LD50 Oral - rat - > 15,000 mg/kg. Genotoxicity in vitro -
mouse - Liver


Suspected human mutagen, limited available toxicological
information. A potent antioxidant derived from green tea.




Acute toxin via skin contact, injection, and possibly other exposure
routes. Possible mutagenic, reproductive toxin, and teratogenic
properties. Possible cardiotoxic effects.




NCI: The hydrochloride salt of a quinazoline derivative with
antineoplastic properties

Glycoprotein which stimulates red-blood cell production, FDA-
approved for treatment of anemia. Potential hazards: Processed
from human albumin, remote risk for contamination with disease-
causing prions (CJD, others); possible reproductive toxin (FDA
pregnancy category C agent), possible tumor promoting agent.
NTP known human carcinogen, IARC Group 1 carcinogen,
OSHA/NIOSH hazardous drug lists.




IARC Group 1/NTP known human carcinogen with confirmed
mutagenic, teratogenic and reproductive toxin properties



Utilized in rheumatoid arthritis treatment, protein, TNF-a blocker,
immunosuppressant, limited information available.


Strong toxin by all routes, ototoxin

Possible neuro/cardio/hepatotoxin effects, potent irritant effects.
Potential for chronic hazards (possible mutagenic, teratogenic,
reproductive toxin, carcinogenic properties). IARC classifies ethanol
in alcoholic beverages as a Group 1carcinogen.

Highly toxic, potent irritant effects. Possible mutagen.

Human mutagen (Human test data available), possible teratogen,
fetotoxin, and reproductive toxin. Exposure may also harm the
central nervous and circulatory (blood) system. FDA-approved
medication for treatment of petit mal-related seizures.

Human mutagen, possible carcinogenic, teratogenic, and/ot
reproductive toxin properties. California Prop 65 carcinogen.
Neurotoxin, irritant, may cause permanent damage to eyes.
Target Organ Effect (blood & bone marrow) Harmful by ingestion,
Carcinogen. Laboratory experiments have shown mutagenic effects.

Extremely flammable, may form explosive peroxides, strong irritant,
possible mutagen, ecotoxin. Dispose of all ether-containing waste
through OEHS. If dated containers are ethyl ether are encountered,
contact OEHS immediately for assistance.

Phenytoin Sodium is a confirmed carcinogen, although amount of
phenytoin sulfate in product is limited (<1%), extreme caution
should be used when administering to avoid exposure.

Possible carcinogenic properties, extensive animal test data
indicating mutagenic, teratogenic, and reproductive toxin properties.

IARC 2B carcinogen/NTP "reasonably anticipated human
carcinogen." Avoid exposure via all routes.


Potent neurotoxin

Vitamin A analog with potential antineoplastic properties. Animal
evidence that agent is potential reproductive toxin, teratogen, and/or
mutagen. May cause damage to unborn fetus. Multiple exposure
routes.
USDEA Schedule II controlled substance, acute toxin: rat oral LD50
18 mg/kg, avoid exposure by all routes.
Irritant, toxin



Many MSDSs for fetal bovine solution indicate that their products
are certified to be free of adventitious agents. Care must be taken
to review MSDSs for all products to determine if certified free of
adventitious agents (bacterial, viral, and prion).


The product has been approved for surgical use in the EU, risk of
contamination with adventitious agents appears to limited, however;
the IBC recommends handling agent under BSL-2 precautions.

Possible irritant/harmful effects via all exposure routes.




RTECs: reproductive toxin




Suspected reproductive toxin and teratogen, rat oral LD50: 134
mg/kg. Potent immunosuppressant properties.


MSDSs for Bacillus subtlilis and Salmonella typhimurium indicate
strong irritant response, with limited toxicological/chronic exposure
information. NIH lists as adjuvant causing strong proinflammatory
response, avoid exposure.




Human mutagen (human test data available), potent CDK (cyclin-
dependent kinase) inhibitor. Agent is a novel antineoplastic
agent with limited available toxicological information.



Moderate toxin with possible reproductive toxin effects




Veterinary drug for treating intestinal disorders. Irritant to eyes,
respiratory system, and skin.
Chronic hazard - sensitizer of lungs/nervous system, avoid all
exposure. Strong poison.



Fluorocarbon compounds typically pose low to moderate toxicity,
with irritant and asphyxiant hazards. Some fluorocarbons are also
classified as potential mutagens.


Drug class has been associated with mutagenic, and/or
teratogenic/reproductive toxin properties.



Novel compound - no data available




Human teratogen and reproductive toxin
Antipsychotic; neuroleptic agent; dopamine receptor antagonist.


Possible reproductive toxin



MSDS indicates that the chemical, physical, and toxicological
properties of this agent have not yet been fully evaluated.


Possible mutagenic and/or teratogenic, (only animal data available).
Potential irritant/harmful effects via all exposure routes.

OSHA Hazards -
Irritant
Suspected human carcinogen, mutagen, teratogen, and
reproductive toxin.




OSHA Hazards - target organ effects to smooth muscle




No known associated chronic hazards indicated, but limited
available toxicological information.

Novel therapy for multiple sclerosis. Possible irritant and/or
harmful effects via inhalation, ingestion, and/or skin contact -
toxicological properties of which have not yet been thoroughly
evaluated. Scientific journals indicate possible
immunosuppressant/antineoplastic properties.
May cause irritation if inhaled, absorbed through skin or
swallowed
Novel


Target Organ Effect: liver & kidneys. Carcinogen, Teratogen,
Reproductive hazard, Mutagen. Overexposure may cause
reproductive disorder(s) based on tests with laboratory
animals.
Irritant, potentially harmful by all exposure routes - possible
neurotoxin. A selective opioid receptor antagonist.



Physical hazards only: moderate toxin

FDA-approved drug for treatment of liver and renal diseases.
MSDS indicates agent is confirmed human mutagen, suspected
reproductive toxin, with possible teratogenic/carcinogenic properties.



Irritants with potential for damaging central nervous system.




OSHA Hazards: Target Organ Effect, Irritant, Teratogen
Teratogenicity: May cause congenital malformation in the fetus.
Presumed human reproductive toxicant
Moderate toxin, possible carcinogen (limited evidence)




Limited hazards, possible irritant effects via inhalation/ingestion.


Toxic; irritating to eyes, respiratory system & skin. Target organ(s):
Central nervous system

Irritant, potentially harmful by all exposure routes - targets smooth
muscles.

NIH: Human acute toxin, carcinogen, teratogen, mutagen,
exposure risk via all routes.

Moderate toxin with reproductive hazard potential



May be toxic to multiple organ systems




Possible mutagenic/reproductive toxin properties.


Confirmed human mutagen, suspected reproductive toxin,
possible teratogen and/or carcinogen. Strong (subacute)
toxin.

Possible mutagen, teratogen, reproductive toxin. May cause
photosensitization and/or allergic sensitization of respiratory
tract. Avoid inhalation and other exposure.

Bioactive peptide which stimulates production of growth
hormone. Irritant and other possible harmful effects. MSDS
indicates that toxicological properties for this agent have not
been fully investigated.
Bioactive peptide which stimulates production of growth
hormone. Irritant and other possible harmful effects. MSDS
indicates that toxicological properties for this agent have not
been fully investigated.
Highly toxic by all exposure routes (mouse oral LD50 65
mg/kg). Strong irritant.
Possible teratogen/mutagen

ACGIH TLV: 0.05 ppm. Strong sensitizer, highly toxic.
Extremely destructive of mucous membrane avoid inhalation
and exposure by all routes.
Possible mutagenic properties. MSDS indicates that threat is
only posed by glutathione in free acid form - and that human
mutagenicity is not yet confirmed = handle with care.

Confirmed human mutagen (human test data available).

Possible teratogenic and reproductive toxin effects (animal
data only). Irritant and possible harmful effects (CNS
depression, circulatory system/gastric) via ingestion,
inhalation, and/or skin contact.
Irritant to mucous membrane and upper respiratory tract, potentially
harmful if inhaled or ingested.
Possible mutagenic properties.

MSDS indicates that chemical, physical, and toxicological properties
have not been evaluated - agent should be considered hazardous
Strong toxin, possible reproductive hazard. Avoid exposure
by all routes.

Possible mutagenic, teratogenic, and/or reproductive toxin effects
(only animal data available). Potentially harmful via all exposure
routes.

NMDA receptor partial agonist that acts at the glycine site.
Simultaneously acts as a promoter of the induction of long-term
potentiation (LTP) and as a suppressor of long-term depression
(LTD). Exhibits nootropic, neuroprotective and antinociceptive
activity, and enhances learning, memory and cognition in vivo. Brain
penetrant. Novel compound
MSDS indicates that agent is novel compound: toxicological
properties have not yet been fully evaluated.



No known associated chronic hazards indicated, but limited
available toxicological information. MSDS for similar protein kinase
C inhibitor (Go-6976) indicates primarily irritant effects.


Irritant to mucous membrane and upper respiratory tract, potentially
harmful if inhaled or ingested.



Confirmed reproductive toxin, suspected teratogen, may impair
fertility.




No MSDS information - novel compound



Irritant, causes skin & serious eye irritation, may cause respiratory
irritation.



Confirmed human teratogen, mutagen, and reproductive toxin.
Possible human carcinogen. Sensitizing agent. Antipsychotic drug.



Experimental teratogenic, mutagenic, and reproductive toxin effects
(human test data available). California Prop 65 Developmental
Toxin.



Possible irritant, may be harmful if inhaled/ingested.



Novel compound with limited available hazard information, in vivo
applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C until demonstrated to be
nonhazardous.
Possible nephrotoxic effects, possible irritant and other harmful
effects via inhalation, ingestion, and skin contact.


Protein, attenuates cardiac injury, limited hazards

Novel antineoplastic agent derived from marine sponge species.
Limited data available.


Combat field dressing derived from shrimp shell chitosan. Product
information sheet indicates low toxicity.



Low hazard.



Low hazard.



Agent is highly toxic by ingestion and skin absorption



Confirmed human reproductive toxin, highly toxic, possible
teratogen. Avoid contact by all exposure routes.




Irritant effects and possibly harmful via ingestion, inhalation, and/or
skin contact, possible mutagenic properties.
Limited health and safety information exists for this agent. Strong
irritant and toxin effects are suspected, exposure by all routes
should be avoided.

OSHA Hazard: Target Organ effect. Harmful by ingestion.


Irritant, moderate toxin - avoid exposure via all routes.

MSDSs indicate that agent is possible human reproductive toxin
with additional potential for teratogenic and mutagenic effects. Most
products are screened for bloodborne pathogens but tests are not
totally conclusive: due to remote possibility of contamination with
bloodborne pathogens BSL-2 precautions are advised during
preparation and administration.

Most products are screened for bloodborne pathogens but tests are
not totally conclusive: due to remote possibility of contamination
with bloodborne pathogens BSL-2 precautions are advised during
preparation and administration. MSDSs also cite potential for
mutagenic/teratogenic properties.

Possible irritant/harmful effects via all exposure routes.




Possible teratogenic and/or reproductive toxin effects (limited animal
data), possible irritant/other harmful effects, avoid contact.
Extremely destructive to tissues of upper respiratory tract, skin,
mucous membrane

Physical hazards only - strong corrosive may cause permanent
damage to eyes and respiratory system, avoid contact.
Irritant and photosensitizer. Target organ: kidneys.




Possible risk of harm to unborn child.




Possible teratogenic/reproductive toxin effects (limited animal data
available), irritant/possible harmful via all exposure routes.



Potential for acute toxicity (mouse oral LD50 11 mg/kg) and
suspected human mutagen properties. There are several variants
of methyl carbamoyladenosines currently being researched for an
array of biomedical purposes - avoid contact by all exposure routes.

Potent neurotoxin, rat oral LD50: 129 mg/kg, harmful via ingestion,
subcuteous/intravenous exposure.
OSHA target organ effect of nerves




Toxic, potentially harmful via all exposure routes: exposure may
damage vascular system.

A novel anti-cancer drug, limited available health & safety
information. Potential cancer threat.


May be harmful if ingested, potential irritant effects. Refer to
specific product MSDS for potential hazards and precautions.




May be harmful if ingested, potential irritant effects. Refer to
specific product MSDS for potential hazards and precautions.




FDA-approved drug for treatment of myeloid leukemia. A
cardiotoxin and a Pregnancy Category D drug (demonstrated risk to
fetus).

The chemical, physical, and toxicological properties of this product
have not been thoroughly investigated.
Human mutagen, suspected teratogen, reproductive toxin, strong
poison.


Possible irritant effects to skin, mucous membrane and respiratory
tract. Other sources: some IgE may be sensitizing agents

Irritant, avoid contact and inhalation. Exposure may adversely
effect central nervous system.
Novel compound with limited available hazard information, in vivo
applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C until demonstrated to be
nonhazardous.
Irritant and other possible harmful effects. Avoid contact with eyes.

Toxic - rat oral LD50: >5000 mg/kg. Severe eye Irritant.

Acute toxin rat oral LD50 2420 µg/kg, human teratogen, suspected
mutagen and reproductive toxin

Limited hazards indicated, possible irritant/other harmful effects

NIOSH Hazardous Drug Guide lists these interferons as having
antineoplastic properties.
Limited available health and safety information available, suspected
irritant and toxic effects, extreme caution advised.
Irritant, low/moderate toxin

May be harmful if inhaled or absorbed through skin. May cause
respiratory tract and eye irritation. May be harmful if swallowed.

Polyethyleneimine is an OSHA irritant in it's pure form

Possible irritant/harmful effects via all exposure routes, California
Prop 65 Developmental Toxin

Antineoplastic agent, used in non-small cell lung cancer treatment -
no carcinogenesis study or toxicological information available.


Tumorigenic, Embyo/Fetotoxic, Mutagen, Teratogen, Reproductive
Hazard

May be irritating to skin and eyes.



Suspected human mutagen, possible human teratogen and
reproductive toxin. Strong ototoxic agent, highly flammable and
possibly explosive, strong sensitizing agent, irritant, and poison -
avoid exposure by all routes.

Irritant effects



Acute toxin via inhalation (Rat LC50 170 mg/m3), suspected
carcinogen, confirmed human mutagen, possible reproductive toxin/
teratogen, sensitizing agent, experimental neoplastic, strong poison
all routes. California Prop 65 carcinogen. Extremely harmful to
environment (aquatic life). All contaminated materials, waste, and
stocks must be disposed of through OEHS. Avoid exposure by all
routes.




A novel, potent microtubule depolymerizer with anti-tumor effects




Antagonist of Sphingosine-1-P2, MSDSs indicate that toxicological
effects have not yet been fully investigated, but indicate that agent is
very hazardous (strong irritant) and that contact via all exposure
routes can have harmful effects .
MSDS indicates that agent is a potent neurotoxin which may also
have irritant effects. Possible mutagenic/reproductive toxin
properties.



Suspected human mutagen, possible human teratogen and
reproductive toxin. Strong ototoxic agent, sensitizing agent, irritant,
and poison - avoid exposure by all routes.



A novel MMP inhibitor




Strong toxin and irritant with possible mutagenic, teratogenic, and
reproductive toxin properties (only animal test data available).


Toxic by ingestion. Delayed target organ effect (liver, male
reproductive system)




Toxic; potentially harmful to newborn child; exposure may damage
to target organs.
Respiratory protein derived from mollusk Megathura crenulata with
possible applications anti-cancer therapy (vaccine carrying vehicle).
Only irritant effects noted on MSDS
Possible irritant, may be harmful if inhaled/ingested/absorbed.


Possible irritant, may be harmful if inhaled/ingested.




Possible irritant, may be harmful if inhaled/ingested.


Possible irritant, may be harmful if inhaled/ingested.


Novel radiosensitizing drug with limited toxicological information
available, possible antineoplastic properties - avoid exposure by all
routes.
Novel compound with unknown toxicological properties, handle with
extreme caution.

Novel compound with unknown toxicological properties, handle with
extreme caution.




Irritant, possible mutagenic/reproductive toxin and low to moderate
toxin properties in association with diazepine compounds
(clozapine, cormelian, lendormine, etc.).



NMDA receptor antagonist/anti-convulsant, irritant

Physical hazards only
MSDS: Potent neurotoxin, may be toxic if allowed to enter
bloodstream, possible reproductive toxin (limited animal data)
additional irritant/harmful effects possible.
A novel HDAC inhibitor. Appears to be chemically related to 3,5-
dimethoxy-hydroxycinnamic acid, which has moderate toxicity and
irritant effects.
May be harmful if inhaled; may cause respiratory tract irritation. May
cause eye or skin irritation.
Possible reproductive toxin. FDA Pregnancy Category C agent.


Toxic if swallowed.


FDA-approved novel antineoplastic agent utilized in treatment of
advanced breast cancer. Possible mutagenic and fetotoxic
properties, and further indicates that carcinogenicity test are on-
going. Exposure should be avoided by all routes.


State DEQ restrictions apply to disposal

Strong sensitizer/allergen. Strong poison (subacute) by all routes.


Irritant, avoid breathing dust, possible mutagenic/reproductive toxin
properties. Avoid all contact.


FDA-approved anti-convulsant/epilepsy treatment medication.
Classified as a Pregnancy Category C drug: sufficient animal
evidence to indicate toxicity to developing fetus.

Strong poison with possible reproductive toxin hazard



OSHA hazards (combustible liquid), Target organ effect(kidney),
skin sensitizer, irritant.


Not known to be toxic



Many of these compounds may be acute toxins. Available data
indicates the following oral LD50 values for rats:

                                   - E. coli 0111:B4 - 48.9
OSHA Target Organ effect; harmful by ingestion, and irritant. mg/kg



FDA-approved hypertension drug, pregnancy category D: may
cause birth defects.




Suspected mutagen, reproductive toxin, and teratogenic
hazards. LD50 (rat oral) is listed at 30 mg/kg: acute toxin.
Low toxicity, possible reproductive toxin. Possible irritant/harmful
effects via all exposure routes, but does not indicate any known
chronic effects.
Irritant by all exposure routes



No known hazards
FDA pregnancy category C agent. MSDS does not indicate hazards


Possible irritant to eyes and skin. May be harmful if ingested.


Possible irritant/harmful effects via ingestion and/or inhalation.



Possible teratogen, California Prop 65 reproductive toxin,
strong poison with possible sensitizing effects.


Possible irritant, may cause strong allergic skin reaction



Irritant to mucous membrane and upper respiratory tract, potentially
harmful if inhaled or ingested.
May be harmful if inhaled; may cause respiratory tract irritation. May
cause skin irritation.
Product MSDS states that toxicological, chemical and physical data
has not yet been fully investigated.



Novel compound with no available toxicological information at time
of review.



Cytokine, exudate produced by TNF-a application. Limited
available information.


Possible irritant effects, low toxicity.



May be harmful if inhaled, absorbed thru the skin, or swallowed;
may cause skin, eye, or respiratory tract irritation.
Possible irritant/harmful effects by all exposure routes, targets
kidneys.



May be harmful if inhaled; may cause respiratory tract irritation. May
cause skin irritation.


May be harmful if inhaled; may cause respiratory tract irritation. May
cause skin irritation.



May be harmful if inhaled; may cause respiratory tract irritation. May
cause skin irritation.
Irritant to mucous membrane and upper respiratory tract, potentially
harmful if inhaled or ingested.

Potent irritant, effecting eyes, mucus membrane, respiratory system,
and skin. Avoid contact by all routes.

Potent irritant of eyes, respiratory system and skin. Possibly
harmful via inhalation/ingestion/skin contact.
Irritating to eyes, respiratory system, and skin. May be harmful if
swallowed.


Herbicide with suspected carcinogenic, teratogenic, mutagenic, and
reproductive toxin effects. MCPP in environment may cause long-
term damage to aquatic environments: dispose of all waste, stocks,
and potentially contaminated materials through OEHS.


Neurokinin-1 receptor antagonist, no significant hazards
indicated.

Potent cell permeable calpain I and II inhibitor


FDA-approved antihypertensive drug, used for treating Tourette
Syndrome. Nicotine blocker, strong poison by all exposure routes.


FDA-approved human/animal sedative: Pregnancy Hazard C. Pfizer
MSDS: acute toxin (rat oral LD50: 31 mg/kg).

Potent irritant via all exposure routes, possibly harmful via ingestion.




Extensive human test data indicating carcinogenic, mutagenic,
reproductive toxin properties; acute toxin (rat oral LD50 12 mg/kg);
possible sensitizing agent. California Prop 65 carcinogen and
developmental toxin. EPA U-Listed Hazard.


Strong neurotoxin and irritant - avoid exposure by all routes.


Novel compound with no available toxicological information: handle
with extreme caution



Possible Sensitizer, May produce an allergic reaction. Ingestion:
Toxic if swallowed. Target Organs: Kidney, Liver, Blood. Acute
toxicity: LD50 Oral - rat - 500 mg/kg LD50 Intraperitoneal - rat - 75
mg/kg LD50 Intraperitoneal - mouse - 50 mg/kg LD50
Subcutaneous - mouse - 138 mg/kg

Human oral LD50 5 - 50 mg/kg - extremely toxic by all
exposure routes. Special state DEQ disposal requirements
apply. Ecotoxic to fish, aquatic invertebrates & algae, may
cause long-term adverse effects in the aquatic environment.
OSHA target organ effects: kidneys, nerves, GI tract. Highly
toxic by ingestion and skin absorption, corrosive and a
possible reproductive hazard with overexposure (animal
data). Rat LD50 oral: 1mg/kg Rat LD50 dermal: 41mg/kg
No associated chronic hazards known, potent irritant to eyes
and respiratory tract, potentially harmful via ingestion,
inhalation, skin contact: avoid exposure.
Exposure can cause: Abdominal pain, nausea, vomiting,
diarrhea; damage to multiple organ systems.
May be harmful via exposure by all routes, potent irritant of
eyes, skin, and respiratory system.



Exposure may seriously damage lungs, heart, and other
organs/organ systems. Possible teratogenic and reproductive
toxin properties (animal test data available).
Irritant, possible harmful effects to CNS. Related to amphetamines.


Possible irritant and/or harmful effects, effecting eyes, mucus
membrane, respiratory system, and skin. Avoid contact by all
routes. Limited toxicological information available.
NIH: Acute toxin, teratogen, reproductive toxin




Possible cardiotoxic and irritant effects.



Exposure may result in extreme light sensitization, strong irritant,
inhalation may result in lung damage. Possible reproductive toxin.


Some methyl/methylene dyes are suspected human mutagens
and/or possible reproductive toxins. Irritant, potentially harmful to
eyes, lungs, CNS, and blood.

Potent Irritant, strong toxin. Highly dangerous via all exposure
routes: avoid contact, possible teratogenic properties.
Slightly hazardous in case of skin contact, eye contact, or ingestion
(irritant).
Possible neurotoxic effects, dangerous via all exposure routes:
avoid contact.

Toxic by inhalation, ingestion, or skin contact.


Possible human teratogen and/or mutagen


Chronic oral developmental/reproductive toxin in rats, human
data not available.

Poison via intravenous route, possible reproductive toxin effects.
Possible reproductive toxin effects, irritant and CNS depression,
possible teratogenic properties. California Prop 65: Developmental
hazard. USDEA Schedule IV drugs.
Suspected human reproductive toxin, teratogen, and mutagen (test
data available)

Potent irritant and sensitizer of the mucus membrane and
respiratory tract with possible teratogenic properties. Avoid
exposure.

Acute toxin, carcinogen and reproductive toxin. Toxic to fish and
other aquatic invertebrates.
Product Info sheet indicates that drug is classified as FDA
pregnancy C, no known mutagenic/clastogenic properties.
Carcinogenesis studies are on-going.
MSDSs: avoid contact and inhalation: possible irritant harmful
effects.

MSDSs: avoid contact and inhalation: possible irritant harmful
effects.
Toxic effects, possible carcinogen, may cause heritable genetic
damage. May cause harm to the unborn child.
Calif. Prop. 65 carcinogen. Target organ(s): Lungs. Kidneys

Toxicological properties not fully investigated handle with extreme
caution.
Endocannabinoid activity enhancer. Possible toxic/irritant effects
via all exposure routes, handle with due caution.
Toxic by ingestion. Irritant effects via all exposure routes, handle
with due caution. Genotoxicity in vitro - Human - lymphocyte
DNA inhibition
Strong toxin, possible mutagen/reproductive hazard. USDEA
Schedule II controlled substance.

Strong toxin, possible mutagen/reproductive hazard. USDEA
Schedule I controlled substance.
Irritant, low toxicity

Irritant, low toxicity
Pyrogen, may cause fevers
Product MSDS states that toxicological, chemical and physical data
has not yet been fully investigated.


Potent neurotoxin, exposure may cause death or irreversible brain
damage - complete toxicological properties have not yet been
determined. Possible teratogenic/reproductive toxin properties.




Acute toxin: rat oral LD50: 45 mg/kg

Suspected human mutagen, strong toxin.



No known hazards


Product MSDS states that toxicological, chemical and physical data
has not yet been fully investigated.


Product MSDS states that toxicological, chemical and physical data
has not yet been fully investigated.




Possible reproductive toxin, possible teratogen. Limited
available information - avoid contact by all routes.



Teratogen, carcinogen, mutagen, and reproductive toxin. CA
Prop 65 toxin
May cause damage to the Central Nervous System. Crosses the
placenta and may pass into breast milk. May be hazardous by
inhalation, ingestion, or skin contact
Strong poison by subcutaneous route

FDA-approved drug for treating opiate/alcohol addiction,
experimental use in treatment of multiple sclerosis. MSDS: Human
mutagen (human test data available) with possible reproductive
toxin effects, and moderate toxic effects.




Anabolic steroid with possible human reproductive toxin properties.




Novel



Toxic via inhalation and ingestion, highly corrosive: contact by any
route may result in severe burns.
MSDS for 3-nitrobenzyl mercaptan indicates that agent is strong
irritant and poison by all exposure routes, avoid contact.

Potent irritant, effecting eyes, mucus membrane, respiratory system,
and skin. Avoid contact by all routes.
Physician's Desk Reference: no evidence of carcinogenic
properties, FDA pregnancy category D.
USDEA Schedule II controlled substance, possible
teratogenic, carcinogenic, and reproductive toxin properties.
California Prop 65 developmental toxin. Avoid exposure by all
routes.
All neomycins are moderate to strong poisons

Does not need to be registered if using a pharmeacuetical grade
formulation - others may need to be
Novel neuroprotectant drug currently in Phase II/II trials: no
toxicological information available at time of review.


Product MSDS states that toxicological properties have not been
thoroughly investigated.



Rash, fever, nausea, abnormal liver function, and possible
reproductive toxicity.
Acute toxins readily absorbed through skin, also highly toxic
via ingestion. Strong evidence of possible mutagenic,
teratogenic, and reproductive toxin effects. N'-
nitrosonornicotine (Nicotine 1'-nitroso-1'-demethyl) is an NTP
suspected/IARC 2B possible carcinogen.
Strong toxins which may be readily absorbed through skin
and highly toxic via ingestion. Evidence of possible
mutagenic, teratogenic, and/or reproductive toxin effects.
FDA-approved hypertension/angina treatment drug,
pregnancy category C: may cause birth defects. Human
reproductive toxin (human test data available), California Prop
65: Causes developmental toxicity.


California Prop 65 developmental hazard, possible
teratogenic properties.


Novel compound with limited available hazard information, in vivo
applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C until demonstrated to be
nonhazardous.

FDA "Orphan Drug" for treating sickle-cell anemia currently in
clinical trials, limited toxicological information available - avoid
exposure

May a a chronic neurotoxic effect



Strong corrosive and irritant, potential teratogen and/or
reproductive toxin.
If a pharmaceutical grade version does NOT need to be registered.
Others judged on case to case basis - as hazard class varies greatly
from agent to agent. Submit MSDS to OEHS.




Irritant properties and other potentially harmful effects.




Multiple hazards suspected - agent is a carbamide. Carbamide
compounds as strongly suspected human carcinogens, teratogens,
mutagens, and reproductive hazards.

Irritant properties and other potentially harmful effects.


Adrenergic neurotransmitter with confirmed human mutagenic
properties and suspected teratogenic/reproductive toxin
effects (animal data only). Acute toxin with rat oral LD50 of
20 mg/kg.




Novel ceramide analog with possible antineoplastic
properties. No toxicological information available.


While there are no known hazards, toxicological data has not
been thoroughly investigated
Antibiotic used for livestock (swine, cattle) and aquacultural
applications. MSDS indicates possible reproductive toxin properties,
irritant effects, and significant threats to the environments (aquatic
organisms).
Harmful by ingestion., Irritant



Material is extremely destructive to tissue of the mucous
membranes and upper respiratory tract, eyes, and skin
FDA: "Fast Track" cancer drug, "small molecule inhibitor." The
limited available information does not identify as carcinogen,
mutagen or teratogen; however, possible reproductive hazard
properties are implied on recruitment notices.
Hormone, appetite suppressor, limited hazards




Harmful by ingestion and dust inhalation. Irritating to eyes,
respiratory system, and skin.
May be harmful if inhaled, or absorbed through the skin. Causes
skin and eye irritation.
A fluoroquinolone with possible teratogenic, mutagenic, and
reproductive toxin properties, potent irritant - avoid inhalation.
Novel compound, toxicological information not available at time of
review: handle with extreme caution and avoid exposure by all
routes. Tumor promoting agent, confirmed human mutagen, toxic
MSDS:
via all exposure routes.

Novel compound with unknown chemical, physical and toxicological
properties

Strong irritant and possible sensitizing agent..

Possible reproductive toxin, strong toxin (LD50 rat oral: 94 mg/kg).

MSDS indicates that agent is novel compound: toxicological
properties have not yet been fully evaluated.
Possible teratogen, low to moderate toxin/irritant effects, may also
cause sensitization of respiratory tract - avoid inhalation.

OSHA target organ effect. Skin sensitizer, Irritant.


Considering that the parent compound is chlordane (multiple
hazards), agent may be fatal if inhaled, swallowed or absorbed
through the skin, as well as a possible carcinogen.

Product information indicates minimal anticipated hazards

Endogenous glucagon-like peptide that
modulates feeding and metabolism; secreted by intestinal
Lcells. Increases cAMP production and inhibits gastric acid
secretion in rat stomach. Also inhibits intestinal glucose
absorption. Reduces fasting ghrelin levels following
peripheral administration and reduces food intake and
weight gain in rats following central or peripheral
administration in vivo.
MSDS indicate that human toxicity is not anticipated

May be moderate poison, potential for reproductive toxicity
associated with palladium metal. Additional possible irritant effects
to eyes, skin, mucouscontact by all exposure routes.
Irritant effects - avoid membrane and respiratory tract.
Possible mutagen, Ames test: mutagenic properties. Potent
(subacute) toxin.

Irritant and possible sensitizing agent. Contact may lead to
sensitization of skin and/or serous damage to eyes.

Possible irritant


Highly toxic - may be FATAL if inhaled, absorbed, or if swallowed.
Target organ effect (CNS, blood, heart, eyes, liver)

Highly Toxic & dangerous for the environment. Toxic in contact with
skin and if swallowed. Very toxic by inhalation. Irritating to
respiratory system and skin. Risk of serious damage to eyes. Toxic:
danger of serious damage to health by prolonged exposure if
swallowed. Very toxic to aquatic
organisms, may cause long-term adverse effects in the aquatic
environment. Readily absorbed through skin. Target organ(s): Liver.
Central nervous system

Highly toxic - may be FATAL if inhaled, absorbed, or if swallowed.
Target organ effect (CNS, blood, heart, eyes, liver)


Novel anti-cancer drug, terpene extracted from the feverfew plant
(Tanacetum parthenium ). Confirmed human mutagen, strong
sensitizing agent (skin and lungs).



Suspected carcinogen, possible mutagenic and teratogenic
properties.

Suspected carcinogen, possible mutagenic and teratogenic
properties.

Suspected carcinogen, possible mutagenic and teratogenic
properties. Possible skin sensitizer and irritant

Chem. Service Inc MSDS: Suspected carcinogen, possible
mutagenic and teratogenic properties. Possible skin sensitizer and
irritant
Suspected carcinogen, possible mutagenic and teratogenic
properties. Possible skin sensitizer and irritant


Strong poison, possible teratogen/reproductive toxin




Novel antineoplastic compound with no available toxicological
information: handle with extreme caution


Possibly harmful via ingestion, skin contact, or inhalation. Avoid
contact



Novel compound




Strong to extreme sensitizing agents, with possible irritant and
harmful effects via all exposure routes. Possible mutagenic,
teratogenic, and/or reproductive toxin effects. Penicillin streptomycin
Strong to extreme sensitizing agents, with confirmed human
mutagenic, teratogenic, and/or reproductive toxin effects and
possible carcinogenic properties. d-penicillamine is a California
Prop 65 developmental toxin and RTECs reported human
tumorigenic agent.
May cause eye irritation and may be harmful if inhaled or absorbed
thru skin. Harmful if swallowed.
Strong poison




Confirmed human mutagen, suspected teratogenic/reproductive
toxin properties. Dangerous via all exposure routes - may be
absorbed though skin. Exposure may also result in deleterious
effects to blood/circulatory system.
MSDS indicates that agent is potent neurotoxin with other possible
irritant/harmful effects.



May be irritating to eyes. Toxicity low, LD (oral-rat) 2100 mg (NaClO
)/kg. No evidence of carcinogenicity




MSDS indicates that agent is highly to acutely toxic with suspected
mutagenic, teratogenic, and reproductive/fetotoxic properties.
Toxic by inhalation, high physical exposure hazard in relation to
frostbite: avoid skin contact. Strong irritant: avoid inhalation.



Novel alkylphospholipid drug with antineoplastic effects. In trials for
use in prostate cancer therapy. Limited information available -
handle with extreme care and avoid contact.

Strong sensitizing agent avoid all contact.




Novel compound with unknown chemical, physical and toxicological
properties



Exposure may induce parkinson-like symptoms, headache,
drowsiness, sedation, dizziness, tremor, impairment of voluntary
movement, dry mouth, diarrhea, nausea, vomiting, GI distress,
nervousness, adverse behavior effects, skin rash, visual
disturbance, hypotension, palpitations, and muscle tightness.
Sensitization: Causes photosensitivity. Exposure to light can result
in allergic reactions resulting in dermatologic lesions, which can
vary from sunburnlike responses to edematous, vesiculated lesions,
or bullae. Target organs: liver and central nervous system

NIH: Acute toxin

May be irritating to mucous membranes & upper respiratory tract

Acutely toxic, possible mutagen
May cause irritation of respiratory tract or slight irritation to skin.
Ingestion may cause nausea, vomiting, and irritation.

Possibly toxic to reproductive syetem. May cause eye irritation and
may be harmful if swallowed, inhaled or absorbed thru skin.

Possible reproductive/fetotoxin, potential cardiotoxic effects. FDA
Pregnancy Category C.
Possible human mutagen and reproductive toxin (no human test
data available). Strong cardio/neurotoxin: avoid exposure.

Strong poison, suspected carcinogen, mutagen, and reproductive
hazard



Irritant effects, possibly harmful if ingested.
Confirmed human mutagen/possible reproductive toxin and a
potential sensitizing agent.
Irritant/toxin by all exposure routes: avoid exposure to dust.



Confirmed carcinogen with suspected human mutagenic,
teratogenic, and reproductive toxin properties: extensive human test
data available.



Harmful (methemoglobin former), irritant (eye, skin, respiratory, skin
sensitizer)
Toxic, carcinogenic, co-carcinogenic, and cancer-promoting agents
which are readily absorbed through skin. Avoid all contact and refer
to MSDS for recommended PPE, engineering controls, deactivation
and disposal options.

Product is potent tumor promoter (may induce a 10 fold increase in
carcinogenicity) suspected carcinogen, confirmed human mutagen
(human data reported) and possible teratogen/reproductive toxin.
Agent is also extremely ("deadly poison") toxic via intravenous route.

Avoid contact and inhalation, irritant and possibly harmful agent
targeting kidneys.




Toxicological effects of this compound have not been thoroughly
studied. Novel.



Possible teratogenic properties (limited animal test data), possible
irritant and/or harmful effects via all exposure routes.

Strong (subacute toxin) which can be fatal via inhalation, ingestion,
or skin exposure, with additional potential for teratogenic and
reproductive toxin effects. Seizure-inducing agent, handle with
extreme care.
Agent is a strong (subacute toxin) which can be harmful via
inhalation, ingestion, or skin exposure, with additional potential for
teratogenic and mutagenic effects. Exposure may cause severe
damage to the gastrointestinal tract.
Toxicological effects of this compound have not been thoroughly
studied. Novel.




OHSA target organ effect of CNS & harmful by ingestion. Acute
toxicity LD50 Oral - rat - 1,100 mg/kg

Moderate poison




Poison by ingestion, possible human teratogen/ reproductive toxin

PJ-34 is a potent poly(ADP-ribose) polymerase (PARP) inhibitor


Irritant via all exposure routes, surfactant.
Low hazard
Limited available health and safety information - irritant and toxin by
all routes.
Contains methanol - highly flammable. Dendrimer alone is a slight
irritant with mild toxicity in rats (oral LD50 > 2500 mg/kg) and rabbits
(dermal LD50 >1000 mg/kg).
Possible irritant effects, low toxicity.

Polyester-based absorbable suture material, limited anticipated
hazards.
Powerful sensitizing agent - avoid exposure.

Powerful sensitizing agent - avoid exposure; be sure formulation
used it tested for AB to HIV and HepB
Possible irritant effects, low toxicity.
Contact may cause very slight eye irritation.
Suspected human mutagen, possible reproductive toxin

Possible irritant effects, low toxicity.

All polymyxins are strong poisons


May be harmful if inhaled, cause skin, eye or respiratory tract
irritation. May be harmful if swallowed.

Contact with eyes may cause serious damage. Possible irritant of
skins, eyes, and upper respiratory tract.

MAY BE HARMFUL IF INHALED, ABSORBED THROUGH SKIN OR
SWALLOWED

May be harmful if inhaled, cause skin, eye or respiratory tract
irritation. May be harmful if swallowed.
May be harmful if inhaled, cause skin, eye or respiratory tract
irritation. May be harmful if swallowed.




May be harmful if inhaled, cause skin, eye or respiratory tract
irritation. May be harmful if swallowed.
May be harmful if inhaled, absorbed through skin, or swallowed.
May cause skin, eye or respiratory tract irritation. Target organ:
nerves.

nonergot dopamine agonist used for treatment for Parkinson's
Disease


Possible teratogen and reproductive toxin.


Suspected human reproductive toxin, teratogen and mutagen.


Possible carcinogen, experimental teratogen. Used to induce
tumorogenesis in rats, strong irritant.

Possible mutagen, carcinogen, and a potential sensitizing agent
with moderate toxic properties.

Confirmed human teratogen, mutagen, and reproductive toxin.



Limited associated hazards suspected


FDA/NADA-approved veterinary anesthetic, possible human
reproductive toxicity.
May cause respiratory tract, skin, or eye irritation. May be harmful if
swallowed, inhaled, or absorbed through skin.
Possible irritant/harmful effects via ingestion/inhalation.

Confirmed human reproductive toxin - multiple effects. Possible
mutagen and teratogen. Strong irritant and poison by all exposure
routes. NIOSH: Oxytocic agent.
Over-the-counter supplement, mixture of antioxidants (tumeric,
green tea, etc.) with alleged anti-aging effects. No associated
hazard indicated, but MSDS could not be located.


MSDS indicates that proteases are strong sensitizing agents which
may damage lung and other tissue. All contact should be avoided.



Irritant, possibly harmful if ingested.




Possible cardio/neurotoxin effects. Irritant to eyes, skin. And
respiratory tract.
May be harmful if inhaled, absorbed through skin, or swallowed.
May cause skin, eye or respiratory tract irritation.


Novel compound with unknown chemical, physical and toxicological
properties. Target Organs: Eyes; Respiratory system; Skin


Irritant, harmful if swallowed. Limited animal data indicates
mutagenic effects in mice with chronic exposure.
Novel HDAC inhibitor, chemically similar to trichostatin A. which has
possible mutagenic and severe irritant effects.
Highly toxic; may be fatal if inhaled, absorbed through the skin, or
swallowed.




Possible reproductive toxin (limited animal data). Potent irritant:
avoid contact with skin, eyes, mucous membrane/respiratory tract.


Novel compound with unknown chemical, physical and toxicological
properties

Numerous scientific journal indicate possible antineoplastic
properties: may induce apoptosis of some cancer cells (colorectal
cancer) but may also prevent apoptosis in other cancer cells
(leukemia HL-60 cells). Recent studies combining use of PDTC
with standard chemotherapeutic agents (DX, paclitaxel, 5-FU) have
shown therapeutic enhancement.

Irritant, possibly harmful if ingested, inhaled, or absorbed into skin.



Hormone, appetite suppressor, limited hazards


Novel compound with unknown chemical, physical and toxicological
properties

Possible mutagenic properties, toxic by ingestion, harmful/irritant
effects via skin contact/inhalation.
Possible carcinogen

Irritant and harmful effects - exposure may damage heart, bladder,
kidneys and other organs. Possible reproductive toxin properties
(animal data available)

Irritating to eyes, respiratory system and skin. May cause
sensitization by inhalation and skin contact.


MSDS: Possible reproductive toxin (limited animal data), additional
irritant/harmful effects.




OSHA target organ effect - nerves. Acute toxicity: LD50
Intraperitoneal - rat - 328 mg/kg


Suspected carcinogen. Target organs: nerves and liver. Mouse IV
LD50: 175 mg/kg



Possible reproductive toxin (no human data available). Possible
irritant/other harmful effects.




Possible reproductive toxin (no human data available).
May be harmful if inhaled, absorbed through skin, or ingested; may
cause respiratory tract irritation.




Irritant, possible mutagen, possible immune system depression,
possible mutagen (animal data only).
Limited available hazard information, in NIH trial for use against
hepatic fibrosis. Handle with care and limit exposure until sufficient
toxicological information become available.
Adverse effects might occur following inhalation. Irritant.


Extremely damaging to respiratory tract and mucous membrane,
may induce severe burns to eyes and skin, avoid all contact.
Possible reproductive toxin (limited animal data).


Phenolic antioxidant with moderate toxicity - primarily an irritant,
may cause severe irritation/damage to eyes.



Highly toxic, may be fatal if swallowed.

Possible mutagen/reproductive toxin, possible sensitizing agent,
questionable carcinogen (animal data only). California Prop 65
carcinogen.human mutagen (limited human test data available),
Suspected
possible reproductive toxin. Exposure via all routes may result in
irritant and/or other harmful effects.
Not expected to be hazardous when handled under normal
conditions with good housekeeping. Possible reproductive toxin
effects


Possible eye and skin irritant.




Novel compound with unknown chemical, physical and toxicological
properties
"Pregnancy Category C," possible reproductive toxin and
teratogenic properties (animal testing only).
Possible carcinogenic properties - animal model only. FDA
pregnancy category B.
Novel compound with unknown chemical, physical and toxicological
properties
Novel compound with unknown chemical, physical and toxicological
properties
May cause allergic reactions, nervous system effects [headache,
dizziness, drowsiness], hepatic, renal, or gastrointestinal effects,
and may cause blood system changes.
Strong irritant and neurotoxin, avoid exposure by all routes.

OSHA target organ effect of nerves and skeletal muscle

Novel compound with limited toxicological information. Recent trials
have indicated antineoplastic properties.



Diabetes therapy drug, possible reproductive toxin - "Pregnancy
Category C"
Novel compound with limited toxicological information. Recent trials
have indicated antineoplastic properties.



Significant physical hazards: highly flammable, reactive, and
corrosive. Contact with skin/lungs may cause severe burns.

Irritant, poison by all routes - avoid contact with/breathing of dust.
Highly flammable.

Irritant, poison by all routes, possible mutagenic and carcinogenic
properties, and use as experimental neoplastic agent.

Novel drug for treatment of dry eye. Has completed Phase 2 trials.
Synthetic form of natural resolvin (a lipid omega 3).
Possible irritant, avoid contact with eyes, skin, respiratory tract.


A novel Stat3 inhibitor which may inhibit tumor growth and induce
apoptosis.

May cause respiratory tract, skin, or eye irritation. May be harmful if
swallowed.

Irritant, neurotoxin, possible teratogenic and/or carcinogenic
properties.

FDA: "Fast Track" cancer drug, proteasome inhibitor, the limited
available information does not identify as carcinogen. National
Cancer Institute identifies as a antineoplastic agent, and cites that
agent readily crosses blood-brain barrier. Possible mutagenic and
reproductive hazard properties are noted. Sigma European
reference (University of Copenhagen/Danish Cancer Society)
indicates that SAHA is a hydroxamic acid derivative related to
PXD101 and Trichostatin A, which are possible mutagens.




Irritant and potential harmful effects via inhalation and ingestion,
hallucinogen, neurotoxin. Avoid all contact.


Protease inhibitor used in anti-viral (HIV) therapy. MSDS does not
indicate significant hazards, the IBC, however; urges extreme
caution be taken when working with protease inhibiting drugs.
Irritant/harmful by all routes.



Irritant/harmful by all routes - severe eye irritant.




Novel compound: MSDS indicates that chemical, physical, and
toxicological properties have not been evaluated - agent should be
considered hazardous

The chemical, physical, and toxicological properties of this agent
have not been fully evaluated. Avoid exposure, consider hazardous.



Irritant
The chemical, physical, and toxicological properties of this agent
have not been fully evaluated.



No known hazards




MSDS indicates that chemical, physical, and toxicological properties
have not been fully evaluated - agent should be handled with
caution.
The chemical, physical, and toxicological properties of this agent
have not been fully evaluated.

Strong toxin (subacute)

May be harmful if inhaled or swallowed; may cause respiratory tract,
skin, and eye irritation.
Possible reproductive toxin, cholesterol lowering drug.

Transfection system with low toxicity and irritant effects.

No toxicological data could be accessed




Possible antineoplastic properties, potent irritant effects.


Irritant and possible harmful effects: eyes, mucus membrane,
respiratory system, and skin. Avoid contact by all routes. MEK
inhibitor.
Novel drug for treatment of traumatic brain injury currently in Phase
2 trials. Closely related to Benazepril Hydrochloride (Daglutril®)
which has possible teratogenic/reproductive toxin effects and is a
renal/hepatotoxin.
Moderate toxin effects. Not to be confused with isothiourea
which is confirmed human mutagen and suspect human
carcinogen with strong toxic properties.
Irritant, poison by all routes - avoid contact with/breathing of dust.
Highly flammable.



No known associated chronic hazards indicated, but limited
available toxicological information: avoid exposure.


No known hazards

Limited available hazard information, hazards associated
include strong irritant/poison by all exposure routes, and
possible carcinogenicity.

Hsp90 inhibitor in phase I/II clinical trials

The chemical, physical, and toxicological properties of this agent
have not been fully evaluated.



Strong irritant, absorbs through skin, damaging to mucous
membrane and lung tissue.
Animal test data available indicating potential carcinogenic,
mutagenic, teratogenic, and reproductive toxin properties.


May be harmful if inhaled; may cause respiratory tract irritation. May
cause skin irritation.

May be harmful if inhaled; may cause respiratory tract irritation. May
cause eye or skin irritation.
Human mutation data reported, neoplastic, and tumorigenic.

Strong poison, Rat oral LD50 99 mg/Kg


Confirmed human mutagen, moderately toxic in animal studies



Possible human teratogen and/or reproductive toxin.



USFDA: Antirenal cancer drug, possible reproductive toxin.



Hazardous in case of eye contact (irritant) or ingestion. Slightly
hazardous in case of skin contact (irritant) or inhalation.


Irritant



Toxic and may impair fertility.

No toxicological or health rating data available.



See "Vasopressin Receptor Antagonists"



May cause skin, eye, and inhalation irritation. Toxic if swallowed.




Novel compound with limited available hazard information,



Not anticipated to pose significant health threat

Not anticipated to pose significant health threat

Novel compound with limited available hazard information,


Harmful by ingestion. Irritant.



Novel antineoplastic stilbene drugs: very limited available health
and safety info, handle as human carcinogen until sufficient hazard
info becomes available.
Human carcinogen, mutagen, and teratogen
Possible irritant to skin, eyes, and respiratory system.




Novel compound with no available toxicological information: handle
with extreme caution


Possible sensitizing agent, possible nephra/hepatotoxin, potential
teratogenic/reproductive toxin properties.

An antimicrobial sulfa-drug with possible teratogenic and
reproductive toxin effects (animal data only). Possible sensitizing
agent.
Irritant


Antipsychotic drug, CNS toxin, possible irritant to skin, eyes, and
respiratory system.

Toxic and may cause harm to unborn child. Risk of explosion




Strong irritant to eyes, respiratory tract and skin, possible harmful if
ingested.


Irritant, potentially harmful by all exposure routes - toxic to kidneys.




FDA: Slight risk of vision loss indicated




NIH: human carcinogen, mutagen, and teratogen

Agent is a potent irritant via all exposure routes, exposure may also
damage eyes, skin, respiratory system, and mucous membrane.
Strong irritant to eyes, respiratory tract and skin.



Mutagen, possible reproductive toxin



Handle as a novel compound



Cytotoxic, mutagenic, reproductive hazard


Severe eye irritant, with low toxicity via inhalation and skin contact .


Reproductive toxin (human test data available), possible teratogen,
sensitizing agent to skin and respiratory tract, possible
cardio/pulmonary toxin effects.
Confirmed human teratogen, mutagen, and reproductive toxin,
suspected human carcinogen.

Acute/extreme toxin via injection. Other sources indicate rat oral
LD50 as low as 0.0001 mg/kg. This agent must be handled with
extreme caution.
Product information sheets indicates that toxic component in
tetanus toxin is eliminated in production of toxoid.

An MSDS for this agent could not be accessed. The compound
closely resembles dioxin, and is suspected to share some of the
same hazard properties (mutagen/teratogen).
IARC Group 2A, suspected human carcinogen.


Irritant, possibly harmful by ingestion/inhalation.


CDC "Select Agent"




Novel compound with limited available hazard information,


Strong irritant and potentially harmful by all routes.




FDA Controlled Substance

Potent irritant with possible harmful effects. Possible sensitizing
agent effecting respiratory system. Avoid exposure by all routes.
NIH CRISP directory indicates possible tumor promoting properties,
other sources indicate use as novel therapy for prostate cancer.


Strong poison, confirmed human mutagen, possible teratogenic,
mutagenic, reproductive toxin, and tumorigenic properties. USDEA
Schedule I controlled substance.




Physical hazards , broth generally has low/moderate toxicity, other
thioglycolates may be strong poisons


Possible reproductive toxin and/or teratogen, strong poison,
sensitizing agent, California Prop 65 Developmental Toxin.


Possible irritant to skin, eyes, and respiratory system. Exposure
may target/damage nerves.

Antipsychotic drug, human mutagen (human test data) potentially
harmful to eyes and CNS, eye/respiratory tract/CNS/skin irritant
effects.
Harmful by inhalation, in contact with skin and if swallowed.
Caution: Avoid contact and inhalation.

Product information sheet indicates that product is produced from
human plasma and that potential for contamination with infectious
viruses and prions exists.
Possible carcinogenic properties - attached product indicates that
elevated animal occurrence of carcinoma may not be relatable to
humans. FDA pregnancy category B.
Novel compound, toxicological information not available at time of
review: handle with extreme caution and avoid exposure by all
routes.
Slightly hazardous in case of skin contact, eye contact, or ingestion
(irritant).
Possible irritant/harmful effects to skin, eyes, and respiratory
system. A new adjuvant product which is reported to have lower
toxicity/side effects than traditional agents (e.g. CFA).
Biohazard, handle as if capable of transmitting infectious agents.
Novel compound, toxicological information not available at time of
review.
Novel compound, toxicological information not available at time of
review: exercise due care



Confirmed human mutagen with potential reproductive toxin
properties.


MSDSs do not indicate known chronic hazards, relation to human
TNF-a, however; warrants careful handling of this material.


MSDSs do not indicate known chronic hazards, relation to human
TNF-a, however; warrants careful handling of this material.

Known human carcinogen.

Possible reproductive toxin effects.

Possible carcinogen, suspected mutagen.

Acute toxin, LD50 Oral - rat - 500 mg/kg Toxicity to daphnia and
other aquatic invertebrates. EC50 - Daphnia pulex (Water flea) -
0.022 mg/l - 48 h used in surgical/first aid applications, product
An anticoagulant
information sheet indicates that product is bioinert and poses no
potential for disease transmission.
May be harmful if inhaled; may cause respiratory tract irritation. May
cause eye or skin irritation.
IARC 2A (Anabolic Steroid) suspected human carcinogen.
Suspected female and male reproductive toxin effects.

Material is irritating to mucous membranes and upper respiratory
tract. Multiple Routes: Causes eye and skin irritation. May be
harmfully inhalation, ingestion, or skin absorption.
Subacute toxin by all exposure routes.

DFG MAK: Confirmed animal carcinogen - relevance to humans
unknown. ACGIH: animal carcinogen. Suspected human
carcinogen. Possible mutagenic, teratogenic, and reproductive
toxin properties, highly toxic to kidneys/other organ systems,
ecotoxin.
DFG MAK: Confirmed human carcinogen.

Possible irritant to skin, eyes, and respiratory system.




See didox
Possible sensitizing agent, exposure may be extremely destructive
to mucous membrane, respiratory tract, and eyes. Also may pose
explosion hazard if managed incorrectly.
Potent immunosuppressant, possible human mutagen

Neurotoxin, potent irritant, possible sensitization effects (skin and
respiratory tract).



Moderate toxin by all exposure routes, irritant and potential
neurotoxin.
Irritant to mucous membrane and upper respiratory tract, potentially
harmful if inhaled or ingested.


Irritant to eyes, respiratory system, and skin. Target organs: nerves
and kidneys.
LD50 Intraperitoneal - mouse - 25 mg/kg Inhalation: May be
harmful if inhaled. May cause respiratory tract irritation. Ingestion:
May be harmful if swallowed. Skin: May be harmful if absorbed
through skin. May cause skin irritation. Eyes: May cause eye
irritation.
Possibly harmful via ingestion, skin contact, or inhalation. Avoid
contact
Possible irritant and toxic effects




Toxicological properties of this agent have not yet been fully
investigated. Handle with extreme caution and avoid contact by all
exposure routes.

Strong (subacute) toxin affecting the heart and all sensory organs -
may cause irreparable damage. Possible teratogenic and
reproductive toxin properties. Strong irritant of skin, eyes, and lungs -
 avoid indicates that compound is potent environmental (aquatic)
MSDS all contact.
toxin - dispose of all URB597 waste through OEHS. Agent may also
induce strong irritant effects via inhalation and/or skin contact.

Limited hazards - avoid inhalation, ingestion, and skin/eye contact.




FDA over-the-counter drug, highly corrosive, strong irritant,
exposure may significantly damage mucus membrane and/or lung
tissue.



IARC Group 2a/NTP "reasonably anticipated human carcinogen,"
confirmed human mutagen, suspected teratogen, and reproductive
toxin. California Prop 65 known carcinogen and developmental
toxin.


Human mutagen and teratogen (human test data available),
possible reproductive toxin. Possible sensitizing agent.
Hypertension drug, possible reproductive toxin. PsyCem MSDS:
possible reproductive toxin.




Novel compound, toxicological information not available at time of
review: handle with extreme caution and avoid exposure by all
routes.




FDA Information Sheet: Pregnancy Category C, may be passed to
fetus in breast milk resulting in harm.
May affect serum sodium levels causing neurological damage
and/or possible renal/hepatic impairment. Physician's Desk
Reference: FDA Pregnancy Category C - animal data indicating
Toxicological effects not fully evaluated, indicates possible harmful
effects via all exposure routes. Chemicon MSDS indicates no
known hazards associated with agent, but adds that toxicological
effects have not been fully studied.
Possible irritant to skin, eyes, and respiratory system.




Target organ effect on cardiovascular system, highly toxic by
inhalation (possibly fatal), also toxic by ingestion & skin absorbtion.
Rat oral LD50: 108 mg/kg
This product is expected to be irritating to contaminated skin, eyes
and other tissues.
MSDS: minimal hazards cited minimal.

Confirmed human mutagen, possible teratogen/reproductive toxin.
California Prop 65 developmental toxin
Drug used in treatment of Alzheimer's Disease. MSDS: strong toxin
by all exposure routes, strong irritant, possible
teratogen/reproductive toxin (animal data only)
Toxicity varies from analog to analog: some compounds are
suspected reproductive toxins and acute toxins.
No known OSHA hazards, potentially harmful if inhaled or ingested.



Novel compound, toxicological information not available at time of
review: handle with extreme caution and avoid exposure by all
routes.


Novel compound, toxicological information not available at time of
review: handle with extreme caution and avoid exposure by all
routes.

No Known OSHA hazards, potentially harmful if inhaled or ingested.



Potent irritant of eyes, respiratory system and skin. Possibly
harmful via inhalation/ingestion/skin contact.
MSDSs indicate extreme toxicity by all routes but add that
toxicological properties have not been determined. Agent
readily permeates skin - avoid exposure by all routes.
Experimental neoplastic agent, questionable carcinogenic
properties. Strong toxin, sensitizing agent, possible carcinogen and
mutagen. Avoid exposure by all routes.
Simple asphyxiant
Irritant of eyes, respiratory system and skin. Harmful via
ingestion. May affect respiration, CNS, and endocrine
systems.
Toxic via all routes: primary exposure threat via inhalation.
Possible teratogenic and reproductive toxin effects (animal test data
only). relative of MD-354, MSDS for MD-354 indicates limited
Close
hazards.



Novel compound with limited chemical, physical, and toxicological
information. An experimental AMPA receptor antagonist.


Highly toxic. Toxic by inhalation, contact with skin, and ingestion.
May cause eye, skin, and upper respiratory irritation. Prolonged
exposure can cause damage to the heart.
Irritant to mucous membrane and respiratory tract, may be harmful if
inhaled or swallowed.

Novel compound with limited chemical, physical, and toxicological
information.



May be harmful if ingested.




Possible carcinogen, teratogen, mutagen, reproductive toxin.



Irritant, low toxicity.


May cause irritation to skin, eyes, and mucous membranes. Limited
toxicological information available.

No known hazards indicated


Possible irritant, may be harmful to respiratory tract and/or mucous
membrane, possible neurotoxic effects.
Confirmed human mutagen, highly toxic, possible teratogenic and
reproductive toxic effects.


Limited available toxicological information available, possible irritant
and toxic effects, extreme caution advised.
Comments




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Consult MSDS for safe handling information/incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form

in vivo applications must be registered with IBC via completion of chemical
hazard form

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Consult MSDS for safe handling information/incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Consult MSDS for safe handling information/incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



Consult MSDS for safe handling information/incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form until
demonstrated to be nonhazardous.
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP




Sensitizing agent: Handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Anesthetic agent with hazardous properties, Handle with extreme caution,
follow safety precautions indicated in MSDS and incorporate into lab CHP.
Anesthetic agent with hazardous properties, Handle with extreme caution,
follow safety precautions indicated in MSDS and incorporate into lab CHP.

Consult MSDS for safe handling information/incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP




Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

USDEA Schedule I controlled substance/sensitizing agent: Handle with
extreme caution, follow safety precautions indicated in MSDS and incorporate
into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Consult MSDS for safe handling information/incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP


Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Consult MSDS for safe handling information/incorporate into lab CHP

USDEA Schedule II controlled substance: Handle with extreme caution, follow
safety precautions indicated in MSDS and incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP




Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

Sensitizing agent: Handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard information in the Group Drugs/Compounds section

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Refer to MSDS for specific arginine compound being utilized: In vivo
applications involving compounds with known/suspected human (human test
data) teratogenic, mutagenic, and/or reproductive toxin effects must be reported
on Appendix C. All other arginine compounds should be handled carefully in
accordance with MSDS with safe handling information incorporated into
laboratory CHP.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Consult MSDS for safe handling information/incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Limited hazard information available, handle with extreme care, follow product
MSDS/incorporate into lab CHP.
Consult MSDS for safe handling information/incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Anesthetic agent with hazardous properties, handle with extreme caution, follow
safety precautions indicated in MSDS and incorporate into lab CHP.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Sensitizing Agent: Handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



Consult MSDS for safe handling information/incorporate into lab CHP




Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



Consult MSDS for safe handling information/incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Although not considered reportable - handle with extreme caution and refer to
MSDS for developing safe handling procedures. Status may change if further
reviews (IARC, NTP, etc.) become available.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP.
Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Consult MSDS for safe handling information/incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Consult MSDS for safe handling information/incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Whenever possible researchers should select BSA products which are assured
to be BSE-free or to have had BSE-contamination risk minimized. If no
assurance of BSE status is available and a risk assessment has not been
conducted indicating minimal BSE-contamination risk, OEHS recommends
performed manipulation under BSL-2 precautions.


Follow safety precautions indicated in MSDS and incorporate into lab CHP

Follow safety precautions indicated in MSDS and incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
in vivo applications MAY need to be registered with IBC via completion of
chemical hazard form provided in Appendix C, depending on source.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Consult MSDS for safe handling information/incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Handle with extreme caution, being sure that adequate ventilation is used.
Follow safety precautions indicated in MSDS and incorporate into lab CHP



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP


Sensitizing agent: Handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Sensitizing agent: Handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.


Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
protocol until demonstrated to be nonhazardous.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Sensitizing agent: Handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




in vivo applications involving CTB with rat oral LD50 < 50 mg/kg must be
registered with IBC via completion of chemical hazard form provided in
Appendix C. CTB products with LD50 > 50 mg/kg do not require reporting
(provide product MSDS to IBC for verification).
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Sensitizing agent - avoid exposure, consult MSDS for safe handling
information/incorporate into lab CHP



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Consult MSDS for safe handling information/incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Consult MSDS for safe handling information/incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Consult MSDS for safe handling information/incorporate into lab CHP


USDEA Schedule II controlled substance/sensitizing agent: Handle with
extreme caution, follow safety precautions indicated in MSDS and incorporate
into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Sensitizing agent - avoid exposure, consult MSDS for safe handling
information/incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C. All use of this agent must further be
registered with OEHS (contact 827-0353 for further information).

Available hazard information limited handle with extreme care: Consult MSDS
for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.
Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.


Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Consult MSDS for safe handling information/incorporate into lab CHP




Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Consult MSDS for safe handling information/incorporate into lab CHP


Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.



Consult MSDS for safe handling information/incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.completion of chemical
in vivo applications must be registered with IBC via
hazard form provided in Appendix C.




Sensitizing agent: handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP

Sensitizing agent: Handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP.

Sensitizing agent: Handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP.

Sensitizing agent: Handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP.

Sensitizing agent: Handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP.

Sensitizing agent: Handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Consult MSDS for safe handling information/incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Consult MSDS for safe handling information/incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Consult MSDS for safe handling information/incorporate into lab CHP



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP


FDA Schedule II controlled drug with significant associated health and
safety hazards, handle with extreme care consult MSDS for handling
information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



USDEA Schedule I controlled substance: Handle with extreme caution, follow
safety precautions indicated in MSDS and incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.completion of chemical
in vivo applications must be registered with IBC via
hazard form provided in Appendix C.




Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.



Consult MSDS for safe handling information/incorporate into lab CHP



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C. Products which are acquired in dilute
concentrations may not require registration, contact the Biosafety Office to
determine requirements prior to completing protocols.



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




Handle Euthasol® with extreme caution, follow safety precautions indicated in
MSDS and incorporate into lab CHP. All other uses of phenytoin/phenytoin-
containing products must be reported on Appendix C of IACUC from.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


USDEA Schedule II controlled substance: Handle with extreme caution, follow
safety precautions indicated in MSDS and incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP



1. Products with MSDSs certifying free of adventious agents: not reportable. 2.
 Products with MSDSs not certifying free of adventitious agents must be
registered as "Biological Hazard" on Appendix C.



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



Novel compound with limited available hazard information, in vivo
applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C until demonstrated to be
nonhazardous.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Consult MSDS for safe handling information/incorporate into lab CHP


FDA approved cholesterol reducing drug, consult MSDS for safe
handling information, incorporate into lab CHP


Novel compound with limited available hazard information, in vivo
applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C until demonstrated to be
nonhazardous.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications with products containing > 37% formaldehyde must
be reported on Appendix C of IACUC protocol. Applications with
products containing ≤ 37% formaldehyde are not reportable and may be
covered via following safety instructions provided on product
MSDS/incorporation into lab CHP.
Consult MSDS for safe handling information/incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.



Consult MSDS for safe handling information/incorporate into lab CHP

in vivo use of all agents meeting IBC criteria for nanoparticles (see link)
must be reported on chemical hazard form provided in Appendix C

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Consult MSDS for safe handling information/incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP.


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP.


Consult MSDS for safe handling information/incorporate into lab CHP



in vivo applications must be registered with IBC via completion of
chemical hazard form provided in Appendix C.
in vivo applications must be registered with IBC via completion of
chemical hazard form provided in Appendix C.


Sensitizing agent: Handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP.



Due to limited available toxicological data, in vivo applications must be
registered with IBC via completion of chemical hazard form provided in
Appendix C.

Due to limited available toxicological data, in vivo applications must be
registered with IBC via completion of chemical hazard form provided in
Appendix C.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of
chemical hazard form provided in Appendix C.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



in vivo applications must be registered with IBC via completion of
chemical hazard form provided in Appendix C.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.




Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



Anesthetic gas with potential reproductive toxic, mutagenic, and teratogenic
properties. Proper engineering controls and Lab CHP with complete SOPs for
safe handling must be in place prior to use of agent.



Consult MSDS for safe handling information/incorporate into lab CHP



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Consult MSDS for safe handling information/incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


USDEA Schedule I controlled substance: Handle with extreme caution, follow
safety precautions indicated in MSDS and incorporate into lab CHP


Cardinal Health MSDS does not indicate adverse properties.



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

Contact Biosafety Office to determine if product requires reporting. Due to
remote possibility of contamination with bloodborne pathogens, BSL-2
precautions are recommended during preparation/adminstration of agent.
Regardless of whether reporting on Appendix C is required, safety precautions
for working with this agent must be included in the laboratory chemical hygiene   http://diagnostics.siemens.com/siemens/en_G
plan.                                                                             LOBAL/gg_diag_FBAs/files/msds/ria/double_
                                                                                  antibody/KCGD-01.pdf
Contact Biosafety Office to determine if product requires reporting. Due to
remote possibility of contamination with bloodborne pathogens, BSL-2
precautions are recommended during preparation/adminstration of agent.
Regardless of whether reporting on Appendix C is required, safety precautions
for working with this agent must be included in the laboratory chemical hygiene
plan.
Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Refer to product MSDS: In vivo applications involving products with unknown
properties and/or suspected/confirmed human teratogenic, mutagenic,
carcinogenic and/or reproductive toxin effects must be reported on Appendix C.
Hazards associated with other products should be addressed in the laboratory
chemical hygiene plan.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP

Propriatary experimental compound from Incyte Corporation. MSDS provided
by PI
Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Consult MSDS for safe handling information/incorporate into lab CHP



Anesthetic gas with potential reproductive toxic and teratogenic properties.
Proper engineering controls and Lab CHP with complete SOPs for safe
handling must be in place prior to use of agent.


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.



Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




Sensitizing agent: Handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP


Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to besafety precautions indicated in MSDS and
Handle with extreme caution, follow nonhazardous.
incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


USDEA Schedule II controlled substance: Handle with extreme caution, follow
safety precautions indicated in MSDS and incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP



in vivo applications involving agents with rat oral LD50 < 50 mg/kg must be
registered with IBC via completion of chemical hazard form provided in
Appendix C. MSDS must be provided to Biosafety Office to validate
Consult MSDS for safe handling exceeding acute toxin into lab CHP
nonreportable agents with LD50sinformation/incorporate criteria (rat oral LD50 >



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




USDEA Schedule II controlled substance: Handle with extreme caution, follow
safety precautions indicated in MSDS and incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP



FDA approved cholesterol reducing drug, handle with caution, consult
MSDS for safe handling information, incorporate into lab CHP


Handle with caution, consult MSDS for safe handling information,
incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP


Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.


Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Consult MSDS for safe handling information/incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP
Handle with caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Consult MSDS for safe handling information/incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP



in vivo applications must be registered with IBC via completion of
chemical hazard form provided in Appendix C.
Consult MSDS for safe handling information/incorporate into lab CHP




in vivo applications must be registered with IBC via completion of
chemical hazard form provided in Appendix C.




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




in vivo applications must be registered with IBC via completion of
chemical hazard form provided in Appendix C.




Consult MSDS for safe handling information/incorporate into lab CHP



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Anesthetic gas with potential reproductive toxic and teratogenic properties.
Proper engineering controls and Lab CHP with complete SOPs for safe
handling must be in place prior to use of agent.
Consult MSDS for safe handling information/incorporate into lab CHP



Sensitizing agent - avoid exposure, consult MSDS for safe handling
information/incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS (for
specific type of methyl/methylene blue dye in use) and incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP


Anesthetic gas with potential reproductive toxic and teratogenic properties.
Proper engineering controls and Lab CHP with complete SOPs for safe
handling must be in place prior to use of agent.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Sensitizing agent - avoid exposure, consult MSDS for safe handling
information/incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
USDEA Schedule II controlled substance: Handle with extreme caution, follow
safety precautions indicated in MSDS and incorporate into lab CHP

USDEA Schedule I controlled substance: Handle with extreme caution, follow
safety precautions indicated in MSDS and incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Consult MSDS for safe handling information/incorporate into lab CHP


Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.
Consult MSDS for safe handling information/incorporate into lab CHP


Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.
Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Consult MSDS for safe handling information/incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



In vivo use of all agents meeting IBC criteria for nanoparticles (see link)
must be reported on chemical hazard form provided in Appendix C

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

USDEA Schedule II controlled substance: Handle with extreme caution, follow
safety precautions indicated in MSDS and incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP


Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.


Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.


Consult MSDS for safe handling information/incorporate into lab CHP



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP. May need to be registered on Appendix C

Anesthetic gas with potential reproductive toxic and teratogenic properties.
Proper engineering controls and Lab CHP with complete SOPs for safe
handling must be in place prior to use of agent.

Consult MSDS for safe handling information/incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Consult MSDS for safe handling information/incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.


Consult MSDS for safe handling information/incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.completion of chemical
in vivo applications must be registered with IBC via
hazard form provided in Appendix C.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Sensitizing agent - avoid exposure, consult MSDS for safe handling
information/incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Sensitizing agent: Handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP. Piercenet MSDS indicates
possible teratogenic properties in addition to irritant/sensitiziing effects.
Consult MSDS for safe handling information/incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Sensitizing agent: Handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP. in vivo applications must be registered with IBC via
completion of chemical hazard form provided in Appendix C.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP. in vivo applications must be registered with IBC via
completion of chemical hazard form provided in Appendix C.




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP. in vivo applications must be registered with IBC via
completion of chemical hazard form provided in Appendix C.
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


USDEA Schedule II controlled substance: Handle with extreme caution, follow
safety precautions indicated in MSDS and incorporate into lab CHP




Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Practice safe handling and incorporate into lab CHP


Practice safe handling and incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Consult MSDS for safe handling information/incorporate into lab CHP




Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Sensitizing agent: Handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP



Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



Consult MSDS for safe handling information/incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Consult MSDS for safe handling information/incorporate into lab CHP



1. in vivo applications involving research-grade reagents must be registered
with IBC via completion of chemical hazard form provided in Appendix C.
                                                                  2. in vivo
applications involving Euthasol™ for euthanization do not require reporting:
incorporate into lab CHP.
Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

Sensitizing agent: Handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP
Sensitizing agent: Handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Consult MSDS for safe handling information/incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Sensitizing agent: Handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Consult MSDS for safe handling information/incorporate into lab CHP


Anesthetic agent: handle with extreme caution, follow safety precautions
indicated in MSDS and incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Consult MSDS for safe handling information/incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP



Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form until
demonstrated to be nonhazardous.
Consult MSDS for safe handling information/incorporate into lab CHP


Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form.

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.




Consult MSDS for safe handling information/incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




Handle with caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.
Consult MSDS for safe handling information/incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Sensitizing agent, with other potentially harmful properties, handle with extreme
caution, follow safety precautions indicated in MSDS and incorporate into lab
CHP applications must be registered with IBC via completion of chemical
in vivo
hazard form provided in Appendix C.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP. Previously required registration as novel compound,
however; recent availability of more complete toxicological information has led
to lifting of IBC required registration status.

Consult MSDS for safe handling information/incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Consult MSDS for safe handling information/incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Limited hazard information available, handle with extreme care, follow product
MSDS/incorporate into lab CHP.
Consult MSDS for safe handling information/incorporate into lab CHP


Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.
Consult MSDS for safe handling information/incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.




Consult MSDS for safe handling information/incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP




Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Handle with caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Consult MSDS for safe handling information/incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.
Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

FDA approved cholesterol reducing drug, consult MSDS for safe
handling information, incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP

Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP


Limited hazard information available, handle with extreme care, follow product
MSDS/incorporate into lab CHP.

Consult MSDS for safe handling information/incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP




Limited hazard information available, handle with extreme care, follow product
MSDS/incorporate into lab CHP.



Consult MSDS for safe handling information/incorporate into lab CHP

Available hazard information limited handle with extreme care: Consult MSDS
for safe handling information/incorporate into lab CHP


Available hazard information limited; handle with extreme care:incorporate into
lab CHP
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.


Consult MSDS for safe handling information/incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Though not reportable, this agent is a strong poison - handle with extreme care:
consult MSDS for safe handling information and incorporate SOPs into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.
Consult MSDS for safe handling information/incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
 in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C until demonstrated to be nonhazardous.


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


 in vivo applications must be registered with IBC via completion of chemical
hazard form until demonstrated to be nonhazardous.


Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP

 in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C until demonstrated to be nonhazardous.

Consult MSDS for safe handling information/incorporate into lab CHP



Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Consult MSDS for safe handling information/incorporate into lab CHP




Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Sensitizing agent, with other potentially harmful effects, handle with extreme
caution, follow safety precautions indicated in MSDS and incorporate into lab
CHP.
Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Consult MSDS for safe handling information/incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP



in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Consult MSDS for safe handling information/incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Consult MSDS for safe handling information/incorporate into lab CHP


Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

USDEA Schedule I controlled substance: Handle with extreme caution, follow
safety precautions indicated in MSDS and incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C. All use of this agent must further be
registered with OEHS (contact 827-0353 for further information).

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Consult MSDS for safe handling information/incorporate into lab CHP


See : Derynck, R et al (1988) EMBO J 7:3737-3743


See : Derynck, R et al (1988) EMBO J 7:3737-3743
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.



Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Consult MSDS for safe handling information/incorporate into lab CHP



in vivo applications must be registered with IBC via completion of biological
hazard form provided in Appendix C.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

in vivo applications must be registered with IBC via completion of biological
hazard form provided in Appendix C.

Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP



in vivo applications must be registered with IBC via completion of biological
hazard form provided in Appendix C.

in vivo applications must be registered with IBC via completion of biological
hazard form provided in Appendix C.



in vivo a pplications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP

in vivo a pplications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.



in vivo a pplications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Limited available hazard information, will be considered reportable chemical at
least until sufficient information is made available.
Sensitizing agent, with other potentially harmful effects, handle with extreme
caution, follow safety precautions indicated in MSDS and incorporate into lab
CHP.

Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP



Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP




Consult MSDS for safe handling information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP



Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




Anesthetic which may be administered as injectable liquid or as gas with
multiple hazards. Proper engineering controls and Lab CHP with complete
SOPs for safe handling must be in place prior to use of agent. In vivo use
must be registered with IBC via completion of chemical hazard form provided in
Appendix C.
in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP




Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Consult MSDS for safe handling information/incorporate into lab CHP




Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP
Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Handle with caution: consult MSDS for safe handling information/incorporate
into lab CHP

Handle with caution: consult MSDS for specific vitamin D analog(S) for safe
handling information/incorporate into lab CHP
Handle with care and avoid exposure.



Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.


Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Handle with care and avoid exposure.



Consult MSDS for safe handling information/incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.
Sensitizing agent: Handle with caution: consult MSDS for safe handling
information/incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP



Handle with caution: consult MSDS for safe handling information/incorporate
into lab CHP
Consult MSDS for safe handling information/incorporate into lab CHP




Novel compound with limited available hazard information, in vivo applications
must be registered with IBC via completion of chemical hazard form provided in
Appendix C until demonstrated to be nonhazardous.

Handle with caution: consult MSDS for safe handling information/incorporate
into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C until demonstrated to be nonhazardous.



Consult MSDS for safe handling information/incorporate into lab CHP




in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

Consult MSDS for safe handling information/incorporate into lab CHP


Handle with extreme caution, follow safety precautions indicated in MSDS and
incorporate into lab CHP

Consult MSDS for safe handling information/incorporate into lab CHP


Consult MSDS for safe handling information/incorporate into lab CHP

in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.


in vivo applications must be registered with IBC via completion of chemical
hazard form provided in Appendix C.

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:12
posted:11/9/2011
language:English
pages:209